+

WO2008046084A2 - Spiroheterocyclic compounds and their uses as therapeutic agents - Google Patents

Spiroheterocyclic compounds and their uses as therapeutic agents Download PDF

Info

Publication number
WO2008046084A2
WO2008046084A2 PCT/US2007/081320 US2007081320W WO2008046084A2 WO 2008046084 A2 WO2008046084 A2 WO 2008046084A2 US 2007081320 W US2007081320 W US 2007081320W WO 2008046084 A2 WO2008046084 A2 WO 2008046084A2
Authority
WO
WIPO (PCT)
Prior art keywords
heteroaryl
aryl
heterocyclyl
aralkyl
cycloalkyl
Prior art date
Application number
PCT/US2007/081320
Other languages
French (fr)
Other versions
WO2008046084A3 (en
Inventor
Mikhail Chafeev
Sultan Chowdhury
Jianmin Fu
Rajender Kamboj
Duanjie Hou
Shifeng Liu
Original Assignee
Xenon Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc. filed Critical Xenon Pharmaceuticals Inc.
Publication of WO2008046084A2 publication Critical patent/WO2008046084A2/en
Publication of WO2008046084A3 publication Critical patent/WO2008046084A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Definitions

  • the present invention is directed to spiro-oxindole compounds.
  • this invention is directed to spiro-oxindole compounds that are sodium channel blockers and are therefore useful in treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions such as hypercholesterolemia, benign prostatic hyperplasia, pruritis, and cancer.
  • Voltage-gated sodium channels transmembrane proteins that initiate action potentials in nerve, muscle and other electrically excitable cells, are a necessary component of normal sensation, emotions, thoughts and movements (Catterall, W.A., Nature (2001 ), Vol. 409, pp. 988-990).
  • These channels consist of a highly processed alpha subunit that is associated with auxiliary beta subunits.
  • the pore-forming alpha subunit is sufficient for channel function, but the kinetics and voltage dependence of channel gating are in part modified by the beta subunits (Goldin et al., Neuron (2000), Vol. 28, pp. 365-368).
  • Each alpha-subunit contains four homologous domains, I to IV, each with six predicted transmembrane segments.
  • the alpha-subunit of the sodium channel forming the ion-conducting pore and containing the voltage sensors regulating sodium ion conduction has a relative molecular mass of 260,000. Electrophysiological recording, biochemical purification, and molecular cloning have identified ten different sodium channel alpha subunits and four beta subunits (Yu, F.H., et al., Sci. STKE (2004), 253; and Yu, F.H., et al., Neurosci. (2003), 20:7577-85).
  • sodium channels include rapid activation and inactivation when the voltage across the plasma membrane of an excitable cell is depolarized (voltage-dependent gating), and efficient and selective conduction of sodium ions through conducting pores intrinsic to the structure of the protein (Sato, C, et al., Nature (2001 ), 409:1047-1051 ).
  • sodium channels are closed. Following membrane depolarization, sodium channels open rapidly and then inactivate. Channels only conduct currents in the open state and, once inactivated, have to return to the resting state, favoured by membrane hyperpolarization, before they can reopen.
  • Different sodium channel subtypes vary in the voltage range over which they activate and inactivate as well as their activation and inactivation kinetics.
  • Na v 1.1 and Na v 1.2 are highly expressed in the brain (Raymond, C. K., et al., J. Biol. Chem. (2004), 279(44):46234-41 ) and are vital to normal brain function. In humans, mutations in Na v 1.1 and Na v 1.2 result in severe epileptic states and in some cases mental decline (Rhodes, T.H., et al., Proc. Natl. Acad. Sci. USA
  • Na 1 Zl .3 as a suitable target for pain therapeutics (Lai, J., et al., Curr. Opin. Neurobiol. (2003), (3):291 -72003; Wood, J. N., et al., J. Neurobiol. (2004), 61(1 ):55-71 ; Chung, J.M., et al., Novartis Found Symp. (2004), 261 :19-27; discussion 27-31 , 47-54).
  • Na v 1.4 expression is essentially limited to muscle (Raymond, C.K., et al., op. cit.). Mutations in this gene have been shown to have profound effects on muscle function including paralysis, (Tamaoka A., Intern. Med. (2003), (9):769-70). Thus, this channel can be considered a target for the treatment of abnormal muscle contractility, spasm or paralysis.
  • the cardiac sodium channel, Na v 1.5 is expressed mainly in the heart ventricles and atria (Raymond, C. K., et al., op. cit), and can be found in the sinovial node, ventricular node and possibly Purkinje cells.
  • the rapid upstroke of the cardiac action potential and the rapid impulse conduction through cardiac tissue is due to the opening of Na/1.5.
  • Na v 1.5 is central to the genesis of cardiac arrhythmias.
  • Mutations in human Na/I .5 result in multiple arrhythmic syndromes, including, for example, long QT3 (LQT3), Brugada syndrome (BS), an inherited cardiac conduction defect, sudden unexpected nocturnal death syndrome (SUNDS) and sudden infant death syndrome (SIDS) (Liu, H. et al., Am. J. Pharmacogenomics (2003), 3(3):173-9).
  • LQT3 long QT3
  • BS Brugada syndrome
  • SUNDS sudden unexpected nocturnal death syndrome
  • SIDS sudden infant death syndrome
  • Sodium channel blocker therapy has been used extensively in treating cardiac arrhythmias.
  • the first antiarrhythmic drug, quinidine discovered in 1914, is classified as a sodium channel blocker.
  • Na v 1.6 encodes an abundant, widely distributed voltage-gated sodium channel found throughout the central and peripheral nervous systems, clustered in the nodes of Ranvier of neural axons (Caldwell, J. H., et al., Proc. Natl. Acad. Sci. USA (2000), 97(10): 5616-20). Although no mutations in humans have been detected, Na v 1.6 is thought to play a role in the manifestation of the symptoms associated with multiple sclerosis and has been considered as a target for the treatment of this disease (Craner, MJ. , et al., Proc. Natl. Acad. ScI. USA (2004), 101(21 ):8168-73).
  • Na/I .7 was first cloned from the pheochromocytoma PC12 cell line (Toledo- Aral, J. J., et al., Proc. Natl.Acad. Sci. USA (1997), 94:1527-1532). Its presence at high levels in the growth cones of small-diameter neurons suggested that it could play a role in the transmission of nociceptive information. Although this has been challenged by experts in the field as Na/I .7 is also expressed in neuroendocrine cells associated with the autonomic system (Klugbauer, N., et al., EMBO J. (1995), 14(6): 1084-90) and as such has been implicated in autonomic processes.
  • Na/1.7 blockers active in a subset of neurons is supported by the finding that two human heritable pain conditions, primary erythermalgia and familial rectal pain, have been shown to map to Na 1 Zl -7 (Yang, Y., et al., J. Med. Genet. (2004), 41 (3): 171 -4).
  • Na v 1.8 The expression of Na v 1.8 is essentially restricted to the DRG (Raymond, C. K., et al., op. cit). There are no identified human mutations for Na/I .8. However, Na v 1.8- null mutant mice were viable, fertile and normal in appearance. A pronounced analgesia to noxious mechanical stimuli, small deficits in noxious thermoreception and delayed development of inflammatory hyperalgesia suggested to the researchers that Na ⁇ /1.8 plays a major role in pain signalling (Akopian, A. N., et al., Nat. Neurosci. (1999), 2(6): 541-8).
  • WO03/037890A2 describes piperidines for the treatment of central or peripheral nervous system conditions, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions.
  • the compounds, compositions and methods of these inventions are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 (Nay1.8) subunit.
  • PN3 Neuronalpha 3
  • Dib-Hajj, S.D., et al. was shown to reside solely in the dorsal root ganglia. It has been demonstrated that Na v 1 -9 underlies neurotrophin (BDNF)-evoked depolarization and excitation, and is the only member of the voltage gated sodium channel superfamily to be shown to be ligand mediated (Blum, R., Kafitz, K.W., Konnerth, A., Nature (2002), 419 (6908):687-93).
  • BDNF neurotrophin
  • NaX is a putative sodium channel, which has not been shown to be voltage gated.
  • NaX is found in neurons and ependymal cells in restricted areas of the CNS, particularly in the circumventricular organs, which are involved in body-fluid homeostasis (Watanabe, E., et al., J. Neurosci. (2000), 20(20):7743-51 ).
  • NaX-null mice showed abnormal intakes of hypertonic saline under both water- and salt-depleted conditions.
  • TTX sodium channel blocker tetrodotoxin
  • Sodium channels are targeted by a diverse array of pharmacological agents. These include neurotoxins, antiarrhythmics, anticonvulsants and local anesthetics (Clare, J.J., et al., Drug Discovery Today (2000) 5:506-520). All of the current pharmacological agents that act on sodium channels have receptor sites on the alpha subunits. At least six distinct receptor sites for neurotoxins and one receptor site for local anesthetics and related drugs have been identified (Cestele, S. et al., Biochimie (2000), Vol. 82, pp. 883-892).
  • the small molecule sodium channel blockers or the local anesthetics and related antiepileptic and antiarrhythmic drugs interact with overlapping receptor sites located in the inner cavity of the pore of the sodium channel (Catterall, W.A., Neuron (2000), 26:13-25). Amino acid residues in the S6 segments from at least three of the four domains contribute to this complex drug receptor site, with the IVS6 segment playing the dominant role. These regions are highly conserved and as such most sodium channel blockers known to date interact with similar potency with all channel subtypes. Nevertheless, it has been possible to produce sodium channel blockers with therapeutic selectivity and a sufficient therapeutic window for the treatment of epilepsy (e.g.
  • Acute and Chronic Pain Drug therapy is the mainstay of management for acute and chronic pain in all age groups, including neonates, infants and children.
  • the pain drugs are classified by the American Pain Society into three main categories: 1) non-opioid analgesics- acetaminophen, and non-steroidal anti-inflammatory drugs (NSAIDs), including salicylates (e.g.
  • Non-opioid analgesics such as acetaminophen and NSAIDs are useful for acute and chronic pain due to a variety of causes including surgery, trauma, arthritis and cancer. NSAIDs are indicated for pain involving inflammation because acetaminophen lacks anti-inflammatory activity. Opioids also lack anti-inflammatory activity. All NSAIDs inhibit the enzyme cyclooxygenase (COX), thereby inhibiting prostaglandin synthesis and reducing the inflammatory pain response. There are at least two COX isoforms, COX-1 and COX-2. Common non-selective COX inhibitors include, ibuprofen and naproxen.
  • COX-1 which is found in platelets, Gl tract, kidneys and most other human tissues, is thought to be associated with adverse effects such as gastrointestinal bleeding.
  • selective COX-2 NSAIDs such as Celecoxib, Valdecoxib and Rofecoxib, have the benefits of nonselective NSAIDs with reduced adverse effect profiles in the gut and kidney.
  • opioid analgesics are recommended by the American Pain Society to be initiated based on a pain-directed history and physical that includes repeated pain assessment. Due to the broad adverse effect profiles associated with opiate use, therapy should include a diagnosis, integrated interdisciplinary treatment plan and appropriate ongoing patient monitoring. It is further recommended that opioids be added to non-opioids to manage acute pain and cancer related pain that does not respond to non-opioids alone. Opioid analgesics act as agonists to specific receptors of the mu and kappa types in the central and peripheral nervous system. Depending on the opioid and its formulation or mode of administration it can be of shorter or longer duration. All opioid analgesics have a risk of causing respiratory depression, liver failure, addiction and dependency, and as such are not ideal for long-term or chronic pain management.
  • Tricyclic antidepressants e.g. capsaicin
  • dextroamphetamine and phenothizines are all used in the clinic as adjuvant therapies or individually in the treatment of pain.
  • the antiepeileptic drugs in particular have enjoyed some success in treating pain conditions. For instance, Gabapentin, which has an unconfirmed therapeutic target, is indicated for neuropathic pain. Other clinical trials are attempting to establish that central neuropathic pain may respond to ion channel blockers such as blockers of calcium, sodium and/or NMDA (N-methyl-D- aspartate) channels.
  • ion channel blockers such as blockers of calcium, sodium and/or NMDA (N-methyl-D- aspartate) channels.
  • NMDA N-methyl-D- aspartate
  • Systemic analgesics such as NSAIDs and opioids are to be distinguished from therapeutic agents which are useful only as local analgesics/anaesthetics.
  • Well known local analgesics such as lidocaine and xylocaine are non-selective ion channel blockers which can be fatal when administered systemically.
  • a good description of non-selective sodium channel blockers is found in Madge, D. et al., J. Med. Chem. (2001 ), 44(2): 115-37.
  • TTX-S target brain tetradotoxin- sensitive sodium channels.
  • Such TTX-S agents suffer from dose- limiting side effects, including dizziness, ataxia and somnolence, primarily due to action at TTX-S channels in the brain.
  • neuropathic pain include, but are not limited to, post-herpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, chronic lower back pain, phantom limb pain, and pain resulting from cancer and chemotherapy, chronic pelvic pain, complex regional pain syndrome and related neuralgias.
  • neuropathic pain symptoms There has been some degree of success in treating neuropathic pain symptoms by using medications, such as gabapentin, and more recently pregabalin, as short-term, first-line treatments.
  • medications such as gabapentin
  • pregabalin as short-term, first-line treatments.
  • pharmacotherapy for neuropathic pain has generally had limited success with little response to commonly used pain reducing drugs, such as NSAIDS and opiates. Consequently, there is still a considerable need to explore novel treatment modalities.
  • the present invention provides compounds, methods of use and compositions that include these compounds to meet these critical needs.
  • the present invention is directed to spiro-oxindole compounds that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
  • the compounds of the present invention are also useful for the treatment of other sodium channel-mediated diseases or conditions, including, but not limited to central nervous conditions such as epilepsy, anxiety, depression and bipolar disease; cardiovascular conditions such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular conditions such as restless leg syndrome, essential tremour and muscle paralysis or tetanus; neuroprotection against stroke, glaucoma, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome.
  • the compounds of the present invention are also useful for the treatment and/or prevention of diseases or conditions, such as hypercholesterolemia, benign prostatic hyperplasia, pruritis, and cancer.
  • the invention provides compounds of formula (I):
  • each is independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R 6
  • R 7 is hydrogen, alkyl, haloalkyl, -R 9 -CN, -R 9 -OR 5 , -R 9 -N(R 4 )R 5 , aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R 6 and R 7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R 8 -CN, -R 8
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) m - (where m is 0, 1 or 2), -CF 2 -, -C(O)O-, -OC(O)-, -C(O)N(R 5 )- or -N(R 5 )C(O)-;
  • R la is hydrogen or -OR S.
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 ,
  • R 1 is aralkyl substituted by -C(O)N(R 6 )R 7 where:
  • R 6 is hydrogen, alkyl, aryl or aralkyl
  • R 7 is hydrogen, alkyl, haloalkyl, -R 9 -CN, -R 9 -OR 5 , -R 9 -N(R 4 )R 5 , aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R 6 and R 7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo,
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each R 2a and R 2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN,
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2a and R 2b may be independently optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, a
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 2a together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; or two adjacent R 2b together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl,
  • each R 3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalk
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R 4 and R 5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, hetero
  • X is N; Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -; and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m -R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • -N C(R 4 )R 5 , -S(O) m R 4 , -OS(O) 2 CF 3 , -R 8 -C(O)R 4 , -C(S)R 4 , -C(R 4 ) 2 C(O)R 5 , -R 8 -C(O)OR 4 , -C(S)OR 4 , -R 8 -C(O)N(R 4 )R 5 , -C(S)N(R 4 )R 5 , -N(R 5 )C(O)R 4 , -N(R 5 )C(S)R 4 , -N(R 5 )C(O)OR 4 , -N(R 5 )C(S)OR 4 , -N(R 5 )C(S)OR 4 , -N(R 5 )C(S)OR 4 , -N(R 5 )C(S)OR 4 , -N(
  • each R 3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalk
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R 4 and R 5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclyl
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • each R 2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO 2 , -R 8 -OR 5 , -R 8 -N(R 4
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO 2
  • each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
  • each R 4 and R 5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R 4 and R 5 are each attached to the same nitrogen atom, then R 4 and R 5 , together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R 8 is
  • the present invention provides compounds of formula (V):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • X is hydrogen or halo;
  • 3 annHd are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each R 2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl,
  • the present invention provides compounds of formula (Vl):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) m - (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ; is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • Y is aryl, heterocyclic or heteroaryl ring
  • Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R 6 )R 7 where: R 6 is hydrogen, alkyl, aryl or aralkyl; and R 7 is hydrogen, alkyl, haloal
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each R 2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aral
  • the present invention provides compounds of formula (VII):
  • t and q are each independently 0, 1 , 2, 3 or 4;
  • v is 1 , 2 or 3;
  • j and k are each independently 0, 1 , 2 or 3;
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-, -OC(O)-, -C(O)N(R 5 )- or -N(R 5 )C(O)-;
  • R 1a is hydrogen or -OR 5 ;
  • X is O or S
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R 6 )R 7 where: R 6 is hydrogen, alkyl, aryl or aralkyl; and R 7 is hydrogen, alkyl, haloal
  • R 1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R 8 -OR 5 , -C(O)OR 5 , halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R 1 is -R 9 -N(R 10 )R 11 , -R 9 -N(R 12 )C(O)R 11 or -R 9 -N(R 10 )C(O)N(R 10 )R 11 where: each R 10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R 11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocycl
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • the present invention provides compounds of formula (VIII): wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1, 2 or 3;
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) 1n - (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • Z is -N(R 5 )- or -O-;
  • R 1 is hydrogen, alky!, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each R 2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aral
  • t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3; Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • p is 1 , 2 or 3, wherein when p is 1 , v is 0, 1 , 2, 3, 4, 5 or 6, when p is 2, v is 0, 1 , 2, 3, 4, 5, 6, 7 or 8, and when p is 3, v is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO
  • each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN,
  • each R 4 and R 5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R 4 and R 5 are each attached to the same nitrogen atom, then R 4 and R 5 , together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R 8 is
  • the present invention provides compounds of formula (X):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-, -OC(O)-, -C(O)N(R 5 )- or -N(R 5 )C(O)-;
  • R is hydrogen or -OR 5 t>.. and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • X is O or S;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1
  • R 1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R 8 -OR 5 , -C(O)OR 5 , halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R 1 is -R 9 -N(R 10 )R 11 , -R 9 -N(R 12 )C(O)R 11 or -R 9 -N(R 10 )C(O)N(R 10 )R 11 where: each R 10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R 11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocycl
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each R 2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
  • each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO 2 , -R 8 -OR 5 , -R 8 -N(
  • the present invention provides compounds of formula (Xl):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ; is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • X is O or S;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)
  • R 6 is hydrogen, alkyl, aryl or aralkyl
  • R 7 is hydrogen, alkyl, haloalkyl, -R 9 -CN, -R 9 -OR 5 , -R 9 -N(R 4 )R 5 , aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R 6 and R 7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo,
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • the invention provides methods for the treatment of pain in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of Na/1.1 , Na v 1 -2, Na /I .3, Na /1.4, Na/I .5, Na v 1.6, Na/I .7, Na/I .8, or Na/I .9 is implicated in the disease state.
  • the invention provides methods of treating a range of sodium channel-mediated diseases or conditions, for example, pain associated with HIV, HIV treatment induced neuropathy, trigeminal neuralgia, post-herpetic neuralgia, eudynia, heat sensitivity, tosarcoidosis, irritable bowel syndrome, Crohns disease, pain associated with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), diabetic neuropathy, peripheral neuropathy, arthritic, rheumatoid arthritis, osteoarthritis, atherosclerosis, paroxysmal dystonia, myasthenia syndromes, myotonia, malignant hyperthermia, cystic fibrosis, pseudoaldosteronism, rhabdomyolysis, hypothyroidism, bipolar depression, anxiety, schizophrenia, sodium channel toxin related illnesses, familial erythermalgia, primary erythermalgia, familial rectal pain, cancer, epilepsy, partial and general tonic seizures
  • the invention provides methods of treating a range of sodium channel-mediated disease or condition through inhibition of ion flux through a voltage- dependent sodium channel in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
  • the invention provides methods of treating or preventing hypercholesterolemia in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
  • the invention provides methods of treating or preventing benign prostatic hyperplasia in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
  • the invention provides methods of treating or preventing pruritis in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
  • the invention provides methods of treating or preventing cancer in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
  • the invention provides pharmaceutical compositions comprising the compounds of the invention, as set forth above, and pharmaceutically acceptable excipients.
  • the present invention relates to a pharmaceutical composition comprising a compound of the invention in a pharmaceutically acceptable carrier and in an amount effective to treat diseases or conditions related to pain when administered to an animal, preferably a mammal, most preferably a human.
  • the invention provides pharmaceutical therapy in combination with one or more other compounds of the invention or one or more other accepted therapies or as any combination thereof to increase the potency of an existing or future drug therapy or to decrease the adverse events associated with the accepted therapy.
  • the present invention relates to a pharmaceutical composition combining compounds of the present invention with established or future therapies for the indications listed in the invention.
  • this invention is directed to the use of the compounds of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or the use of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the preparation of a medicament for the treatment of pain in a mammal.
  • this invention is directed to the use of the compounds of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or the use of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the preparation of a medicament for the treatment of sodium channel-mediated disease or condition in a mammal.
  • C 7 -Ci 2 alkyl describes an alkyl group, as defined below, having a total of 7 to 12 carbon atoms
  • C 4 -C 12 cycloalkylalkyl describes a cycloalkylalkyl group, as defined below, having a total of 4 to 12 carbon atoms.
  • the total number of carbons in the shorthand notation does not include carbons that may exist in substituents of the group described. For example, the following terms have the meaning indicated:
  • C 1 -C 1O aIRyI refers to an alRyl radical as defined below containing one to ten carbon atoms.
  • the C r C 10 alRyl readical may be optionally substituted as defined below for an alRyl group.
  • C 2 -C 12 alRynyl refers to an alRnyl radical as defined below containing two to twelve carbon atoms.
  • the C 2 -C 12 alRnyl radical may be optionally substituted as defined below for an alRenyl group.
  • CrC ⁇ alRoxy refers to an alRoxy radical as defined below containing one to twelve carbon atoms.
  • the alRyl part of the C 1 -C ⁇ aIRoXy radical may be optionally substituted as defined below for an alRyl group.
  • C 2 -C 12 alRoxyalRyl refers to an alRoxyalRyl radical as defined below containing two to twelve carbon atoms. Each alRyl part of the C 2 -C 12 alRoxyalRyl radical may be optionally substituted as defined below for an alRyl group.
  • C 7 -C 12 aralRyr' refers to an aralRyl group as defined below containing seven to twelve carbon atoms. The aryl part of the C 7 -C 12 aralRyl radical may be optionally substituted as described below for an aryl group. The alRyl part of the C 7 -C 12 aralRyl radical may be optionally substituted as defined below for an alRyl group.
  • C 7 -C 12 aralRenyl refers to an aralRenyl group as defined below containing seven to twelve carbon atoms.
  • the aryl part of the C 7 -C 12 aralRenyl radical may be optionally substituted as described below for an aryl group.
  • the alRenyl part of the C 7 -Ci 2 aralRenyl radical may be optionally substituted as defined below for an alRenyl group.
  • C 3 -C 12 cycloalRyl refers to a cycloalRyl radical as defined below having three to twelve carbon atoms.
  • the C 3 -C 12 cycloalRyl radical may be optionally substituted as defined below for a cycloalRyl group.
  • C 4 -C 12 cycloalRylalRyr refers to a cycloalRylalRyl radical as defined below having four to twelve carbon atoms.
  • the C 4 -C 12 cycloalRylalRyl radical may be optionally substituted as defined below for a cycloalRylalRyl group.
  • Amino refers to the -NH 2 radical.
  • Cyano refers to the -CN radical.
  • Hydroxyl refers to the -OH radical.
  • Neitro refers to the -NO 2 radical.
  • Trifluoromethyl refers to the -CF 3 radical.
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms, preferably one to eight carbon atoms or one to six carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (/so-propyl), n-butyl, /i-pentyl, 1 ,1-dimethylethyl (f-butyl), 3-methylhexyl, 2-methylhexyl, and the like.
  • an alkyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 14 , -OC(O)-R 14 , -N(R 14 ) 2 , -C(O)R 14 , -C(O)OR 14 , -C(O)N(R 14 ) 2 , -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (where t is 1 to 2), -S(O) 4 OR 16 (where t is 1 to 2), -S(O) 1 R 16 (where t is O to 2) and -S(O),N(R 14 )
  • Alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, e.g., ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1 ,4-dienyl, and the like.
  • an alkenyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 14 , -OC(O)-R 14 , -N(R 14 ) 2 , -C(O)R 14 , -C(O)OR 14 , -C(O)N(R 14 ) 2 , -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )C(O)R 16 ,
  • each R 14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R 16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted unless otherwise indicated.
  • Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
  • an alkylene chain may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 14 , -OC(O)-R 14 , -N(R 14 ) 2 , -C(O)R 14 , -C(O)OR 14 , -C(O)N(R 14 ) 2 , -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (where t is 1 to 2), -S(O) 1 OR 16 (where t is 1 to 2), -S(O) 1 R 16 (where t is O to 2) and -S(O) t N(R 14
  • alkenylene or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one double bond and having from two to twelve carbon atoms, e.g., ethenylene, propenylene, /i-butenylene, and the like.
  • the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond.
  • the points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
  • an alkenylene chain may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 14 , -OC(O)-R 14 , -N(R 14 ) 2 , -C(O)R 14 , -C(O)OR 14 , -C(O)N(R 14 ) 2 , -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (where t is 1 to 2), -S(O) t OR 16 (where t is 1 to 2), -S(O) 1 R 16 (where t is O to 2) and -S(O),N(R 14 , -OC(O)
  • Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one triple bond and having from two to twelve carbon atoms, e.g., propynylene, n-butynylene, and the like.
  • the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond.
  • the points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
  • an alkynylene chain may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 14 , -OC(O)-R 14 , -N(R 14 ) 2 , -C(O)R 14 , -C(O)OR 14 , -C(O)N(R 14 ) 2 , -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (where t is 1 to 2), -S(O) 4 OR 16 (where t is 1 to 2), -S(O) 1 R 16 (where t is O to 2) and -S(O) t N(
  • Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • an alkynyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -OR 14 , -OC(O)-R 14 , -N(R 14 ) 2 , -C(O)R 14 , -C(O)OR 14 , -C(O)N(R 14 ) 2 , -N(R 14 )C(O)OR 16 , -N(R 14 )C(O)R 16 , -N(R 14 )S(O) t R 16 (where t is 1 to 2), -S(O) 1 OR 16 (where t is 1 to 2), -S(O) 1 OR 16 (
  • Alkoxy refers to a radical of the formula -OR a where R 3 is an alkyl radical as defined above containing one to twelve carbon atoms.
  • the alkyl part of the alkoxy radical may be optionally substituted as defined above for an alkyl radical.
  • Alkoxyalkyl refers to a radical of the formula -R 3 -O-R 3 where each R 3 is independently an alkyl radical as defined above.
  • the oxygen atom may be bonded to any carbon in either alkyl radical.
  • Each alkyl part of the alkoxyalkyl radical may be optionally substituted as defined above for an alkyl group.
  • Aryl refers to aromatic monocyclic or multicyclic hydrocarbon ring system consisting only of hydrogen and carbon and containing from 6 to 18 carbon atoms, where the ring system may be partially saturated.
  • Aryl groups include, but are not limited to groups such as fluorenyl, phenyl and naphthyl.
  • aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals optionally substituted by one or more substituents independently selected from the group consisting of alkyl, akenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl, heteroaryl, heteroarylalkyl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R 14 ) 2 , -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 ) 2 , -R 15 -N(R 14 )C(O)OR 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N(R 14 )C(O)R 16 , -R 15 -N
  • Alkyl refers to a radical of the formula -R 3 R b where R 3 is an alkyl radical as defined above and R b is one or more aryl radicals as defined above, e.g., benzyl, diphenylmethyl and the like.
  • the aryl radical(s) may be optionally substituted as described above.
  • Aryloxy refers to a radical of the formula -OR b where R b is an aryl group as defined above.
  • R b is an aryl group as defined above.
  • the aryl part of the aryloxy radical may be optionally substituted as defined above.
  • Alkenyl refers to a radical of the formula -R c R b where R c is an alkenyl radical as defined above and R b is one or more aryl radicals as defined above, which may be optionally substituted as described above.
  • the aryl part of the aralkenyl radical may be optionally substituted as described above for an aryl group.
  • the alkenyl part of the aralkenyl radical may be optionally substituted as defined above for an alkenyl group.
  • “Aralkyloxy” refers to a radical of the formula -OR b where R b is an aralkyl group as defined above.
  • the aralkyl part of the aralkyloxy radical may be optionally substituted as defined above.
  • “Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
  • Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptly, and cyclooctyl.
  • Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
  • cycloalkyl is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, oxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R 14 ) 2 , -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 ) 2 , -R 15 -N(R 14 )C(O)OR 16 , -R 15 -
  • Cycloalkylalkyl refers to a radical of the formula -R 3 Rd where R 3 is an alkyl radical as defined above and R d is a cycloalkyl radical as defined above.
  • the alkyl radical and the cycloalkyl radical may be optionally substituted as defined above.
  • “Fused” refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
  • a fused ring can be represented by, for
  • Halo refers to bromo, chloro, fluoro or iodo.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 -fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl and the like.
  • the alkyl part of the haloalkyl radical may be optionally substituted as defined above for an alkyl group.
  • Heterocyclyl refers to a stable 3- to 18-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized; and the heterocyclyl radical may be partially or fully saturated.
  • heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1 ,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and
  • heterocyclyl is meant to include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R 14 ) 2 , -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 ) 2 , -R 15 -N(R 14 )C(O)OR 16 , -R 15 -C(O)N(R
  • Heterocyclylalkyl refers to a radical of the formula -R a R e where R 3 is an alkyl radical as defined above and R e is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl radical at the nitrogen atom.
  • the alkyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for an alkyl group.
  • the heterocyclyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for a heterocyclyl group.
  • Heteroaryl refers to a 5- to 18-membered aromatic ring radical which consists of one to seventeen carbon atoms and from one to ten heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[ ⁇ ][1 ,4]dioxepinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1 ,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothioph
  • heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, oxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 15 -OR 14 , -R 15 -OC(O)-R 14 , -R 15 -N(R 14 ) 2> -R 15 -C(O)R 14 , -R 15 -C(O)OR 14 , -R 15 -C(O)N(R 14 ) 2 , -R 15 -N
  • Heteroarylalkyl refers to a radical of the formula -R a R f where R a is an alkyl radical as defined above and R f is a heteroaryl radical as defined above.
  • the heteroaryl part of the heteroarylalkyl radical may be optionally substituted as defined above for a heteroaryl group.
  • the alkyl part of the heteroarylalkyl radical may be optionally substituted as defined above for an alkyl group.
  • Heteroarylalkenyl refers to a radical of the formula -R b R f where R b is an alkenyl radical as defined above and R f is a heteroaryl radical as defined above.
  • the heteroaryl part of the heteroarylalkenyl radical may be optionally substituted as defined above for a heteroaryl group.
  • the alkenyl part of the heteroarylalkenyl radical may be optionally substituted as defined above for an alkenyl group.
  • Trihaloalkyl refers to an alkyl radical, as defined above, that is substituted by three halo radicals, as defined above, e.g., trifluoromethyl.
  • the alkyl part of the trihaloalkyl radical may be optionally substituted as defined above for an alkyl group.
  • Trihaloalkoxy refers to a radical of the formula -OR 9 where R 9 is a trihaloalkyl group as defined above.
  • the trihaloalkyl part of the trihaloalkoxy group may be optionally substituted as defined above for a trihaloalkyl group.
  • Analgesia refers to an absence of pain in response to a stimulus that would normally be painful.
  • Allodynia refers to a condition in which a normally innocuous sensation, such as pressure or light touch, is perceived as being extremely painful.
  • Prodrugs is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention.
  • prodrug refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable.
  • a prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention.
  • Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood.
  • the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam)).
  • prodrugs are provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
  • prodrug is also meant to include any covalently bonded carriers, which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.
  • Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the invention and the like.
  • the invention disclosed herein is also meant to encompass all pharmaceutically acceptable compounds of any of formulae (l)-(XI)being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 O, 18 0, 31 P, 32 P, 35 S, 18 F, 36 CI, 123 I, and 125 I, respectively.
  • radiolabeled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action on the sodium channels, or binding affinity to pharmacologically important site of action on the sodium channels.
  • Certain isotopically-labelled compounds of any of formulae (I)-(XI)), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Isotopically-labeled compounds of any of formulae (l)-(XI) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples and Preparations as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • the invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reducation, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically are identified by administering a radiolabeled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its coversion products from the urine, blood or other biological samples.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • “Mammal” includes humans and both domestic animals such as laboratory animals and household pets, (e.g. cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildelife and the like.
  • Optional or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
  • optionally substituted aryl means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
  • “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1 ,2-disulfonic
  • “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, ⁇ /-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic bases are is
  • solvate refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
  • the solvent may be water, in which case the solvate may be a hydrate.
  • the solvent may be an organic solvent.
  • the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesqui hydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms.
  • the compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
  • a “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
  • “Therapeutically effective amount” refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of a sodium channel-mediated disease or condition in the mammal, preferably a human.
  • a compound of the invention which constitutes a "therapeutically effective amount” will vary depending on the compound, the condition and its severity, the manner of administration, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • Treating covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes: (i) preventing the disease or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it;
  • disease and condition may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
  • the compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centres and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallisation.
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
  • a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
  • the present invention includes tautomers of any said compounds.
  • intermediate compounds of any of formulae (I)-(XI) and all polymorphs of the aforementioned species and crystal habits thereof are intermediate compounds of any of formulae (I)-(XI) and all polymorphs of the aforementioned species and crystal habits thereof.
  • the chemical naming protocol and structure diagrams used herein are a modified form of the I. U. P. A. C. nomenclature system, using the ACD/Name Version 9.07 software program and/or ChemDraw Version 10.0 software naming program, wherein the compounds of the invention are named herein as derivatives of the central core structure, i.e., the 2-oxindole structure.
  • a substituent group is named before the group to which it attaches.
  • cyclopropylethyl comprises an ethyl backbone with cyclopropyl substituent.
  • each is independently a fused aryl ring, a fused heterocyclyl ring or a fused heteroaryl ring;
  • Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R 6
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each R 2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl
  • One embodiment provides compounds of formula (I), wherein: v is 1 ;
  • one is a fused aryl ring and the other a fused heterocyclic ring or a fused heteroaryl ring;
  • R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)R 5 , -R 8 -N(R 4 )R 5 , -R 8 -C(O)N(R 4 )R 5 , -R 8 -N(R 5 )C(O)R 4 , -R 8 -S(O) m R 4 (where m is 0, 1 or 2), -R 8 -CN or -R 8 -NO 2
  • Another embodiment provides compounds of formula (I), wherein: v is 1 ;
  • R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)R 5 , -R 8 -N(R 4 )R 5 , -R 8 -C(O)N(R 4 )R 5 , -R 8 -N(R 5 )C(O)R 4 , -R 8 -S(O) m R 4 (where m is 0, 1 or 2), -R 8 -CN or -R 8 -NO 2
  • the invention provides compounds of formula (II):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • a annHd are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m -R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)
  • each R 2a and R 2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO 2 , -R 8 -OR 5 , -R 8 -N(R 4 )R 5 ,
  • -N C(R 4 )R 5 , -S(O) m R 4 , -OS(O) 2 CF 3 , -R 8 -C(O)R 4 , -C(S)R 4 , -C(R 4 ) 2 C(O)R 5 , -R 8 -C(O)OR 4 , -C(S)OR 4 , -R 8 -C(O)N(R 4 )R 5 , -C(S)N(R 4 )R 5 , -N(R 5 )C(O)R 4 , -N(R 5 )C(S)R 4 , -N(R 5 )C(O)OR 4 , -N(R 5 )C(S)OR 4 , -N(R 5 )C(S)OR 4 , -N(R 5 )C(S)OR 4 , -N(R 5 )C(S)OR 4 , -N(
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN,
  • R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 ,
  • R 8 -C(O)R 5 R 8 -C(O)R 5 , -R 8 -N(R 4 )R 5 , -R 8 -C(O)N(R 4 )R 5 , -R 8 -N(R 5 )C(O)R 4 ,-R 8 -S(O) m R 4 (where m is 0, 1 or 2), -R 8 -CN or -R 8 -NO 2 ; each R 2 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; and two adjacent R 3 together with the carbon ring atoms to which they are directly attached, form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • Another embodiment provides compounds of formula (II), wherein: j is 0 and k is 1 ; Q is -O-;
  • R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 ,
  • each R 3 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; or two adjacent R 3 together with the carbon ring atoms to which they are directly attached, form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; and each R 2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy. Specific examples of this embodiment include, but are not limited to, the following compounds:
  • the invention provides compounds of formula (III):
  • p and q are each independently 0, 1 , 2, 3 or 4; v is 0, 1 or 2; represents an optional double bond;
  • X is N; Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -; and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m -R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or
  • R 1 is aralkyl substituted by -C(O)N(R 6 )R 7 where: R 6 is hydrogen, alkyl, aryl or aralkyl; and
  • R 7 is hydrogen, alkyl, haloalkyl, -R 9 -CN, -R 9 -OR 5 , -R 9 -N(R 4 )R 5 , aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R 6 and R 7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R 8 -CN, -R 8
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl,
  • X is N;
  • R 1 is hydrogen, aikyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m -R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclylalkyl or the heteroarylalkyl group is optionally substituted by one or more substituents selected from
  • Z is -C(O)- or -C(S)-;
  • X is C
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m -R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclylalkyl or the heteroarylalkyl group is optionally substituted by one or more substituents selected from the group consisting of oxo
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl,
  • a further embodiment provides compounds of formula (III), wherein: v is 1 ; X is C; D is N;
  • Z is -C(O)- or -C(S)-;
  • each and v — ' are independently a fused aryl ring or a fused heteroaryl ring. Specific examples of this embodiment include, but are not limited to, the following compounds:
  • the invention provides compounds of formula (IV):
  • t and q are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3; Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) m - (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO
  • each R 2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO 2 , -R 8 -OR 5 , -R 8 -
  • One embodiment provides compounds of formula (IV), wherein: j is 0; k is 1;
  • Another embodiment provides compounds of formula (IV), wherein: j is O; k is 1 ; Q is -O-;
  • Another embodiment provides compounds of formula (IV), wherein: j is O; k is 1 ; Q is -O-;
  • Another embodiment provides compounds of formula (IV), wherein: j is O; k is 1 ; Q is -O-;
  • the invention provides compounds of formula (V):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) m - (where m is 0, 1 or 2), -CF 2 -, -C(O)O-
  • R 1a is hydrogen or -OR 5 ;
  • X is hydrogen or halo;
  • Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-O-
  • R 7 is hydrogen, alkyl, haloalkyl, -R 9 -CN, -R 9 -OR 5 , -R 9 -N(R 4 )R 5 , aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R 6 and R 7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R 8 -CN, -R 8
  • each R 2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, ary
  • One embodiment provides compounds of formula (V), wherein: j is O; k is O; p is 2; Q is -O- or -NH-;
  • X is hydrogen or fluoro
  • R 1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)R 5 , -R 8 -N(R 4 )R 5 , -R 8 -C(O)N(R 4 )R 5 , -R 8 -N(R 5 )C(O)R 4 , -R 8 -S(O) m R 4 (where m is 0, 1 or 2), -R 8 -CN or -R 8 -NO 2
  • Another embodiment provides compounds of formula (V), wherein: j is O; k is O;
  • Q is -O-, -S(O) m - (m is 0 or 2) or -NH-;
  • X is hydrogen or fluoro
  • R 1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)R 5 , -R 8 -N(R 4 )R 5 , -R 8 -C(O)N(R 4 )R 5 , -R 8 -N(R 5 )C(O)R 4 , -R 8 -S(O) m R 4 (where m is 0, 1 or 2), -R 8 -CN, or -R 8 -NO 2
  • Another embodiment provides compounds of formula (V), wherein: j is O; k is O; P is 2;
  • Q is -O-, -S- or -NH-;
  • X is hydrogen or fluoro;
  • R 1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alky!, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)R 5 , -R 8 -N(R 4 )R 5 , -R 8 -C(O)N(R 4 )R 5 , -R 8 -N(R 5 )C(O)R 4 , -R 8 -S(O) m R 4 (where m is 0, 1 or 2), -R 8 -CN or -R 8 -NO 2
  • Another embodiment provides compounds of formula (V), wherein: j is O; k is O;
  • Q is -O-, -S- or -NH-;
  • X is hydrogen or fluoro
  • R 1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)R 5 , -R 8 -N(R 4 )R 5 , -R 8 -C(O)N(R 4 )R 5 , -R 8 -N(R 5 )C(O)R 4 , -R 8 -S(O) m R 4 (where m is 0, 1 or 2), -R 8 -CN or -R 8 -NO 2
  • the invention provides compounds of formula (Vl):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) 1n - (where m is O 1 1 or 2), -CF 2 -, -C(O)O-, -OC(O)-, -C(O)N(R 5 )- or -N(R 5 )C(O)-;
  • R 1a is hydrogen or -OR 5 ; is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • Y is aryl, heterocyclic or heteroaryl ring;
  • Z is -C(O)-, -C(S)-, -S(O)- or -S(O) 2 -;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is O, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R 6 )R 7 where: R 6 is hydrogen, alkyl, aryl or aralkyl; and R 7 is hydrogen, alkyl, halo
  • R 1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R 8 -OR 5 , -C(O)OR 5 , halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R 1 is -R 9 -N(R 10 )R 11 , -R 9 -N(R 12 )C(O)R 11 or -R 9 -N(R 10 )C(O)N(R 10 )R 11 where: each R 10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R 11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocycl
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • One embodiment provides compounds of formula (Vl), wherein: j is O; k is 2; Q is -O-; Z is -C(O)-; is a fused aryl ring; and Y is aryl or heteroaryl.
  • Another embodiment provides compounds of formula (Vl), wherein: j is O; k is 2; Q is -O-; Z is -C(O)-; is a fused heteroaryl ring; and Y is aryl or heteroaryl.
  • the invention provides compounds of formula (VII):
  • t and q are each independently 0, 1, 2, 3 or 4; v is 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3; Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ; and v — ' are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • X is O or S;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(
  • R 1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R 8 -OR 5 , -C(O)OR 5 , halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R 1 is -R 9 -N(R 10 )R 11 , -R 9 -N(R 12 )C(O)R 11 or -R 9 -N(R 10 )C(O)N(R 10 )R 11 where: each R 10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R 11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocycl
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO 2
  • each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO 2 , -R 8 -OR 5 , -R 8 -N(
  • One embodiment provides compounds of formula (VII), wherein: j is 0; k is 1 ; v is 1 ; X is O or S;
  • aryl ring is a fused aryl ring; and is a fused heteroaryl ring or a fused aryl ring.
  • Another embodiment provides compounds of formula (VII), wherein: j is O; k is 1; v is 1 ; X is O or S;
  • the invention provides compounds of formula (VIII):
  • t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3; Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • Z is -N(R 5 )- or -O-;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN,
  • each R 4 and R 5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R 4 and R 5 are each attached to the same nitrogen atom, then R 4 and R 5 , together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R 8 is
  • One embodiment provides compounds of formula (VIII), wherein: j is O; k is 1 ; Z is -O-; Q is -O-; X is O or S; and and and v — ' are each independently a fused aryl ring or a fused heteroaryl ring.
  • Specific examples of this aspect include, but are not limited to, the following compounds:
  • Another embodiment provides compounds of formula (VIII), wherein: j is O; k is 1 ; Z is -NH-; Q is -O-; X is O or S;
  • the invention provides compounds of formula (IX):
  • t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1, 2 or 3; Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) m - (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ;
  • p is 1 , 2 or 3, wherein when p is 1 , v is 0, 1 , 2, 3, 4, 5 or 6, when p is 2, v is 0, 1 , 2, 3, 4, 5, 6, 7 or 8; and when p is 3, v is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R 2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl,
  • One embodiment provides compounds of formula (IX), wherein: j is 0; k is 1 ; each R 2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
  • each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R 2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 8 -CN, -R 8 -NO
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and and are each independently a fused aryl ring.
  • Another embodiment provides compounds of formula (IX), wherein: j is O; k is 1 ; p is 1; v is 2, 3 or 4; Q is -O-;
  • each of the fused ring may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy and aryl.
  • substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy and aryl.
  • the invention provides compounds of formula (X):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-, -C(O)N(R 5 )- or -N(R 5 )C(O)-;
  • R 1a is hydrogen or -OR 5 ;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R 8 -C(O)R 5 , -R 8 -C(O)OR 5 , -R 8 -C(O)N(R 4 )R 5 , -S(O) 2 -R 5 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2 or -R 9 -O-R 9 -OR 5 ; or R 1 is aralkyl substituted by -C(O)N(R
  • R 7 is hydrogen, alkyl, haloalkyl, -R 9 -CN, -R 9 -OR 5 , -R 9 -N(R 4 )R 5 , aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R 6 and R 7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R 8 -CN, -R 8
  • each R 2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl,
  • each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R 2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aral
  • X is O or S; Q is -O-; and and are each independently a fused aryl ring.
  • Specific examples of this aspect include, but are not limited to, the following compounds:
  • Another embodiment provides compounds of formula (X), wherein: j is O; k is 1 ;
  • X is O or S; Q is -O-;
  • the invention provides compounds of formula (Xl):
  • Q is -C(R 1a )H-, -C(O)-, -O-, -N(R 5 )-, -S(O) n ,- (where m is 0, 1 or 2), -CF 2 -, -C(O)O-,
  • R 1a is hydrogen or -OR 5 ; is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
  • X is O or S;
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R a -C(O)R 5 , -R S -C(O)OR 5 , -R b -C(0)N(R 4 )R a , -S(O) 2 -R 3 , -R 9 -S(O) m R 5 (where m is 0, 1 or 2), -R 8 -OR 5 , -R 8 -CN, -R 9 -P(O)(OR 5 ) 2
  • R 6 is hydrogen, alkyl, aryl or aralkyl
  • R 7 is hydrogen, alkyl, haloalkyl, -R 9 -CN, -R 9 -OR 5 , -R 9 -N(R 4 )R 5 , aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R 6 and R 7 , together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R 6 and R 7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo,
  • R 12 is hydrogen, alkyl, aryl, arakyl or -C(O)R 5 ; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R 10 and R 11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R 8 -CN, -R 8 -OR 5 , -R 8 -C(O)R 5 , heterocyclyl and heteroaryl; or R 1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl,
  • One embodiment provides compounds of formula (Xl), wherein: j is 0; k is 1 ; q is 1 ; Q is -O-; X is O or S is a fused heteroaryl ring;
  • Another embodiment provides compounds of formula (XIV), wherein: j is O; k is 1 ; Q is -O-; X is O or S; q is 2; is a fused aryl ring; and two adjacent R 3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl.
  • One embodiment of the invention describes a method of treating or preventing hypercholesterolemia in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
  • Another embodiment of the invention describes a method of treating or preventing benign prostatic hyperplasia in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
  • Another embodiment of the invention describes a method of treating or preventing pruritis in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
  • Another embodiment of the invention describes a method of treating or preventing cancer in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
  • the present invention relates to compounds, pharmaceutical compositions and methods of using the compounds and pharmaceutical compositions for the treatment of sodium channel-mediated diseases, preferably diseases related to pain, central nervous conditions such as epilepsy, anxiety, depression and bipolar disease; cardiovascular conditions such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular conditions such as restless leg syndrome and muscle paralysis or tetanus; neuroprotection against stroke, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome, by administering to a patient in need of such treatment an effective amount of a sodium channel blocker modulating, especially inhibiting, agent.
  • diseases related to pain central nervous conditions
  • cardiovascular conditions such as arrhythmias, atrial fibrillation and ventricular fibrillation
  • neuromuscular conditions such as restless leg syndrome and muscle paralysis or tetanus
  • neuroprotection against stroke neural trauma and multiple sclerosis
  • channelopathies such as erythromyalgia and familia
  • the present invention provides a method for treating a patient for, or protecting a patient from developing, a sodium channel-mediated disease, especially pain, comprising administering to an animal, such as a mammal, especially a human patient in need thereof, a therapeutically effective amount of a compound of the invention or a pharmaceutical composition comprising a compound of the invention wherein the compound modulates the activity of one or more voltage-dependent sodium channels.
  • the general value of the compounds of the invention in mediating, especially inhibiting, the sodium channel ion flux can be determined using the assays described below in the Biological Assays section.
  • the general value of the compounds in treating conditions and diseases may be established in industry standard animal models for demonstrating the efficacy of compounds in treating pain. Animal models of human neuropathic pain conditions have been developed that result in reproducible sensory deficits (allodynia, hyperalgesia, and spontaneous pain) over a sustained period of time that can be evaluated by sensory testing. By establishing the degree of mechanical, chemical, and temperature induced allodynia and hyperalgesia present, several physiopathological conditions observed in humans can be modeled allowing the evaluation of pharmacotherapies.
  • ectopic activity in the injured nerve corresponds to the behavioural signs of pain.
  • intravenous application of the sodium channel blocker and local anesthetic lidocaine can suppress the ectopic activity and reverse the tactile allodynia at concentrations that do not affect general behaviour and motor function (Mao, J. and Chen, L. L, Pain (2000), 87:7-17). Allimetric scaling of the doses effective in these rat models, translates into doses similar to those shown to be efficacious in humans (Tanelian, D. L. and Brose, W. G., Anesthesiology (1991 ), 74(5):949-951 ).
  • Lidoderm® lidocaine applied in the form of a dermal patch
  • Sodium channel blockers have clinical uses in addition to pain. Epilepsy and cardiac arrhythmias are often targets of sodium channel blockers. Recent evidence from animal models suggest that sodium channel blockers may also be useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and in patients with multiple sclerosis (MS) (Clare, J.J. et al., op. cit. and Anger, T. et al., op. cit.).
  • MS multiple sclerosis
  • the compounds of the invention modulate, preferably inhibit, ion flux through a voltage-dependent sodium channel in a mammal, especially in a human. Any such modulation, whether it be partial or complete inhibition or prevention of ion flux, is sometimes referred to herein as “blocking” and corresponding compounds as “blockers”.
  • the compounds of the invention modulates the activity of a sodium channel downwards, inhibits the voltage-dependent activity of the sodium channel, and/or reduces or prevents sodium ion flux across a cell membrane by preventing sodium channel activity such as ion flux.
  • the compounds of the instant invention are sodium channel blockers and are therefore useful for treating diseases and conditions in humans and other organisms, including all those human diseases and conditions which are the result of aberrant voltage-dependent sodium channel biological activity or which may be ameliorated by modulation of voltage-dependent sodium channel biological activity.
  • a sodium channel-mediated disease or condition refers to a disease or condition which is ameliorated upon modulation of the sodium channel and includes, but is not limited to, pain, central nervous conditions such as epilepsy, anxiety, depression and bipolar disease; cardiovascular conditions such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular conditions such as restless leg syndrome and muscle paralysis or tetanus; neuroprotection against stroke, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome.
  • a sodium channel-mediated disease or condition also includes pain associated with HIV, HIV treatment induced neuropathy, trigeminal neuralgia, glossopharyngeal neuralgia, neuropathy secondary to metastatic infiltration, adiposis dolorosa, thalamic lesions, hypertension, autoimmune disease, asthma, drug addiction (e.g.
  • opiate benzodiazepine, amphetamine, cocaine, alcohol, butane inhalation
  • Alzheimer dementia, age-related memory impairment, Korsakoff syndrome, restenosis, urinary dysfunction, incontinence, parkinson's disease, cerebrovascular ischemia, neurosis, gastrointestinal disease, sickle cell anemia, transplant rejection, heart failure, myocardial infarction, reperfusion injury, intermittant claudication, angina, convulsion, respiratory disorders, cerebral or myocardial ischemias, long-QT syndrome, Catecholeminergic polymorphic ventricular tachycardia, ophthalmic diseases, spasticity, spastic paraplegia, myopathies, myasthenia gravis, paramyotonia congentia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, alopecia, anxiety disorders, psychotic disorders, mania, paranoia, seasonal affective disorder, panic disorder, obsessive compulsive disorder (OCD), phobia
  • pain refers to all categories of pain and is recognized to include, but is not limited to, neuropathic pain, inflammatory pain, nociceptive pain, idiopathic pain, neuralgic pain, orofacial pain, burn pain, burning mouth syndrome, somatic pain, visceral pain, myofacial pain, dental pain, cancer pain, chemotherapy pain, trauma pain, surgical pain, post-surgical pain, childbirth pain, labor pain, reflex sympathetic dystrophy, brachial plexus avulsion, neurogenic bladder, acute pain (e.g.
  • musculoskeletal and post-operative pain chronic pain, persistent pain, peripherally mediated pain, centrally mediated pain, chronic headache, migraine headache, familial hemiplegic migraine, conditions associated with cephalic pain, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, pain following stroke, thalamic lesions, radiculopathy.HIV pain, post-herpetic pain, non- cardiac chest pain, irritable bowel syndrome and pain associated with bowel disorders and dyspepsia, and combinations thereof.
  • the compounds identified in the instant specification inhibit the ion flux through a voltage-dependent sodium channel.
  • the compounds are state or frequency dependent modifers of the sodium channels, having a low affinity for the rested/closed state and a high affinity for the inactivated state. These compounds are likely to interact with overlapping sites located in the inner cavity of the sodium conducting pore of the channel similar to that described for other state-dependent sodium channel blockers (Cestele, S., et al., op. cit). These compounds may also be likely to interact with sites outside of the inner cavity and have allosteric effects on sodium ion conduction through the channel pore.
  • the present invention relates to compounds, pharmaceutical compositions and methods of using the compounds and pharmaceutical compositions for the treatment or prevention of diseaes or conditions such as benign prostatic hyperplasia (BPH) 1 hypercholesterolemia, cancer and pruritis (itch).
  • BPH benign prostatic hyperplasia
  • itch pruritis
  • Benign prostatic hyperplasia also known as benign prostatic hypertrophy, is one of the most common diseases affecting aging men.
  • BPH is a progressive condition which is characterized by a nodular enlargement of prostatic tissue resulting in obstruction of the urethra. Consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder, acute urinary retention and an increased incidence of urinary tract infection.
  • BPH has a high public health impact and is one of the most common reasons for surgical intervention among elderly men. Attempts have been made to clarify the etiology and pathogenesis and, to that end, experimental models have been developed. Spontaneous animal models are limited to the chimpanzee and the dog. BPH in man and the dog share many common features. In both species, the development of BPH occurs spontaneously with advanced age and can be prevented by early/prepubertal castration. A medical alternative to surgery is very desirable for treating BHP and the consequences.
  • prostatic epithelial hyperplasia in both man and the dog is androgen sensitive, undergoing involution with androgen deprivation and resuming epithelial hyperplasia when androgen is replaced.
  • Cells originating from the prostate gland have been shown to express high levels of voltage gated sodium channels, lmmunostaining studies clearly demonstrated evidence for voltage gated sodium channels in prostatic tissues (Prostate Cancer Prostatic Dis. 2005; 8(3):266-73).
  • Hypercholesterolemia i.e., elevated blood cholesterol
  • atherosclerosis coronary artery disease
  • hyperlipidemia stroke
  • hyperinsulinemias hypertension
  • obesity diabetes
  • CVD cardiovascular diseases
  • myocardial ischemia myocardial ischemia
  • heart attack lowering the levels of total serum cholesterol in individuals with high levels of cholesterol has been known to reduce the risk of these diseases.
  • the lowering of low density lipoprotein cholesterol in particular is an essential step in the prevention of CVD.
  • the invention provides compounds which are useful as antihypercholesterolemia agents and their related conditions.
  • the present compounds may act in a variety of ways. While not wishing to be bound to any particular mechanism of action, the compounds may be direct or indirect inhibitors of the enzyme acyl CoA: cholesterol acyl transferase (ACAT) that results in inhibition of the esterification and transport of cholesterol across the intestinal wall. Another possibility may be that the compounds of the invention may be direct or indirect inhibitors of cholesterol biosynthesis in the liver. It is possible that some compounds of the invention may act as both direct or indirect inhibitors of ACAT and cholesterol biosynthesis.
  • acyl CoA cholesterol acyl transferase
  • Pruritus commonly known as itch
  • itch is a common dermatological condition. While the exact causes of pruritis are complex and poorly understood, there has long been acknowledged to have interactions with pain. In particular, it is believed that sodium channels likely communicate or propagate along the nerve axon the itch signals along the skin. Transmission of the itch impulses results in the unpleasant sensation that elicits the desire or reflex to scratch.
  • the mildly painful stimuli from scratching are effective in abolishing the itch sensation.
  • analgesics such as opioids can generate severe pruritus.
  • the antagonistic interaction between pain and itch can be exploited in pruritus therapy, and current research concentrates on the identification of common targets for future analgesic and antipruritic therapy.
  • itch or skin irritation include, but are not limited to: a) psoriatic pruritis, itch due to hemodyalisis, aguagenic pruritus, and itching caused by skin disorders (e.g., contact dermatitis), systemic disorders, neuropathy, psychogenic factors or a mixture thereof; b) itch caused by allergic reactions, insect bites, hypersensitivity (e.g., dry skin, acne, eczema, psoriasis), inflammatory conditions or injury; c) itch associated with vulvar vestibulitis; and d) skin irritation or inflammatory effect from administration of another therapeutic such as, for example, antibiotics, antivirals and antihistamines.
  • another therapeutic such as, for example, antibiotics, antivirals and antihistamines.
  • the compounds of the invention are also useful in treating or preventing certain hormone sensitive cancers, such as prostate cancer (adenocarcinoma), breast cancer, ovarian cancer, testicular cancer, thyroid neoplasia.
  • hormone sensitive cancers such as prostate cancer (adenocarcinoma), breast cancer, ovarian cancer, testicular cancer, thyroid neoplasia.
  • the voltage gated sodium channels have been demonstrated to be expressed in prostate and breast cancer cells. Up-regulation of neonatal Na(v)1.5 occurs as an integral part of the metastatic process in human breast cancer and could serve both as a novel marker of the metastatic phenotype and a therapeutic target (Clin. Cancer Res.2005, Aug. 1 ; 11(15): 5381-9).
  • Functional expression of voltage-gated sodium channel alpha-subunits, specifically Nav1.7 is associated with strong metastatic potential in prostate cancer (CaP) in vitro.
  • the compounds of the invention are also useful in treating or preventing symptoms associated with BPH such as, but not limited to, acute urinary retention and urinary tract infection.
  • the compounds of the invention are also useful in treating or preventing certain endocrine imbalances or endocrinopathies such as congenital adrenal hyperplasia , hyperthyroidism, hypothyroidism, osteoporosis, osteomalacia, rickets, Cushing's Syndrome, Conn's syndrome, hyperaldosteronism, hypogonadism, hypergonadism, infertility, fertility and diabetes.
  • certain endocrine imbalances or endocrinopathies such as congenital adrenal hyperplasia , hyperthyroidism, hypothyroidism, osteoporosis, osteomalacia, rickets, Cushing's Syndrome, Conn's syndrome, hyperaldosteronism, hypogonadism, hypergonadism, infertility, fertility and diabetes.
  • the present invention readily affords many different means for identification of sodium channel modulating agents that are useful as therapeutic agents. Identification of modulators of sodium channel can be assessed using a variety of in vitro and in vivo assays, e.g. measuring current, measuring membrane potential, measuring ion flux, (e.g. sodium or guanidinium), measuring sodium concentration, measuring second messengers and transcription levels, and using e.g., voltage-sensitive dyes, radioactive tracers, and patch-clamp electrophysiology.
  • in vitro and in vivo assays e.g. measuring current, measuring membrane potential, measuring ion flux, (e.g. sodium or guanidinium), measuring sodium concentration, measuring second messengers and transcription levels, and using e.g., voltage-sensitive dyes, radioactive tracers, and patch-clamp electrophysiology.
  • One such protocol involves the screening of chemical agents for ability to modulate the activity of a sodium channel thereby identifying it as a modulating agent.
  • a competitive binding assay with known sodium channel toxins such as tetrodotoxin, alpha-scorpion toxins, aconitine, BTX and the like, may be suitable for identifying potential therapeutic agents with high selectivity for a particular sodium channel.
  • the use of BTX in such a binding assay is well known and is described in McNeal, E.T., et al., J. Med. Chem. (1985), 28(3):381-8; and Creveling, C.R., et al., Methods in Neuroscience, Vol.8: Neurotoxins (Conn PM Ed) (1992), pp. 25-37, Academic Press, New York.
  • the assays can be carried out in cells, or cell or tissue extracts expressing the channel of interest in a natural endogenous setting or in a recombinant setting.
  • the assays that can be used include plate assays which measure Na+ influx through surrogate markers such as 14 C-guanidine influx or determine cell depolarization using fluorescent dyes such as the FRET based and other fluorescent assays or a radiolabeled binding assay employing radiolabeled aconitine, BTX, TTX or STX. More direct measurements can be made with manual or automated electrophysiology systems.
  • the guanidine influx assay is explained in more detail below in the Biological Assays section.
  • Throughput of test compounds is an important consideration in the choice of screening assay to be used. In some strategies, where hundreds of thousands of compounds are to be tested, it is not desirable to use low throughput means. In other cases, however, low throughput is satisfactory to identify important differences between a limited number of compounds. Often it will be necessary to combine assay types to identify specific sodium channel modulating compounds.
  • Electrophysiological assays using patch clamp techniques is accepted as a gold standard for detailed characterization of sodium channel compound interactions, and as described in Bean et al., op. tit. and Leuwer, M., et al., op. tit.
  • LTS manual low-throughput screening
  • MTS medium-throughput screening
  • HTS high-throughput screening
  • Planar electrodes are capable of achieving high- resistance, cells-attached seals followed by stable, low-noise whole-cell recordings that are comparable to conventional recordings.
  • a suitable instrument is the PatchXpress 7000A (Axon Instruments Inc, Union City, CA).
  • a variety of cell lines and culture techniques, which include adherent cells as well as cells growing spontaneously in suspension are ranked for seal success rate and stability.
  • Immortalized cells e.g. HEK and CHO
  • stably expressing high levels of the relevant sodium ion channel can be adapted into high-density suspension cultures.
  • assays can be selected which allow the investigator to identify compounds which block specific states of the channel, such as the open state, closed state or the resting state, or which block transition from open to closed, closed to resting or resting to open. Those skilled in the art are generally familiar with such assays.
  • Binding assays are also available, however these are of only limited functional value and information content. Designs include traditional radioactive filter based binding assays or the confocal based fluorescent system available from Evotec OAI group of companies (Hamburg, Germany), both of which are HTS. Radioactive flux assays can also be used. In this assay, channels are stimulated to open with veratridine or aconitine and held in a stabilized open state with a toxin, and channel blockers are identified by their ability to prevent ion influx. The assay can use radioactive 22 [Na] and 14 [C] guanidinium ions as tracers. FlashPlate & Cytostar-T plates in living cells avoids separation steps and are suitable for HTS. Scintillation plate technology has also advanced this method to HTS suitability.
  • HTS FLIPR system membrane potential kit
  • Sodium dyes can be used to measure the rate or amount of sodium ion influx through a channel. This type of assay provides a very high information content regarding potential channel blockers. The assay is functional and would measure Na+ influx directly. CoroNa Red, SBFI and/or sodium green (Molecular Probes, Inc. Eugene OR) can be used to measure Na influx; all are Na responsive dyes. They can be used in combination with the FLIPR instrument. The use of these dyes in a screen has not been previously described in the literature. Calcium dyes may also have potential in this format.
  • FRET based voltage sensors are used to measure the ability of a test compound to directly block Na influx.
  • HTS systems include the VIPRTM Il FRET system (Aurora Biosciences Corporation, San Diego, CA, a division of Vertex Pharmaceuticals, Inc.) which may be used in conjunction with FRET dyes, also available from Aurora Biosciences.
  • This assay measures sub-second responses to voltage changes. There is no requirement for a modifier of channel function.
  • the assay measures depolarization and hyperpolarizations, and provides ratiometric outputs for quantification.
  • a somewhat less expensive MTS version of this assay employs the FLEXstationTM (Molecular Devices Corporation) in conjunction with FRET dyes from Aurora Biosciences.
  • Other methods of testing the compounds disclosed herein are also readily known and available to those skilled in the art.
  • SAR SAR between test compounds and the sodium channel. Certain substituents on the core structure of the test compound tend to provide more potent inhibitory compounds. SAR analysis is one of the tools those skilled in the art may now employ to identify preferred embodiments of the compounds of the invention for use as therapeutic agents.
  • Modulating agents so identified are then tested in a variety of in vivo models so as to determine if they alleviate pain, especially chronic pain or other conditions such as arrhythmias, epilepsy, benign prostatic hyperplasia (BPH), hypercholesterolemia, cancer and pruritis (itch) with minimal adverse events.
  • BPH benign prostatic hyperplasia
  • itch pruritis
  • a successful therapeutic agent of the present invention will meet some or all of the following criteria.
  • Oral availability should be at or above 20%.
  • Animal model efficacy is less than about 0.1 ⁇ g to about 100 mg/Kg body weight and the target human dose is between 0.1 ⁇ g to about 100 mg/Kg body weight, although doses outside of this range may be acceptable ("mg/Kg” means milligrams of compound per kilogram of body mass of the subject to whom it is being administered).
  • the therapeutic index or ratio of toxic dose to therapeutic dose
  • the potency (as expressed by IC 50 value) should be less than 10 ⁇ M, preferably below 1 ⁇ M and most preferably below 50 nM.
  • the IC 50 is a measure of the amount of compound required to achieve 50% inhibition of ion flux through a sodium channel, over a specific time period, in an assay of the invention.
  • Compounds of the present invention in the guanidine influx assay have demonstrated IC-50s ranging from less than a nanomolar to less than 10 micromolar.
  • the compounds of the invention can be used in in vitro or in vivo studies as exemplary agents for comparative purposes to find other compounds also useful in treatment of, or protection from, the various diseases disclosed herein.
  • Another aspect of the invention relates to inhibiting Na v 1.1, Na/1.2, Na 1 /! .3,
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Inhibition of Na v 1.1 , Na/I .2, Na v 1.3, Na/I .4, Na v 1.5, Na/I .6, Na/I .7, Na*/I .8, or Na/I .9 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
  • compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
  • compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient.
  • Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units.
  • composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this invention.
  • a pharmaceutical composition of the invention may be in the form of a solid or liquid.
  • the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form.
  • the carrier(s) may be liquid, with the compositions being, for example, an oral syrup, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.
  • the pharmaceutical composition When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
  • the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
  • a solid composition will typically contain one or more inert diluents or edible carriers.
  • binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
  • excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like
  • lubricants such as magnesium stearate or Sterotex
  • glidants such as colloidal silicon dioxide
  • sweetening agents such as sucrose or saccharin
  • a flavoring agent such as peppermint, methyl sal
  • the pharmaceutical composition When the pharmaceutical composition is in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.
  • a liquid carrier such as polyethylene glycol or oil.
  • the pharmaceutical composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension.
  • the liquid may be for oral administration or for delivery by injection, as two examples.
  • preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
  • a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.
  • the liquid pharmaceutical compositions of the invention may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • Physiological saline is a preferred adjuvant.
  • a liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained. Typically, this amount is at least 0.01% of a compound of the invention in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition.
  • Preferred oral pharmaceutical compositions contain between about 4% and about 50% of the compound of the invention.
  • Preferred pharmaceutical compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10% by weight of the compound prior to dilution of the invention.
  • the pharmaceutical composition of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base.
  • the base for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
  • Thickening agents may be present in a pharmaceutical composition for topical administration.
  • the composition may include a transdermal patch or iontophoresis device.
  • Topical formulations may contain a concentration of the compound of the invention from about 0.1 to about 10% w/v (weight per unit volume).
  • the pharmaceutical composition of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug.
  • the composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient.
  • bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.
  • the pharmaceutical composition of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit.
  • the composition may include materials that form a coating shell around the active ingredients.
  • the materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents.
  • the active ingredients may be encased in a gelatin capsule.
  • the pharmaceutical composition of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound. Suitable agents that may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome.
  • the pharmaceutical composition of the invention may consist of dosage units that can be administered as an aerosol.
  • aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s).
  • the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit.
  • the pharmaceutical compositions of the invention may be prepared by methodology well known in the pharmaceutical art.
  • a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution.
  • a surfactant may be added to facilitate the formation of a homogeneous solution or suspension.
  • Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
  • the compounds of the invention are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.
  • a therapeutically effective daily dose is (for a 70 kg mammal) from about 0.001 mg/kg (Ae., 0.7 mg) to about 100 mg/kg (Ae., 7.0 gm); preferaby a therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg/kg (Ae., 7 mg) to about 50 mg/kg (Ae., 3.5 gm); more preferably a therapeutically effective dose is (for a 70 kg mammal) from about 1 mg/kg (Ae., 70 mg) to about 25 mg/kg (Ae., 1.75 gm).
  • the total dose required for each treatment can be administered by multiple doses or in a single dose over the course of the day, if desired. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the diagnostic pharmaceutical compound or composition can be administered alone or in conjunction with other diagnostics and/or pharmaceuticals directed to the pathology, or directed to other symptoms of the pathology.
  • the recipients of administration of compounds and/or compositions of the invention can be any vertebrate animal, such as mammals.
  • the preferred recipients are mammals of the Orders Primate (including humans, apes and monkeys), Arteriodactyla (including horses, goats, cows, sheep, pigs), Rodenta (including mice, rats, rabbits, and hamsters), and Carnivora (including cats, and dogs).
  • the preferred recipients are turkeys, chickens and other members of the same order.
  • the most preferred recipients are humans.
  • compositions can be formulated as transdermal compositions or transdermal delivery devices ("patches"). Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive. Such transdermal patches may be used to provide continuous pulsatile, or on demand delivery of the compounds of the present invention as desired.
  • compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • Controlled release drug delivery systems include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770 and 4,326,525 and in P. J. Kuzma et al, Regional Anesthesia 22 (6): 543-551 (1997), all of which are incorporated herein by reference.
  • compositions of the invention can also be delivered through intra-nasal drug delivery systems for local, systemic, and nose-to-brain medical therapies.
  • Controlled Particle Dispersion (CPD)TM technology traditional nasal spray bottles, inhalers or nebulizers are known by those skilled in the art to provide effective local and systemic delivery of drugs by targeting the olfactory region and paranasal sinuses.
  • the invention also relates to an intravaginal shell or core drug delivery device suitable for administration to the human or animal female.
  • the device may be comprised of the active pharmaceutical ingredient in a polymer matrix, surrounded by a sheath, and capable of releasing the compound in a substantially zero order pattern on a daily basis similar to devises used to apply testosterone as desscribed in PCT Patent No. WO 98/50016.
  • the compounds of the invention may be usefully combined with one or more other compounds of the invention or one or more other therapeutic agent or as any combination thereof, in the treatment of sodium channel-mediated diseases and conditions.
  • a compound of formula (I) may be administered simultaneously, sequentially or separately in combination with other therapeutic agents, including, but not limited to: • opiates analgesics, e.g.
  • morphine heroin, cocaine, oxymorphine, levorphanol, levallorphan, oxycodone, codeine, dihydrocodeine, propoxyphene, nalmefene, fentanyl, hydrocodone, hydromorphone, meripidine, methadone, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine and pentazocine; • non-opiate analgesics, e.g. acetomeniphen, salicylates (e.g. aspirin);
  • nonsteroidal antiinflammatory drugs e.g. ibuprofen, naproxen, fenoprofen, ketoprofen, celecoxib, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin and zomepirac;
  • NSAIDs nonsteroidal antiinflammatory drugs
  • anticonvulsants e.g. carbamazepine, oxcarbazepine, lamotrigine, valproate, topiramate, gabapentin and pregabalin;
  • antidepressants such as tricyclic antidepressants, e.g. amitriptyline, clomipramine, despramine, imipramine and nortriptyline;
  • COX-2 selective inhibitors e.g. celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, and lumiracoxib;
  • alpha-adrenergics e.g. doxazosin, tamsulosin, clonidine, guanfacine, dexmetatomidine, modafinil, and 4-amino-6,7-dimethoxy-2-(5- methane sulfonamido-1 ,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline;
  • barbiturate sedatives e.g. amobarbital, aprobarbital, butabarbital, butabital, mephobarbital, metharbital, methohexital, pentobarbital, phenobartital, secobarbital, talbutal, theamylal and thiopental; • tachykinin (NK) antagonist, particularly an NK-3, NK-2 or NK-1 antagonist, e.g.
  • NK chykinin
  • coal-tar analgesics in particular paracetamol
  • serotonin reuptake inhibitors e.g. paroxetine, sertraline, norfluoxetine (fluoxetine desmethyl metabolite), metabolite demethylsertraline, "3 fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine, trazodone and fluoxetine;
  • serotonin reuptake inhibitors e.g. paroxetine, sertraline, norfluoxetine (fluoxetine desmethyl metabolite), metabolite demethylsertraline, "3 fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenflur
  • noradrenaline (norepinephrine) reuptake inhibitors e.g. maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, buproprion, buproprion metabolite hydroxybuproprion, nomifensine and viloxazine (Vivalan®)), especially a selective noradrenaline reuptake inhibitor such as reboxetine, in particular (S,S)-reboxetine, and venlafaxine duloxetine neuroleptics sedative/anxiolytics; • dual serotonin-noradrenaline reuptake inhibitors, such as venlafaxine, venlafaxine metabolite O- desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine, milnacipran and imipramine;
  • acetylcholinesterase inhibitors such as donepezil
  • 5-HT3 antagonists such as ondansetron
  • mGluR metabotropic glutamate receptor
  • corticosteroid such as dexamethasone
  • antiarrhythmics e.g. mexiletine and phenytoin
  • muscarinic antagonists e.g., tolterodine, propiverine, tropsium t chloride, darifenacin, solifenacin, temiverine and ipratropium;
  • vanilloid receptor agonists e.g. resinferatoxin
  • antagonists e.g. capsazepine
  • sedatives e.g. glutethimide, meprobamate, methaqualone, and dichloralphenazone
  • antidepressants such as mirtazapine
  • topical agents e.g. lidocaine, capsacin and resiniferotoxin
  • muscle relaxants such as benzodiazepines, baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol and orphrenadine;
  • Sodium channel-mediated diseases and conditions that may be treated and/or prevented using such combinations include but not limited to, pain, central and peripherally mediated, acute, chronic, neuropathic as well as other diseases with associated pain and other central nervous disorders such as epilepsy, anxiety, depression and bipolar disease; or cardiovascular disorders such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular disorders such as restless leg syndrome and muscle paralysis or tetanus; neuroprotection against stroke, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome.
  • “combination” refers to any mixture or permutation of one or more compounds of the invention and one or more other compounds of the invention or one or more additional therapeutic agent. Unless the context makes clear otherwise, “combination” may include simultaneous or sequentially delivery of a compound of the invention with one or more therapeutic agents. Unless the context makes clear otherwise, “combination” may include dosage forms of a compound of the invention with another therapeutic agent. Unless the context makes clear otherwise, “combination” may include routes of administration of a compound of the invention with another therapeutic agent. Unless the context makes clear otherwise, “combination” may include formulations of a compound of the invention with another therapeutic agent. Dosage forms, routes of administration and pharmaceutical compositions include, but are not limited to, those described herein.
  • kits that contain a pharmaceutical composition which includes one or more compounds of the above formulae.
  • the kit also includes instructions for the use of the pharmaceutical composition for modulating the activity of ion channels, for the treatment of pain, as well as other utilities as disclosed herein.
  • a commercial package will contain one or more unit doses of the pharmaceutical composition.
  • a unit dose may be an amount sufficient for the preparation of an intravenous injection.
  • compounds which are light and/or air sensitive may require special packaging and/or formulation.
  • packaging may be used which is opaque to light, and/or sealed from contact with ambient air, and/or formulated with suitable coatings or excipients.
  • Suitable protecting groups include hydroxy, amino, mercapto and carboxylic acid.
  • Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (e.g., f-butyldimethylsilyl, f-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like.
  • Suitable protecting groups for amino, amidino and guanidino include f-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or arylalkyl), p-methoxybenzyl, trityl and the like.
  • Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.
  • Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P. G. M.
  • the protecting group may also be a polymer resin such as a Wang resin or a 2-chlorotrityl- chloride resin.
  • R 1 , R 2 and R 3 are defined as in the Specification unless specifically defined otherwise.
  • X is Cl or Br.
  • R" is an alkyl group.
  • one v -—-' is a fused aryl ring and the
  • v — J is a fused furan ring and can be synthesized following the general procedure as described in REACTION SCHEME 1.1.
  • Compound (1.1-3) can be treated with a lithium base such as, but not limited to, n-butyllithium, sec-butyllithium or te/t-butyllithium at low temperature (0 0 C or -78 0 C) followed by reaction with zinc chloride to form the zinc intermediate (1.1-4) in situ.
  • a lithium base such as, but not limited to, n-butyllithium, sec-butyllithium or te/t-butyllithium at low temperature (0 0 C or -78 0 C
  • the coupling of intermediate (1.1- 4) and a halo compound (1.1-5) can be achieved in the presence of a palladium catalyst such as, but not limited to, tetrakis(triphenylphosphine)palladium(0), palladium acetate, or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'- bis(diphenylphosphino)ferrocene or 2-(di-terf-butylphosphino)biphenyl, in a solvent such as, but not limited to, dimethoxyethane, dioxane, or tetrahydrofuran to provide the coupled product (1.1-6).
  • a palladium catalyst such as, but not limited to, tetrakis(triphenylphosphine)palladium(0), pal
  • Compound (1.1-6) is treated with a base, such as, but not limited to, cesium carbonate or potassium carbonate in the presence of dihaloethane (1.1-7) such as, but not limited to, 1 ,2-diiodoethane to produce compound (1.1-8) as the formula (I) of the invention.
  • a base such as, but not limited to, cesium carbonate or potassium carbonate
  • dihaloethane (1.1-7) such as, but not limited to, 1 ,2-diiodoethane to produce compound (1.1-8) as the formula (I) of the invention.
  • the compounds of formula (II) of the invention where are each fused phenyl ring, Q is -O-, j is 0 and k is 1 can be synthesized following the general procedure as described in REACTION SCHEME 2.1.
  • Reaction of the acridone compound (2.1-1) with an electrophile (2.1-2) in the presence of a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, ⁇ /, ⁇ /-dimethylformamide provides compound (2.1-3).
  • a base such as, but not limited to, sodium hydride or cesium carbonate
  • a solvent such as, but not limited to, tetrahydrofuran, acetone, ⁇ /, ⁇ /-dimethylformamide
  • the removal of the hydroxyl group at the C-9 position can be achieved by treating compound (2.1-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (2.1-6) with thionyl chloride and triethylamine then reduction with zinc dust to give compound (2.1-7).
  • Compound (2.1-7) is treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide, sodium hydride or sodium hydroxide followed by reaction with paraformaldehyde to generate the hydroxymethyl intermediate (2.1-8).
  • a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine
  • an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate or di- terf-but
  • the removal of the hydroxyl group at the C-3 position can be achieved by treating compound (3.1-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (3.1-6) with thionyl chloride and triethylamine then reduction with zinc dust to give compound (3.1-7).
  • Compound (3.1-7) is treated with a base such as, but not limited to, sodium hydroxide, lithium hydroxide or ⁇ /, ⁇ /-diisopropylethylamine followed by reaction with ⁇ -halo acetonitrile (3.1-8) to generate the cyano intermediate (3.1-9).
  • the removal of the hydroxyl group at the C-3 position can be achieved by treating compound (3.2-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (3.2-6) with thionyl chloride and triethylamine then reduction with zinc dust to give compound (3.2-7).
  • Compound (3.2-7) is treated with a base such as, but not limited to, sodium hydroxide, lithium hydroxide or ⁇ /, ⁇ /-diisopropylethylamine followed by reaction with formaldehyde to generate the hydroxymethyl intermediate (3.2-8).
  • a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine
  • an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-
  • a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-tert-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofuran provides the cyclized product (3.2-10) as the formula (III) of the invention.
  • a ligand such as, but not limited to, tripheny
  • Compound (4.1-7) is treated with a dihalomethane (4.1-8) such as, but not limited to, iodochloromethane in the presence of a base such as, but not limited to, cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran or acetonitrile to afford the compound (4.1-9) as formula (IV) of the invention.
  • a dihalomethane (4.1-8) such as, but not limited to, iodochloromethane
  • a base such as, but not limited to, cesium carbonate
  • a solvent such as, but not limited to, tetrahydrofuran or acetonitrile
  • Reaction of the phenol compound (4.2-2) with a Grignard reagent (4.2-3) at low temperature (0 0 C) allows the formation of a phenoxymagnesium halide intermediate that can react with the keto-carbonyl group of the isatin compound (4.2-1) in a solvent, such as, but not limited to, tetrahydrofuran or dichloromethane to afford the oxindole compound (4.2-4).
  • a solvent such as, but not limited to, tetrahydrofuran or dichloromethane
  • the removal of the hydroxyl group at the C-3 position can be achieved by treating compound (4.2-4) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid.
  • compound (4.2-5) is treated with a silyl compound, such as, but not limited to, trimethylsilyl chloride, to generate the silyl ether intermediate which is treated with a metal reagent such as, but not limited to, ytterbium (III) trifluoromethanesulfonate or scandium (III) trifluoromethanesulfonate and formaldehyde to afford compound (4.2-6).
  • a metal reagent such as, but not limited to, ytterbium (III) trifluoromethanesulfonate or scandium (III) trifluoromethanesulfonate and formaldehyde
  • compound (4.2-5) can be treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide or sodium hydroxide followed by reaction with formaldehyde to generate compound (4.2-6).
  • a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine
  • an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-terf
  • chloroimine compound (4.2-8) Treatment of the spiro-compound (4.2-7) with phosphorous pentachloride in a solvent, such as, but not limited to, toluene affords chloroimine compound (4.2-8).
  • Compound (4.2-8) is treated with an azide reagent such as, but not limited to, hydrogen azide in a solvent such as, but not limited to, benzene to afford compound (4.2-9) as formula (IV) of the invention.
  • Compounds of formula (4.3-1) can react with an aryl or heteroaryl boronic acid (4.3-2) in the presence of a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine)palladium(0), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'- bis(diphenylphosphino)ferrocene or 2-(di-ter£-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, or tetrahedrofuran to provide the coupled product of
  • a palladium catalyst such
  • the removal of the hydroxyl group can be achieved by treating the compound (4.4-5) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid to generate the compound of formula (4.4-6).
  • a silane reagent such as triethylsilane
  • an acid such as, but not limited to, trifluoroacetic acid
  • Compound (4.4-6) can be treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide or sodium hydroxide followed by reaction with formaldehyde to generate compound (4.4-7).
  • a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine
  • an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodica
  • Reaction of the bromo compound (5.1-1) with an electrophile (5.1-2) in the presence of a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, ⁇ /, ⁇ /-dimethylformamide provides compound (5.1-3).
  • Reaction of an anion, generated from compound (5.1-4) and a base (5.1-5), with compound (5.1-3) in a solvent, such as, but not limited to, tetrahydrofuran gives compound (5.1-6).
  • the corresponding anion can be generated by treating compound (5.1-4) with a Grignard reagent such as, but not limited to, isopropylmagnesium chloride or phenylmagnesium chloride (5.1-5) at low temperature (0 0 C or -78 0 C).
  • a Grignard reagent such as, but not limited to, isopropylmagnesium chloride or phenylmagnesium chloride (5.1-5) at low temperature (0 0 C or -78 0 C).
  • Q is NBoc
  • the ortho anion can be generated by treating compound (5.1-4) with an alkyllithium reagent (5.1-5) such as, but not limited to, terf-butyllithium or n-butyllithium.
  • the removal of the hydroxyl group at the C-3 position can be achieved by treating compound (5.1-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (5.1-6) with thionyl chloride and triethylamine followed by reduction with zinc dust to give compound (5.1-7).
  • a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (5.1-6) with thionyl chloride and triethylamine followed by reduction with zinc dust to give compound (5.1-7).
  • fused aryl ring is fused aryl ring
  • Q is -O-
  • j is 0,
  • k is 2
  • Z is -C(O)-, or -C(S)-, and can be synthesized following the general procedure as described in REACTION SCHEME 6.1.
  • a Grignard reagent or alkyl lithium reagent such as, but not limited to, isopropylmagnesium chloride or n-butyllithium (6.1-5) at low temperature (0 0 C or -78 0 C) forms an anion that reacts with the keto-carbonyl group of the isatin compound (6.1-3) in a solvent, such as, but not limited to, tetrahydrofuran to afford the compound oxindole (6.1-6).
  • a protecting group (PG1 ) by employment of, such as, but not limited to, tert-butyl(chloro) dimethyl silane, chlorotrimethylsilane or chloromethyl methyl ether with a base, such as, but not limited to, imidazole, triethylamine or sodium hydride to give compound (6.1-7).
  • compound (6.1-7) is treated with an alkyl lithium reagent, such as, but not limited to, n-butyllithium, sec-butyllithium or tert-butyllithium at low temperature (0 0 C or -78 0 C), the anion is formed by metal-halogen exchange, which reacts with an alkyl halide (6.1-8), to afford compound (6.1-9).
  • an alkyl lithium reagent such as, but not limited to, n-butyllithium, sec-butyllithium or tert-butyllithium at low temperature (0 0 C or -78 0 C
  • the anion is formed by metal-halogen exchange, which reacts with an alkyl halide (6.1-8), to afford compound (6.1-9).
  • the protecting group, PG 1 and PG 2 are silyl group, they can be removed by treating with a fluoride reagent, such as, but not limited to, tetrabutylammonium fluoride or cesium flu
  • a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine
  • an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate or di-te/t
  • compound (6.1-11) can be treated with a sulfur reagent such as, but not limited to, 2,4- bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (6.1-12) as formula (Vl) of the invention.
  • a sulfur reagent such as, but not limited to, 2,4- bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (6.1-12) as formula (Vl) of the invention.
  • Compound (7.1-7) can be reduced to the corresponding alcohol using a reducing agent such as, but not limited to, diisobutylaluminum hydride, then oxidized to the aldehyde compound (7.1-8) with an oxidant such as, but not limited to, 1 ,1,1-tris(acetyloxy)1 ,1-dihydro-1,2- benziodoxol-3-(1f/)-one in a solvent, such as, but not limited to, methylene chloride.
  • a reducing agent such as, but not limited to, diisobutylaluminum hydride
  • an oxidant such as, but not limited to, 1 ,1,1-tris(acetyloxy)1 ,1-dihydro-1,2- benziodoxol-3-(1f/)-one in a solvent, such as, but not limited to, methylene chloride.
  • Reaction of compound (7.1-8) with a Wittig reagent (7.1-10) in a solvent, such as, but not limited to, methylene chloride, tetrahydrofuran or toluene provides compound (7.1- 11) after acidic hydrolysis.
  • the aldehyde compound (7.1-11) can be oxidized with an oxidant such as, but not limited to, pyridinium chlorochromate in a solvent, such as, but not limited to, methylene chloride or tetrahydrofuran.
  • the acid (7.1-12) can couple with an amine (7.1-13) under reaction conditions known to those skilled in the art to form the amide (7.1-14).
  • compound (7.1-15) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (7.1-16) as formula (VII) of the invention.
  • a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (7.1-16) as formula (VII) of the invention.
  • Compound (8.1-6) can be obtained by the treatment of compound (8.1-4) with an isocyanate reagent (8.1-5) in the presence of a base such as, but not limited to, trientyl amine in a solvent, such as, but not limited to, methylene chloride or tetrahydrofuran.
  • a base such as, but not limited to, trientyl amine
  • a solvent such as, but not limited to, methylene chloride or tetrahydrofuran.
  • the ester in compound (8.1-7) is reduced to the alcohol to generate compound (8.1-8) using a reducing reagent, such as, but not limited to, sodium boron hydride in a solvent, such as, but not limited to, methanol.
  • a reducing reagent such as, but not limited to, sodium boron hydride in a solvent, such as, but not limited to, methanol.
  • Compound (8.1-8) is further deprotected to afford compound (8.1-9) via method known to the skilled in the art depending the type of protecting group.
  • a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine
  • an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate or di-terf-buty
  • compound (8.1-10) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (8.1-11) as the formula (VIII) of the invention.
  • a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (8.1-11) as the formula (VIII) of the invention.
  • compound (8.2-5) with a dihalomethylene reagent (8.2-6) such as, but not limited to, chloroiodomethane in the presence of a base such as, but not limited to, cesium carbonate provides compound (8.2-7) in a solvent, such as, but not limited to, acetone or tetrahydrofuran.
  • a solvent such as, but not limited to, acetone or tetrahydrofuran.
  • Compound (8.2-7) can be hydrolyzed under reaction conditions known to the skilled in the art to give compound (8.2-8).
  • the acid (8.2-8) can undergo Curtius rearrangement with diphenyl phosphoryl azide and terf-butanol to afford compound (8.2-9).
  • a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-terf-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, sodium terf-butoxide or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofur
  • the protecting group tert- butyloxyl in compound (8.2-11) can be removed under conditions known to the skilled in the art to give compound (8.2-12).
  • Intramolecular cyclization of compound (8.2-12) employing a reagent, such as, but not limited to, 1 ,1'-carbonyldiimidazole in a solvent such as, but not limited to, tetrahydrofuran, or methylene chloride affords compound (8.2-13) as the formula (VIII) of the invention.
  • compound (8.2-13) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)- 1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (8.2-14) as formula (VIII) of the invention.
  • a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)- 1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (8.2-14) as formula (VIII) of the invention.
  • Reaction of the phenol compound (9.1-2) with a Grignard reagent (9.1-3) at low temperature (0 0 C) allows the formation of a phenoxymagnesium halide intermediate that can react with the keto-carbonyl group of the isatin compound (9.1-1) in a solvent, such as, but not limited to, tetrahydrofuran or dichloromethane to afford the oxindole compound (9.1-4).
  • a solvent such as, but not limited to, tetrahydrofuran or dichloromethane
  • the removal of the hydroxyl group at the C-3 position can be achieved by treating compound (9.1-4) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid.
  • compound (9.1-5) It can also be achieved by treating compound (9.1-4) with SOCI 2 /N Et 3 followed by reduction with Zn dust to give compound (9.1-5).
  • Compound (9.1-5) is treated with a silyl compound, such as, but not limited to, trimethylsilyl chloride, to generate the silyl ether intermediate which is treated with a metal reagent such as, but not limited to, ytterbium (III) trifluoromethanesulfonate or scandium (III) trifluoromethanesulfonate and formaldehyde to afford compound (9.1-6).
  • a silyl compound such as, but not limited to, trimethylsilyl chloride
  • a metal reagent such as, but not limited to, ytterbium (III) trifluoromethanesulfonate or scandium (III) trifluoromethanesulfonate and formaldehyde to afford compound (9.1-6).
  • compound (9.1-5) can be treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide or sodium hydroxide followed by reaction with formaldehyde to generate compound (9.1-6).
  • a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide or sodium hydroxide followed by reaction with formaldehyde to generate compound (9.1-6).
  • Intramolecular cyclization of compound (9.1-6) via Mitsunobu reaction employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-tert-butyl azodicarboxylate or tetramethyl diazenedicarboxamide, in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate provides compound (9.1-7).
  • a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine
  • an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-
  • N-alkylation of compound (9.1-7) is achieved by the treatment of compound (9-1-7) with a base such as, but not limited to, sodium hydride or cesium carbonate and a bromoalkyl phthalimide (9.1-8) in a solvent such as, but not limited to, tetrahydrofuran, acetonitrile, acetone.
  • a base such as, but not limited to, sodium hydride or cesium carbonate
  • a bromoalkyl phthalimide (9.1-8) in a solvent such as, but not limited to, tetrahydrofuran, acetonitrile, acetone.
  • the removal of the phthalimide protecting group can be achieved by treating compound (9.1-9) with hydrazine in a solvent, such as, but not limited to, ethanol or methanol provides compound (9.1-10).
  • Intramolecular cyclization of compound (9.1-10) is achieved by refluxing compound (9.1-10) with catalytic amount of an acid such as, but not limited to, p-toluenesulfonic acid in a solvent, such as, but not limited to, xylene to produce the cyclized amidine compound (9.1-11) as the formula (IX) of the invention.
  • an acid such as, but not limited to, p-toluenesulfonic acid
  • a solvent such as, but not limited to, xylene
  • compound (10.1-3) is then protected with an acyl protecting group to afford compound (10.1-4).
  • Compound (10.1-4) is then coupled with an amine (10.1-5) to give the amide compound (10.1-6) using HOBt and a coupling reagent such as, but not limited to, EDCI, in a solvent, such as, but not limited to, tetrahydrofuran under conditions known to those skilled in the art.
  • a coupling reagent such as, but not limited to, EDCI
  • a solvent such as, but not limited to, tetrahydrofuran under conditions known to those skilled in the art.
  • the removal of the acyl protecting group can be achieved by treating compound (10.1-6) with a base such as sodium hydroxide in a solvent, such as, but not limited to, ethanol to generate an alcohol intermediate, which can then be converted to compound (10.1-7) using thionyl chloride.
  • Intramolecular cyclization of compound (10.1-7) via Friedel-Crafts reaction employing a Lewis acid reagent such as, but not limited to, zinc chloride in a solvent such as, but not limited to, tetrahydrofuran, or dichloromethane affords compound (10.1-8).
  • the removal of the MOM protecting group can be achieved by treating compound (10.1-8) with an acid such as but not limited to, acetic acid.
  • compound (10.1-9) is then treated with a dihalomethane such as, but not limited to, chloroiodomethane in the presence of a base such as, but not limited to, cesium carbonate to provide compound (10.1-10) as formula (X) of the invention where X is O.
  • Compound (10.1-10) can be further treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (10.1-11) of formula (X) of the invention where X is S.
  • a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (10.1-11) of formula (X) of the invention where X is S.
  • an aryl or heteroaryl hydroxy compound (11.1-5) e.g., sesamol
  • a Grignard reagent (11.1-6) at low temperature (0 0 C) provides the aryloxymagnesium halide intermediate, which reacts with the keto-carbonyl group of the isatin compound (11.1-4) in a solvent, such as, but not limited to, methylene chloride to afford the oxindole compound (11.1-7).
  • a solvent such as, but not limited to, methylene chloride
  • the removal of the tertiary hydroxyl group at C-3 position can be achieved by treating compound (11.1-7) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid to afford the compound (11.1-8).
  • the compound (11.1-8) is treated with a dihalomethylene reagent such as, but not limited to, iodochloroiodomethane, in the presence of a base such as, but not limited to, cesium carbonate, in a solvent such as, but not limited to, tetrahydrofuran, to afford compound (11.1-9) as Formula (Xl) of the invention where X is O.
  • a dihalomethylene reagent such as, but not limited to, iodochloroiodomethane
  • a base such as, but not limited to, cesium carbonate
  • a solvent such as, but not limited to, tetrahydrofuran
  • compound (11.1-9) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (11.1-10) as formula (Xl) of the invention where X is S.
  • a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (11.1-10) as formula (Xl) of the invention where X is S.
  • the mixture was stirred at -78 0 C for 1 h and ambient temperature for 16 h.
  • the reaction was quenched with saturated aqueous ammonium chloride (50 mL) at 0 0 C, and concentrated to remove most of tetrahydrofuran.
  • the residue was extracted with ethyl acetate (180 mL), washed with water and brine, dried over anhydrous sodium sulfate and filtered.
  • This example describes an in vitro assay for testing and profiling test agents against human or rat sodium channels stably expressed in cells of either an endogenous or recombinant origin.
  • the assay is also useful for determining the IC-50 of a sodium channel blocking compound.
  • the assay is based on the guanidine flux assay described by Reddy, N. L., et al., J Med Chem (1998), 41(17):3298-302.
  • the guanidine influx assay is a radiotracer flux assay used to determine ion flux activity of sodium channels in a high-throughput microplate-based format.
  • the assay uses 14 C-guanidine hydrochloride in combination with various known sodium channel modulators, to assay the potency of test agents. Potency is determined by an IC-50 calculation. Selectivity is determined by comparing potency of the compound for the channel of interest to its potency against other sodium channels (also called 'selectivity profiling 1 ).
  • Each of the test agents is assayed against cells that express the channels of interest.
  • Voltage gated sodium channels are either TTX sensitive or insensitive. This property is useful when evaluating the activities of a channel of interest when it resides in a mixed population with other sodium channels.
  • Table 1 summarizes cell lines useful in screening for a certain channel activity in the presence or absence of TTX.
  • Cells expressing the channel of interest are grown according to the supplier or in the case of a recombinant cell in the presence of selective growth media such as G418 (Gibco/lnvitrogen).
  • the cells are disassociated from the culture dishes with an enzymatic solution (1X) Trypsin/EDTA (Gibco/lnvitrogen) and analyzed for density and viability using haemocytometer (Neubauer).
  • Disassociated cells are washed and resuspended in their culture media then plated into Scintiplates (Beckman Coulter Inc.) (approximately 100,000 cells/ well) and incubated at 37 °C/5 % CO 2. for 20-24 hours.
  • LNHBSS Low sodium HEPES-buffered saline solution
  • 1mM Choline Chloride, 20 nM HEPES (Sigma), 1mM Calcium Chloride, 5mM Potassium Chloride, 1 mM Magnesium Chloride, 10 mM Glucose agents diluted with LNHBSS are added to each well.
  • concentrations of test agent may be used.
  • the activation/radiolabel mixture contains aconitine (Sigma), and 14 C-guanidine hydrochloride (ARC).
  • the Scintiplates are incubated at ambient temperature. Following the incubation, the Scintplates are extensively washed with LNHBSS supplemented with guanidine (Sigma). The Scintiplates are dried and then counted using a Wallac MicroBeta TriLux (Perkin-Elmer Life Sciences). The ability of the test agent to block sodium channel activity is determined by comparing the amount of 14 C-guanidine present inside the cells expressing the different sodium channels. Based on this data, a variety of calculations, as set out elsewhere in this specification, may be used to determine whether a test agent is selective for a particular sodium channel.
  • IC-50 value of a test agent for a specific sodium channel may be determined using the above general method.
  • IC-50 may be determined using a 3, 8, 10, 12 or 16 point curve in duplicate or triplicate with a starting concentration of 1 , 5 or 10 ⁇ M diluted serially with a final concentration reaching the sub-nanomolar, nanomolar and low micromolar ranges.
  • the mid-point concentration of test agent is set at 1 ⁇ M, and sequential concentrations of half dilutions greater or smaller are applied (e.g. 0.5 ⁇ M; 5 ⁇ M and 0.25 ⁇ M; 10 ⁇ M and 0.125 ⁇ M; 20 ⁇ M etc.).
  • the fold selectivity, factor of selectivity or multiple of selectivity is calculated by dividing the IC-50 value of the test sodium channel by the reference sodium channel, for example, Na v 1.5.
  • Synthetic Example 1 when tested in the above assay using a known cell line that expresses a sodium channel, demonstrated an IC 50 (nM) activity level from 10 nM to 10O nM.
  • Cells expressing the channel of interest are cultured in DMEM growth media (Gibco) with 0.5mg/mL G418, +/-1% PSG, and 10% heat-inactivated fetal bovine serum at 37C° and 5% CO 2 .
  • DMEM growth media Gibco
  • PSG +/-1% PSG
  • heat-inactivated fetal bovine serum 37C° and 5% CO 2 .
  • cells are plated on 10mm dishes.
  • a single "diary" protocol with a holding potential of -11OmV is created to record the resting state current (10ms test pulse), the current after fast inactivation (5 ms pre-pulse of -80 to -50 m V follow by a 10 ms test pulse), and the current during various holding potentials (35 ms ramp to test pulse levels).
  • Compounds are applied during the "diary" protocol and the block is monitored at 15 s intervals.
  • the voltage-dependence of the steady-state inactivation in the presence of the compound is determined.
  • Compounds that block the resting state of the channel decrease the current elicited during test pulses from all holding potentials, whereas compounds that primarily block the inactivated state decrease the current elicited during test pulses at more depolarized potentials.
  • the currents at the resting state (l rest ) and the currents during the inactivated state (l ⁇ na ct ⁇ vated) are used to calculate steady-state affinity of compounds. Based on the Michaelis- Menton model of inhibition, the K r and K 1 are calculated as the concentration of compound needed to cause 50% inhibition of the l rest or the l ⁇ na c t ⁇ vat e d > respectively.
  • V max is the rate of inhibition
  • h is the Hill coefficient (for interacting sites)
  • K m is
  • the analgesia effect produced by administering a compound of the invention is observed through heat-induced tail-flick in mice.
  • the test includes a heat source consisting of a projector lamp with a light beam focused and directed to a point on the tail of a mouse being tested.
  • the tail-flick latencies which are assessed prior to drug treatment, and in response to a noxious heat stimulus, i.e., the response time from applying radiant heat on the dorsal surface of the tail to the occurrence of tail flick, are measured and recorded at 40, 80, 120 and 160 minutes.
  • a study can be designed wherein in the first part of the study, a certain number of animals undergo assessment of baseline tail flick latency once a day over two consecutive days. . These animals are then randomly assigned to one of the several different treatment groups (depending on how many compounds are tested) including a vehicle control, a morphine control, and compounds are administered intramuscularly at 30 mg/kg. Following dose administration, the animals are closely monitored for signs of toxicity including tremor or seizure, hyperactivity, shallow, rapid or depressed breathing and failure to groom. The optimal incubation time for each compound is determined via regression analysis. The analgesic activity of the test compounds is expressed as a percentage of the maximum possible effect (%MPE) and is calculated using the following formula:
  • Postdrug latency the latency time for each individual animal taken before the tail is removed (flicked) from the heat source after receiving drug.
  • Predrug latency the latency time for each individual animal taken before the tail is flicked from the heat source prior to receiving drug.
  • Cut-off time (10 s) is the maximum exposure to the heat source.
  • the formalin test is used as an animal model of acute pain.
  • animals are briefly habituated to the plexiglass test chamber on the day prior to experimental day for 20 minutes.
  • animals are randomly injected with the test articles.
  • 50 ⁇ l_ of 10% formalin is injected subcutaneously into the plantar surface of the left hind paw of the rats.
  • Video data acquisition began immediately after formalin administration, for duration of 90 minutes.
  • the images are captured using the Actimetrix Limelight software which stores files under the Mlii extension, and then converts it into the MPEG-4 coding.
  • the videos are then analyzed using behaviour analysis software "The Observer 5.1", (Version 5.0, Noldus Information Technology, Wageningen, The Netherlands).
  • the video analysis is done by watching the animal behaviour and scoring each according to type, and defining the length of the behaviour (Dubuisson and Dennis, 1977). Scored behaviours include: (1) normal behaviour, (2) putting no weight on the paw, (3) raising the paw, or (4) licking/biting or scratching the paw. Elevation, favoring, or excessive licking, biting and scratching of the injected paw indicate a pain response. Analgesic response or protection from compounds is indicated if both paws are resting on the floor with no obvious favoring, excessive licking, biting or scratching of the injected paw.
  • %MPIE Percent Maximal Potential Inhibitory Effect
  • pain score The %MPIEs can is calculated by a series of steps, where the first is to sum the length of non-normal behaviours (behaviours 1 ,2,3) of each animal. A single value for the vehicle group is obtained by averaging all scores within the vehicle treatment group. The following calculation yields the MPIE value for each animal:
  • the pain score is calculated from a weighted scale as described above.
  • the duration of the behaviour is multiplied by the weight (rating of the severity of the response), and divided by the total length of observation to determine a pain rating for each animal.
  • the calculation is represented by the following formula:
  • Pain rating [ 0(To) + 1(T1 ) + 2(T2) + 3(T3) ] / ( To + T1 + T2 + T3 ) CFA Induced Chronic Inflammatory Pain
  • test and control articles are administrated to the animals, and the nociceptive thresholds measured at defined time points after drug administration to determine the analgesic responses to each of the six available treatments.
  • the time points used are previously determined to show the highest analgesic effect for each test compound.
  • Thermal nociceptive thresholds of the animals are assessed using the Hargreaves test. Animals are placed in a Plexiglas enclosure set on top of an elevated glass platform with heating units. The glass platform is thermostatically controlled at a temperature of approximately 30 °C for all test trials. Animals are allowed to accommodate for 20 minutes following placement into the enclosure until all exploration behaviour ceases.
  • the Model 226 Plantar/Tail Stimulator Analgesia Meter (UTC, Woodland Hills, CA) is used to apply a radiant heat beam from underneath the glass platform to the plantar surface of the hind paws. During all test trials, the idle intensity and active intensity of the heat source are set at 1 and 45 respectively, and a cut off time of 20 seconds is employed to prevent tissue damage.
  • the response thresholds of animals to tactile stimuli are measured using the Model 2290 Electrovonfrey anesthesiometer (MTC Life Science, Woodland Hills, CA) following the Hargreaves test. Animals are placed in an elevated Plexiglas enclosure set on a mire mesh surface. After 10 minutes of accommodation, pre-calibrated Von Frey hairs are applied perpendicularly to the plantar surface of both paws of the animals in an ascending order starting from the 0.1 g hair, with sufficient force to cause slight buckling of the hair against the paw. Testing continues until the hair with the lowest force to induce a rapid flicking of the paw is determined or when the cut off force of approximately 20 g is reached. This cut off force is used because it represent approximately 10% of the animals' body weight and it serves to prevent raising of the entire limb due to the use of stiffer hairs, which would change the nature of the stimulus.
  • the hypealgesia caused by an intra-planar incision in the paw can be measured by applying increased tactile stimuli to the paw until the animal withdraws its paw from the applied stimuli.
  • animals are anaesthetized under 3.5% isofluorane, which is delivered via a nose cone, a 1 cm longitudinal incision was made using a number 10 scalpel blade in the plantar aspect of the left hind paw through the skin and fascia, starting 0.5 cm from the proximal edge of the heel and extending towards the toes.
  • the skin is apposed using 2, 3-0 sterilized silk sutures.
  • the injured site is covered with Polysporin and Betadine. Animals are returned to their home cage for overnight recovery.
  • the withdrawal thresholds of animals to tactile stimuli for both operated (ipsilateral) and unoperated (contralateral) paws can be measured using the Model 2290 Electro vo nfrey anesthesiometer (HTC Life Science, Woodland Hills, CA). Animals are placed in an elevated Plexiglas enclosure set on a mire mesh surface. After at least 10 minutes of acclimatization, pre-calibrated Von Frey hairs are applied perpendicularly to the plantar surface of both paws of the animals in an ascending order starting from the 10 g hair, with sufficient force to cause slight buckling of the hair against the paw. Testing continues until the hair with the lowest force to induce a rapid flicking of the paw is determined or when the cut off force of approximately 20 g is reached. This cut off force is used because it represent approximately 10% of the animals' body weight and it serves to prevent raising of the entire limb due to the use of stiffer hairs, which would change the nature of the stimulus. Neuropathic pain model; Chronic Constriction Injury
  • the response thresholds of animals to tactile stimuli were measured using the Model 2290 Electrovonfrey anesthesiometer (HTC Life Science, Woodland Hills, CA). Animals were placed in an elevated Plexiglas enclosure set on a mire mesh surface. After 10 minutes of accommodation, pre-calibrated Von Frey hairs were applied perpendicularly to the plantar surface of both paws of the animals in an ascending order starting from the 0.1 g hair, with sufficient force to cause slight buckling of the hair against the paw. Testing continues until the hair with the lowest force to induce a rapid flicking of the paw is determined or when the cut off force of approximately 20 g is reached.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to structurally diverse spiroheterocyclic compounds according to the general formulae (I)-(XI) as a stereoisomer, eπantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Description

HETEROCYLIC DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS
FIELD OF THE INVENTION
The present invention is directed to spiro-oxindole compounds. In particular, this invention is directed to spiro-oxindole compounds that are sodium channel blockers and are therefore useful in treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions such as hypercholesterolemia, benign prostatic hyperplasia, pruritis, and cancer.
BACKGROUND OF THE INVENTION
Voltage-gated sodium channels, transmembrane proteins that initiate action potentials in nerve, muscle and other electrically excitable cells, are a necessary component of normal sensation, emotions, thoughts and movements (Catterall, W.A., Nature (2001 ), Vol. 409, pp. 988-990). These channels consist of a highly processed alpha subunit that is associated with auxiliary beta subunits. The pore-forming alpha subunit is sufficient for channel function, but the kinetics and voltage dependence of channel gating are in part modified by the beta subunits (Goldin et al., Neuron (2000), Vol. 28, pp. 365-368). Each alpha-subunit contains four homologous domains, I to IV, each with six predicted transmembrane segments. The alpha-subunit of the sodium channel, forming the ion-conducting pore and containing the voltage sensors regulating sodium ion conduction has a relative molecular mass of 260,000. Electrophysiological recording, biochemical purification, and molecular cloning have identified ten different sodium channel alpha subunits and four beta subunits (Yu, F.H., et al., Sci. STKE (2004), 253; and Yu, F.H., et al., Neurosci. (2003), 20:7577-85).
The hallmarks of sodium channels include rapid activation and inactivation when the voltage across the plasma membrane of an excitable cell is depolarized (voltage-dependent gating), and efficient and selective conduction of sodium ions through conducting pores intrinsic to the structure of the protein (Sato, C, et al., Nature (2001 ), 409:1047-1051 ). At negative or hyperpolarized membrane potentials, sodium channels are closed. Following membrane depolarization, sodium channels open rapidly and then inactivate. Channels only conduct currents in the open state and, once inactivated, have to return to the resting state, favoured by membrane hyperpolarization, before they can reopen. Different sodium channel subtypes vary in the voltage range over which they activate and inactivate as well as their activation and inactivation kinetics.
The sodium channel family of proteins has been extensively studied and shown to be involved in a number of vital body functions. Research in this area has identified variants of the alpha subunits that result in major changes in channel function and activities, which can ultimately lead to major pathophysiological conditions. Implicit with function, this family of proteins are considered prime points of therapeutic intervention. Nav1.1 and Nav1.2 are highly expressed in the brain (Raymond, C. K., et al., J. Biol. Chem. (2004), 279(44):46234-41 ) and are vital to normal brain function. In humans, mutations in Nav1.1 and Nav1.2 result in severe epileptic states and in some cases mental decline (Rhodes, T.H., et al., Proc. Natl. Acad. Sci. USA
(2004),101(30):11147-52; Kamiya, K., et al., J. Biol. Chem. (2004), 24(11 ) :2690-8; Pereira, S., et al., Neurology (2004), 63(1):191-2). As such both channels have been considered as validated targets for the treatment of epilepsy (see PCT Published Patent Publication No. WO 01/38564). Na/I .3 is broadly expressed throughout the body (Raymond, C. K., et al., op. cit.). It has been demonstrated to have its expression upregulated in the dorsal horn sensory neurons of rats after nervous system injury (Hains, B. D., et al., J. Neurosci. (2003), 23(26):8881-92). Many experts in the field have considered Na1Zl .3 as a suitable target for pain therapeutics (Lai, J., et al., Curr. Opin. Neurobiol. (2003), (3):291 -72003; Wood, J. N., et al., J. Neurobiol. (2004), 61(1 ):55-71 ; Chung, J.M., et al., Novartis Found Symp. (2004), 261 :19-27; discussion 27-31 , 47-54).
Nav1.4 expression is essentially limited to muscle (Raymond, C.K., et al., op. cit.). Mutations in this gene have been shown to have profound effects on muscle function including paralysis, (Tamaoka A., Intern. Med. (2003), (9):769-70). Thus, this channel can be considered a target for the treatment of abnormal muscle contractility, spasm or paralysis.
The cardiac sodium channel, Nav1.5, is expressed mainly in the heart ventricles and atria (Raymond, C. K., et al., op. cit), and can be found in the sinovial node, ventricular node and possibly Purkinje cells. The rapid upstroke of the cardiac action potential and the rapid impulse conduction through cardiac tissue is due to the opening of Na/1.5. As such, Nav1.5 is central to the genesis of cardiac arrhythmias. Mutations in human Na/I .5 result in multiple arrhythmic syndromes, including, for example, long QT3 (LQT3), Brugada syndrome (BS), an inherited cardiac conduction defect, sudden unexpected nocturnal death syndrome (SUNDS) and sudden infant death syndrome (SIDS) (Liu, H. et al., Am. J. Pharmacogenomics (2003), 3(3):173-9). Sodium channel blocker therapy has been used extensively in treating cardiac arrhythmias. The first antiarrhythmic drug, quinidine, discovered in 1914, is classified as a sodium channel blocker.
Nav1.6 encodes an abundant, widely distributed voltage-gated sodium channel found throughout the central and peripheral nervous systems, clustered in the nodes of Ranvier of neural axons (Caldwell, J. H., et al., Proc. Natl. Acad. Sci. USA (2000), 97(10): 5616-20). Although no mutations in humans have been detected, Nav1.6 is thought to play a role in the manifestation of the symptoms associated with multiple sclerosis and has been considered as a target for the treatment of this disease (Craner, MJ. , et al., Proc. Natl. Acad. ScI. USA (2004), 101(21 ):8168-73).
Na/I .7 was first cloned from the pheochromocytoma PC12 cell line (Toledo- Aral, J. J., et al., Proc. Natl.Acad. Sci. USA (1997), 94:1527-1532). Its presence at high levels in the growth cones of small-diameter neurons suggested that it could play a role in the transmission of nociceptive information. Although this has been challenged by experts in the field as Na/I .7 is also expressed in neuroendocrine cells associated with the autonomic system (Klugbauer, N., et al., EMBO J. (1995), 14(6): 1084-90) and as such has been implicated in autonomic processes. The implicit role in autonomic functions was demonstrated with the generation of Nav1.7 null mutants; deleting Nay/I .7 in all sensory and sympathetic neurons resulted in a lethal perinatal phenotype. (Nassar, et al., Proc. Natl. Acad. Sci. USA (2004), 101 (34): 12706- 11.). In contrast, by deleting the Na/1.7 expression in a subset of sensory neurons that are predominantly nociceptive, a role in pain mechanisms, was demonstrated (Nassar, et al., op. cit). Further support for Na/1.7 blockers active in a subset of neurons is supported by the finding that two human heritable pain conditions, primary erythermalgia and familial rectal pain, have been shown to map to Na1Zl -7 (Yang, Y., et al., J. Med. Genet. (2004), 41 (3): 171 -4).
The expression of Nav1.8 is essentially restricted to the DRG (Raymond, C. K., et al., op. cit). There are no identified human mutations for Na/I .8. However, Nav1.8- null mutant mice were viable, fertile and normal in appearance. A pronounced analgesia to noxious mechanical stimuli, small deficits in noxious thermoreception and delayed development of inflammatory hyperalgesia suggested to the researchers that Naγ/1.8 plays a major role in pain signalling (Akopian, A. N., et al., Nat. Neurosci. (1999), 2(6): 541-8). Blocking of this channel is widely accepted as a potential treatment for pain (Lai, J, et al., op. cit; Wood, J. N., et al., op. cit; Chung, J. M., et al., op. cit). PCT Published Patent Application No. WO03/037274A2 describes pyrazole- amides and sulfonamides for the treatment of central or peripheral nervous system conditions, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. PCT Published Patent Application No. WO03/037890A2 describes piperidines for the treatment of central or peripheral nervous system conditions, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of these inventions are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 (Nay1.8) subunit. The tetrodotoxin insensitive, peripheral sodium channel Na/I .9, disclosed by
Dib-Hajj, S.D., et al. (see Dib-Hajj, S.D., et al., Proc. Natl. Acad. ScL USA (1998), 95(15):8963-8) was shown to reside solely in the dorsal root ganglia. It has been demonstrated that Nav1 -9 underlies neurotrophin (BDNF)-evoked depolarization and excitation, and is the only member of the voltage gated sodium channel superfamily to be shown to be ligand mediated (Blum, R., Kafitz, K.W., Konnerth, A., Nature (2002), 419 (6908):687-93). The limited pattern of expression of this channel has made it a candidate target for the treatment of pain (Lai, J, et al., op. cit.; Wood, J. N., et al., op. cit; Chung, J. M. et al., op. cit).
NaX is a putative sodium channel, which has not been shown to be voltage gated. In addition to expression in the lung, heart, dorsal root ganglia, and Schwann cells of the peripheral nervous system, NaX is found in neurons and ependymal cells in restricted areas of the CNS, particularly in the circumventricular organs, which are involved in body-fluid homeostasis (Watanabe, E., et al., J. Neurosci. (2000), 20(20):7743-51 ). NaX-null mice showed abnormal intakes of hypertonic saline under both water- and salt-depleted conditions. These findings suggest that the NaX plays an important role in the central sensing of body-fluid sodium level and regulation of salt intake behaviour. Its pattern of expression and function suggest it as a target for the treatment of cystic fibrosis and other related salt regulating maladies.
Studies with the sodium channel blocker tetrodotoxin (TTX) used to lower neuron activity in certain regions of the brain, indicate its potential use in the treatment of addiction. Drug-paired stimuli elicit drug craving and relapse in addicts and drug- seeking behavior in rats. The functional integrity of the basolateral amygdala (BLA) is necessary for reinstatement of cocaine-seeking behaviour elicited by cocaine- conditioned stimuli, but not by cocaine itself. BLA plays a similar role in reinstatement of heroin-seeking behavior. TTX-induced inactivation of the BLA on conditioned and heroin-primed reinstatement of extinguished heroin-seeking behaviour in a rat model (Fuchs, R.A. and See, R.E., Psychopharmacology (2002) 160(4):425-33).
This closely related family of proteins has long been recognised as targets for therapeutic intervention. Sodium channels are targeted by a diverse array of pharmacological agents. These include neurotoxins, antiarrhythmics, anticonvulsants and local anesthetics (Clare, J.J., et al., Drug Discovery Today (2000) 5:506-520). All of the current pharmacological agents that act on sodium channels have receptor sites on the alpha subunits. At least six distinct receptor sites for neurotoxins and one receptor site for local anesthetics and related drugs have been identified (Cestele, S. et al., Biochimie (2000), Vol. 82, pp. 883-892).
The small molecule sodium channel blockers or the local anesthetics and related antiepileptic and antiarrhythmic drugs, interact with overlapping receptor sites located in the inner cavity of the pore of the sodium channel (Catterall, W.A., Neuron (2000), 26:13-25). Amino acid residues in the S6 segments from at least three of the four domains contribute to this complex drug receptor site, with the IVS6 segment playing the dominant role. These regions are highly conserved and as such most sodium channel blockers known to date interact with similar potency with all channel subtypes. Nevertheless, it has been possible to produce sodium channel blockers with therapeutic selectivity and a sufficient therapeutic window for the treatment of epilepsy (e.g. lamotrignine, phenytoin and carbamazepine) and certain cardiac arrhythmias (e.g. lignocaine, tocainide and mexiletine). However, the potency and therapeutic index of these blockers is not optimal and have limited the usefulness of these compounds in a variety of therapeutic areas where a sodium channel blocker would be ideally suited. Management of Acute and Chronic Pain Drug therapy is the mainstay of management for acute and chronic pain in all age groups, including neonates, infants and children. The pain drugs are classified by the American Pain Society into three main categories: 1) non-opioid analgesics- acetaminophen, and non-steroidal anti-inflammatory drugs (NSAIDs), including salicylates (e.g. aspirin), 2) opioid analgesics and 3) co-analgesics. Non-opioid analgesics such as acetaminophen and NSAIDs are useful for acute and chronic pain due to a variety of causes including surgery, trauma, arthritis and cancer. NSAIDs are indicated for pain involving inflammation because acetaminophen lacks anti-inflammatory activity. Opioids also lack anti-inflammatory activity. All NSAIDs inhibit the enzyme cyclooxygenase (COX), thereby inhibiting prostaglandin synthesis and reducing the inflammatory pain response. There are at least two COX isoforms, COX-1 and COX-2. Common non-selective COX inhibitors include, ibuprofen and naproxen. Inhibition of COX-1, which is found in platelets, Gl tract, kidneys and most other human tissues, is thought to be associated with adverse effects such as gastrointestinal bleeding. The development of selective COX-2 NSAIDs, such as Celecoxib, Valdecoxib and Rofecoxib, have the benefits of nonselective NSAIDs with reduced adverse effect profiles in the gut and kidney. However, evidence now suggests that chronic use of certain selective COX-2 inhibitors can result in an increased risk of stroke occurrence.
The use of opioid analgesics is recommended by the American Pain Society to be initiated based on a pain-directed history and physical that includes repeated pain assessment. Due to the broad adverse effect profiles associated with opiate use, therapy should include a diagnosis, integrated interdisciplinary treatment plan and appropriate ongoing patient monitoring. It is further recommended that opioids be added to non-opioids to manage acute pain and cancer related pain that does not respond to non-opioids alone. Opioid analgesics act as agonists to specific receptors of the mu and kappa types in the central and peripheral nervous system. Depending on the opioid and its formulation or mode of administration it can be of shorter or longer duration. All opioid analgesics have a risk of causing respiratory depression, liver failure, addiction and dependency, and as such are not ideal for long-term or chronic pain management.
A number of other classes of drugs may enhance the effects of opioids or NSAIDSs, have independent analgesic activity in certain situations, or counteract the side effects of analgesics. Regardless of which of these actions the drug has, they are collectively termed "coanalgesics". Tricyclic antidepressants, antiepileptic drugs, local anaesthetics, glucocorticoids, skeletal muscle relaxants, anti-spasmodil agents, antihistamines, benzodiazepines, caffeine, topical agents (e.g. capsaicin), dextroamphetamine and phenothizines are all used in the clinic as adjuvant therapies or individually in the treatment of pain. The antiepeileptic drugs in particular have enjoyed some success in treating pain conditions. For instance, Gabapentin, which has an unconfirmed therapeutic target, is indicated for neuropathic pain. Other clinical trials are attempting to establish that central neuropathic pain may respond to ion channel blockers such as blockers of calcium, sodium and/or NMDA (N-methyl-D- aspartate) channels. Currently in development are low affinity NMDA channel blocking agents for the treatment of neuropathic pain. The literature provides substantial pre- clinical electrophysiological evidence in support of the use of NMDA antagonists in the treatment of neuropathic pain. Such agents also may find use in the control of pain after tolerance to opioid analgesia occurs, particularly in cancer patients.
Systemic analgesics such as NSAIDs and opioids are to be distinguished from therapeutic agents which are useful only as local analgesics/anaesthetics. Well known local analgesics such as lidocaine and xylocaine are non-selective ion channel blockers which can be fatal when administered systemically. A good description of non-selective sodium channel blockers is found in Madge, D. et al., J. Med. Chem. (2001 ), 44(2): 115-37.
Several sodium channel modulators are known for use as anticonvulsants or antidepressants, such as carbamazepine, amitriptyline, lamotrigine and riluzole, all of which target brain tetradotoxin- sensitive (TTX-S) sodium channels. Such TTX-S agents suffer from dose- limiting side effects, including dizziness, ataxia and somnolence, primarily due to action at TTX-S channels in the brain. Sodium Channels Role in Pain Sodium channels play a diverse set of roles in maintaining normal and pathological states, including the long recognized role that voltage gated sodium channels play in the generation of abnormal neuronal activity and neuropathic or pathological pain (Chung, J. M. et al.). Damage to peripheral nerves following trauma or disease can result in changes to sodium channel activity and the development of abnormal afferent activity including ectopic discharges from axotomised afferents and spontaneous activity of sensitized intact nociceptors. These changes can produce long-lasting abnormal hypersensitivity to normally innocuous stimuli, or allodynia. Examples of neuropathic pain include, but are not limited to, post-herpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, chronic lower back pain, phantom limb pain, and pain resulting from cancer and chemotherapy, chronic pelvic pain, complex regional pain syndrome and related neuralgias.
There has been some degree of success in treating neuropathic pain symptoms by using medications, such as gabapentin, and more recently pregabalin, as short-term, first-line treatments. However, pharmacotherapy for neuropathic pain has generally had limited success with little response to commonly used pain reducing drugs, such as NSAIDS and opiates. Consequently, there is still a considerable need to explore novel treatment modalities.
There remains a limited number of potent effective sodium channel blockers with a minimum of adverse events in the clinic. There is also an unmet medical need to treat neuropathic pain and other sodium channel associated pathological states effectively and without adverse side effects. The present invention provides compounds, methods of use and compositions that include these compounds to meet these critical needs.
SUMMARY OF THE INVENTION
The present invention is directed to spiro-oxindole compounds that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. The compounds of the present invention are also useful for the treatment of other sodium channel-mediated diseases or conditions, including, but not limited to central nervous conditions such as epilepsy, anxiety, depression and bipolar disease; cardiovascular conditions such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular conditions such as restless leg syndrome, essential tremour and muscle paralysis or tetanus; neuroprotection against stroke, glaucoma, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome. The compounds of the present invention are also useful for the treatment and/or prevention of diseases or conditions, such as hypercholesterolemia, benign prostatic hyperplasia, pruritis, and cancer.
Accordingly, in one aspect, the invention provides compounds of formula (I):
Figure imgf000009_0001
wherein: each t is independently 0, 1 , 2, 3 or 4; v is 1 , 2 or 3;
each
Figure imgf000009_0002
is independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN; R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is O1 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3,
-R8-C(O)R4; -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. In another aspect, the invention provides compounds of formula (II):
Figure imgf000012_0001
wherein: t, v and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-, -OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; Rla is hydrogen or -OR S.
Figure imgf000013_0001
and
Figure imgf000013_0002
are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5,
-R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5,
-R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a and R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5,
-R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a and R2b may be independently optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR\ -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4,
-R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; or two adjacent R2b together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. In another aspect, the invention provides compounds of formula (III):
Figure imgf000016_0001
wherein: p and q are each independently 0, 1 , 2, 3 or 4; v is 0, 1 or 2; represents an optional double bond;
J, Q and E are each independently -N=, -CR2b=, -NR2b- or -C(R2b)2-; each D and X are independently N or C, provided when D is N, X is C, or when D is C,
X is N; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-;
Figure imgf000016_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5,
-R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5,
-N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R\ -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. In another aspect, the invention provides compounds of formula (IV):
Figure imgf000020_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5; X, W and E are each independently -N= or -CH=;
Figure imgf000020_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5JS(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2) -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
In another aspect, the present invention provides compounds of formula (V):
Figure imgf000023_0001
wherein: t and p are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5; X is hydrogen or halo;
Figure imgf000023_0002
3 annHd are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -Rδ-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or
-R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3,
-R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
In another aspect, the present invention provides compounds of formula (Vl):
Figure imgf000026_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000026_0002
is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
Y is aryl, heterocyclic or heteroaryl ring;
Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or
-R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
In another aspect, the present invention provides compounds of formula (VII):
Figure imgf000029_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; v is 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-, -OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000030_0001
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl,
-R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)πN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
In another aspect, the present invention provides compounds of formula (VIII):
Figure imgf000033_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1, 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)1n- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(0)-; R1a is hydrogen or -OR5; Z is -N(R5)- or -O-;
Figure imgf000033_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alky!, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or
-R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. In another aspect, the present invention provides compounds of formula (IX):
Figure imgf000036_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3; Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(0)-; R1a is hydrogen or -OR5; p is 1 , 2 or 3, wherein when p is 1 , v is 0, 1 , 2, 3, 4, 5 or 6, when p is 2, v is 0, 1 , 2, 3, 4, 5, 6, 7 or 8, and when p is 3, v is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10;
v—y and v — / are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3,
-R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl, and wherein each of the fused ring may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy and aryl. each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
In another aspect, the present invention provides compounds of formula (X):
Figure imgf000039_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-, -OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-;
R is hydrogen or -OR 5 t>..
Figure imgf000039_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl,
-R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5,
-R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R\ -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alky!, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
In another aspect, the present invention provides compounds of formula (Xl):
Figure imgf000042_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000042_0002
is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; or R1 and R2 together with the adjacent nitrogen atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
In another aspect, the invention provides methods for the treatment of pain in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
In another aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of Na/1.1 , Nav1 -2, Na /I .3, Na /1.4, Na/I .5, Nav1.6, Na/I .7, Na/I .8, or Na/I .9 is implicated in the disease state. In another aspect, the invention provides methods of treating a range of sodium channel-mediated diseases or conditions, for example, pain associated with HIV, HIV treatment induced neuropathy, trigeminal neuralgia, post-herpetic neuralgia, eudynia, heat sensitivity, tosarcoidosis, irritable bowel syndrome, Crohns disease, pain associated with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), diabetic neuropathy, peripheral neuropathy, arthritic, rheumatoid arthritis, osteoarthritis, atherosclerosis, paroxysmal dystonia, myasthenia syndromes, myotonia, malignant hyperthermia, cystic fibrosis, pseudoaldosteronism, rhabdomyolysis, hypothyroidism, bipolar depression, anxiety, schizophrenia, sodium channel toxin related illnesses, familial erythermalgia, primary erythermalgia, familial rectal pain, cancer, epilepsy, partial and general tonic seizures, restless leg syndrome, arrhythmias, fibromyalgia, neuroprotection under ischaemic conditions caused by stroke, glaucoma or neural trauma, tachy-arrhythmias, atrial fibrillation and ventricular fibrillation. In another aspect, the invention provides methods of treating a range of sodium channel-mediated disease or condition through inhibition of ion flux through a voltage- dependent sodium channel in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above. In another aspect, the invention provides methods of treating or preventing hypercholesterolemia in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
In another aspect, the invention provides methods of treating or preventing benign prostatic hyperplasia in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
In another aspect, the invention provides methods of treating or preventing pruritis in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
In another aspect, the invention provides methods of treating or preventing cancer in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as set forth above.
In another aspect, the invention provides pharmaceutical compositions comprising the compounds of the invention, as set forth above, and pharmaceutically acceptable excipients. In one embodiment, the present invention relates to a pharmaceutical composition comprising a compound of the invention in a pharmaceutically acceptable carrier and in an amount effective to treat diseases or conditions related to pain when administered to an animal, preferably a mammal, most preferably a human.
In another aspect, the invention provides pharmaceutical therapy in combination with one or more other compounds of the invention or one or more other accepted therapies or as any combination thereof to increase the potency of an existing or future drug therapy or to decrease the adverse events associated with the accepted therapy. In one embodiment, the present invention relates to a pharmaceutical composition combining compounds of the present invention with established or future therapies for the indications listed in the invention. In another aspect, this invention is directed to the use of the compounds of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or the use of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the preparation of a medicament for the treatment of pain in a mammal.
In another aspect, this invention is directed to the use of the compounds of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or the use of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the invention, as set forth above, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the preparation of a medicament for the treatment of sodium channel-mediated disease or condition in a mammal.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
Certain chemical groups named herein are preceded by a shorthand notation indicating the total number of carbon atoms that are to be found in the indicated chemical group. For example; C7-Ci2alkyl describes an alkyl group, as defined below, having a total of 7 to 12 carbon atoms, and C4-C12cycloalkylalkyl describes a cycloalkylalkyl group, as defined below, having a total of 4 to 12 carbon atoms. The total number of carbons in the shorthand notation does not include carbons that may exist in substituents of the group described. For example, the following terms have the meaning indicated:
"C1-C1OaIRyI" refers to an alRyl radical as defined below containing one to ten carbon atoms. The CrC10alRyl readical may be optionally substituted as defined below for an alRyl group.
"C2-C12alRynyl" refers to an alRnyl radical as defined below containing two to twelve carbon atoms. The C2-C12alRnyl radical may be optionally substituted as defined below for an alRenyl group.
"CrC^alRoxy" refers to an alRoxy radical as defined below containing one to twelve carbon atoms. The alRyl part of the C1-C^aIRoXy radical may be optionally substituted as defined below for an alRyl group.
"C2-C12alRoxyalRyl" refers to an alRoxyalRyl radical as defined below containing two to twelve carbon atoms. Each alRyl part of the C2-C12alRoxyalRyl radical may be optionally substituted as defined below for an alRyl group. "C7-C12aralRyr' refers to an aralRyl group as defined below containing seven to twelve carbon atoms. The aryl part of the C7-C12aralRyl radical may be optionally substituted as described below for an aryl group. The alRyl part of the C7-C12aralRyl radical may be optionally substituted as defined below for an alRyl group.
"C7-C12aralRenyl" refers to an aralRenyl group as defined below containing seven to twelve carbon atoms. The aryl part of the C7-C12aralRenyl radical may be optionally substituted as described below for an aryl group. The alRenyl part of the C7-Ci2aralRenyl radical may be optionally substituted as defined below for an alRenyl group.
"C3-C12cycloalRyl" refers to a cycloalRyl radical as defined below having three to twelve carbon atoms. The C3-C12cycloalRyl radical may be optionally substituted as defined below for a cycloalRyl group.
"C4-C12cycloalRylalRyr refers to a cycloalRylalRyl radical as defined below having four to twelve carbon atoms. The C4-C12cycloalRylalRyl radical may be optionally substituted as defined below for a cycloalRylalRyl group. In addition to the foregoing, as used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated: "Amino" refers to the -NH2 radical. "Cyano" refers to the -CN radical. "Hydroxyl" refers to the -OH radical. "Imino" refers to the =NH substituent. "Nitro" refers to the -NO2 radical. "Oxo" refers to the =0 substituent. "Thioxo" refers to the =S substituent. "Trifluoromethyl" refers to the -CF3 radical. "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms, preferably one to eight carbon atoms or one to six carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (/so-propyl), n-butyl, /i-pentyl, 1 ,1-dimethylethyl (f-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR14, -OC(O)-R14, -N(R14)2, -C(O)R14, -C(O)OR14, -C(O)N(R14)2, -N(R14)C(O)OR16, -N(R14)C(O)R16, -N(R14)S(O)tR16 (where t is 1 to 2), -S(O)4OR16 (where t is 1 to 2), -S(O)1R16 (where t is O to 2) and -S(O),N(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted unless otherwise indicated.
"Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, e.g., ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1 ,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR14, -OC(O)-R14, -N(R14)2, -C(O)R14, -C(O)OR14, -C(O)N(R14)2, -N(R14)C(O)OR16, -N(R14)C(O)R16,
-N(R14)S(O)tR16 (where t is 1 to 2), -S(O)tOR16 (where t is 1 to 2), -S(0)tR16 (where t is O to 2) and -S(O)tN(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted unless otherwise indicated.
"Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR14, -OC(O)-R14, -N(R14)2, -C(O)R14, -C(O)OR14, -C(O)N(R14)2, -N(R14)C(O)OR16, -N(R14)C(O)R16, -N(R14)S(O)tR16 (where t is 1 to 2), -S(O)1OR16 (where t is 1 to 2), -S(O)1R16 (where t is O to 2) and -S(O)tN(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted unless otherwise indicated.
"Alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one double bond and having from two to twelve carbon atoms, e.g., ethenylene, propenylene, /i-butenylene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR14, -OC(O)-R14, -N(R14)2, -C(O)R14, -C(O)OR14, -C(O)N(R14)2, -N(R14)C(O)OR16, -N(R14)C(O)R16, -N(R14)S(O)tR16 (where t is 1 to 2), -S(O)tOR16 (where t is 1 to 2), -S(O)1R16 (where t is O to 2) and -S(O),N(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted unless otherwise indicated.
"Alkynylene" or "alkynylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one triple bond and having from two to twelve carbon atoms, e.g., propynylene, n-butynylene, and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR14, -OC(O)-R14, -N(R14)2, -C(O)R14, -C(O)OR14, -C(O)N(R14)2, -N(R14)C(O)OR16, -N(R14)C(O)R16, -N(R14)S(O)tR16 (where t is 1 to 2), -S(O)4OR16 (where t is 1 to 2), -S(O)1R16 (where t is O to 2) and -S(O)tN(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halo groups), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted unless otherwise indicated. "Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -OR14, -OC(O)-R14, -N(R14)2, -C(O)R14, -C(O)OR14, -C(O)N(R14)2, -N(R14)C(O)OR16, -N(R14)C(O)R16, -N(R14)S(O)tR16 (where t is 1 to 2), -S(O)1OR16 (where t is 1 to 2), -S(O)1R16 (where t is O to 2) and -S(O)tN(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted.
"Alkoxy" refers to a radical of the formula -ORa where R3 is an alkyl radical as defined above containing one to twelve carbon atoms. The alkyl part of the alkoxy radical may be optionally substituted as defined above for an alkyl radical.
"Alkoxyalkyl" refers to a radical of the formula -R3-O-R3 where each R3 is independently an alkyl radical as defined above. The oxygen atom may be bonded to any carbon in either alkyl radical. Each alkyl part of the alkoxyalkyl radical may be optionally substituted as defined above for an alkyl group.
"Aryl" refers to aromatic monocyclic or multicyclic hydrocarbon ring system consisting only of hydrogen and carbon and containing from 6 to 18 carbon atoms, where the ring system may be partially saturated. Aryl groups include, but are not limited to groups such as fluorenyl, phenyl and naphthyl. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents independently selected from the group consisting of alkyl, akenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl, heteroaryl, heteroarylalkyl, -R15-OR14, -R15-OC(O)-R14, -R15-N(R14)2, -R15-C(O)R14, -R15-C(O)OR14, -R15-C(O)N(R14)2, -R15-N(R14)C(O)OR16, -R15-N(R14)C(O)R16, -R15-N(R14)S(O)tR16 (where t is 1 to 2), -R15-S(O)tOR16 (where t is 1 to 2), -R15-S(O),R16 (where t is 0 to 2) and -R15-S(O)tN(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a direct bond or a straight or branched alkylene or alkenylene chain; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted. "Aralkyl" refers to a radical of the formula -R3Rb where R3 is an alkyl radical as defined above and Rb is one or more aryl radicals as defined above, e.g., benzyl, diphenylmethyl and the like. The aryl radical(s) may be optionally substituted as described above.
"Aryloxy" refers to a radical of the formula -ORb where Rb is an aryl group as defined above. The aryl part of the aryloxy radical may be optionally substituted as defined above.
"Aralkenyl" refers to a radical of the formula -RcRb where Rc is an alkenyl radical as defined above and Rb is one or more aryl radicals as defined above, which may be optionally substituted as described above. The aryl part of the aralkenyl radical may be optionally substituted as described above for an aryl group. The alkenyl part of the aralkenyl radical may be optionally substituted as defined above for an alkenyl group.
"Aralkyloxy" refers to a radical of the formula -ORb where Rb is an aralkyl group as defined above. The aralkyl part of the aralkyloxy radical may be optionally substituted as defined above. "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptly, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, oxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R15-OR14, -R15-OC(O)-R14, -R15-N(R14)2, -R15-C(O)R14, -R15-C(O)OR14, -R15-C(O)N(R14)2, -R15-N(R14)C(O)OR16, -R15-N(R14)C(O)R16, -R15-N(R14)S(O)tR16 (where t is 1 to 2), -R15-S(O)tOR16 (where t is 1 to 2), -R15-S(O)tR16 (where t is 0 to 2) and -R15-S(O),N(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a direct bond or a straight or branched alkylene or alkenylene chain; and each R16 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted.
"Cycloalkylalkyl" refers to a radical of the formula -R3Rd where R3 is an alkyl radical as defined above and Rd is a cycloalkyl radical as defined above. The alkyl radical and the cycloalkyl radical may be optionally substituted as defined above. "Fused" refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom. As used herein, a fused ring can be represented by, for
example,
Figure imgf000054_0001
or simply A.
"Halo" refers to bromo, chloro, fluoro or iodo.
"Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 -fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl and the like. The alkyl part of the haloalkyl radical may be optionally substituted as defined above for an alkyl group.
"Heterocyclyl" refers to a stable 3- to 18-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1 ,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1 ,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, the term "heterocyclyl" is meant to include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R15-OR14, -R15-OC(O)-R14, -R15-N(R14)2, -R15-C(O)R14, -R15-C(O)OR14, -R15-C(O)N(R14)2, -R15-N(R14)C(O)OR16, -R15-N(R14)C(O)R16, -R15-N(R14)S(O)tR16 (where t is 1 to 2), -R15-S(O)tOR16 (where t is 1 to 2), -R15-S(O)tR16 (where t is 0 to 2) and -R15-S(O)tN(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a direct bond or a straight or branched alkylene or alkenylene chain; and each R16 is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted.
"Heterocyclylalkyl" refers to a radical of the formula -RaRe where R3 is an alkyl radical as defined above and Re is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl radical at the nitrogen atom. The alkyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for an alkyl group. The heterocyclyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for a heterocyclyl group.
"Heteroaryl" refers to a 5- to 18-membered aromatic ring radical which consists of one to seventeen carbon atoms and from one to ten heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[ύ][1 ,4]dioxepinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1 ,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-phenyl-1/-/-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, the term "heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, oxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R15-OR14, -R15-OC(O)-R14, -R15-N(R14)2> -R15-C(O)R14, -R15-C(O)OR14, -R15-C(O)N(R14)2, -R15-N(R14)C(O)OR16, -R15-N(R14)C(O)R16, -R15-N(R14)S(O)tR16 (where t is 1 to 2), -R15-S(O)tOR16 (where t is 1 to 2), -R15-S(O),R16 (where t is 0 to 2) and -R15-S(O),N(R14)2 (where t is 1 to 2) where each R14 is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R15 is independently a direct bond or a straight or branched alkylene or alkenylene chain; and each R16 is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of the above substituents is unsubstituted.
"Heteroarylalkyl" refers to a radical of the formula -RaRf where Ra is an alkyl radical as defined above and Rf is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkyl radical may be optionally substituted as defined above for a heteroaryl group. The alkyl part of the heteroarylalkyl radical may be optionally substituted as defined above for an alkyl group.
"Heteroarylalkenyl" refers to a radical of the formula -RbRf where Rb is an alkenyl radical as defined above and Rf is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkenyl radical may be optionally substituted as defined above for a heteroaryl group. The alkenyl part of the heteroarylalkenyl radical may be optionally substituted as defined above for an alkenyl group.
"Trihaloalkyl" refers to an alkyl radical, as defined above, that is substituted by three halo radicals, as defined above, e.g., trifluoromethyl. The alkyl part of the trihaloalkyl radical may be optionally substituted as defined above for an alkyl group. "Trihaloalkoxy" refers to a radical of the formula -OR9 where R9 is a trihaloalkyl group as defined above. The trihaloalkyl part of the trihaloalkoxy group may be optionally substituted as defined above for a trihaloalkyl group.
"Analgesia" refers to an absence of pain in response to a stimulus that would normally be painful. "Allodynia" refers to a condition in which a normally innocuous sensation, such as pressure or light touch, is perceived as being extremely painful.
"Prodrugs" is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term "prodrug" refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention. Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam)). A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention. Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the invention and the like.
The invention disclosed herein is also meant to encompass all pharmaceutically acceptable compounds of any of formulae (l)-(XI)being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 150, 17O, 180, 31P, 32P, 35S, 18F, 36CI, 123I, and 125I, respectively. These radiolabeled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action on the sodium channels, or binding affinity to pharmacologically important site of action on the sodium channels. Certain isotopically-labelled compounds of any of formulae (I)-(XI)), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of any of formulae (l)-(XI)can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples and Preparations as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
The invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reducation, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically are identified by administering a radiolabeled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its coversion products from the urine, blood or other biological samples. "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
"Mammal" includes humans and both domestic animals such as laboratory animals and household pets, ( e.g. cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildelife and the like.
"Optional" or "optionally" means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
"Pharmaceutically acceptable carrier, diluent or excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
"Pharmaceutically acceptable salt" includes both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1 ,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1 ,5- disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
"Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, Λ/-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
Often crystallizations produce a solvate of the compound of the invention. As used herein, the term "solvate" refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesqui hydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
A "pharmaceutical composition" refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor. "Therapeutically effective amount" refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of a sodium channel-mediated disease or condition in the mammal, preferably a human. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, the manner of administration, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
"Treating" or "treatment" as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes: (i) preventing the disease or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it;
(ii) inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or
(iv) relieving the symptoms resulting from the disease or condition, i.e., relieving pain without addressing the underlying disease or condition.As used herein, the terms "disease" and "condition" may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
The compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centres and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallisation. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any said compounds.
Also within the scope of the invention are intermediate compounds of any of formulae (I)-(XI) and all polymorphs of the aforementioned species and crystal habits thereof. The chemical naming protocol and structure diagrams used herein are a modified form of the I. U. P. A. C. nomenclature system, using the ACD/Name Version 9.07 software program and/or ChemDraw Version 10.0 software naming program, wherein the compounds of the invention are named herein as derivatives of the central core structure, i.e., the 2-oxindole structure. For complex chemical names employed herein, a substituent group is named before the group to which it attaches. For example, cyclopropylethyl comprises an ethyl backbone with cyclopropyl substituent. In chemical structure diagrams, all bonds are identified, except for some carbon atoms, which are assumed to be bonded to sufficient hydrogen atoms to complete the valency. Thus, for example, a compound of formula (IV) wherein p is 0, t is 0, q is 2, j is
0, k is1 , Q is -O-, E is -N=, W is -CH=, X is -CH=,
Figure imgf000062_0001
is a fused phenyl ring,
Figure imgf000062_0002
is a fused phenyl ring and two R3S together with the carbon ring atoms to which they are attached form a fused dioxolyl ring; Ae., a compound of the following formula:
Figure imgf000062_0003
is named herein as spiro[furo[2,3-/][1 ,3]benzodioxole-7,9'-imidazo[1 ,2-a]indole]. In one aspect, the invention provides compounds of formula (I):
Figure imgf000063_0001
wherein: each t is independently 0, 1, 2, 3 or 4; v is 1 , 2 or 3;
each
Figure imgf000063_0002
is independently a fused aryl ring, a fused heterocyclyl ring or a fused heteroaryl ring;
Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or
-R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3,
-R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
One embodiment provides compounds of formula (I), wherein: v is 1 ;
one
Figure imgf000066_0001
is a fused aryl ring and the other
Figure imgf000066_0002
a fused heterocyclic ring or a fused heteroaryl ring;
R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; and each R3 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H- spiro[furo[3,2-/]indolizine-8,3l-indole]-2l,4(1lH)-dione
1'-{[5-(trifluoromethyl)-2-thienyl]methyl}-6,7-dihydro-4H- spiro[furo[3,2-/]indolizine-8>3'-indole]-2',4(1'/-/)-dione
Figure imgf000066_0003
Figure imgf000067_0001
1'-[(5-chloro-2-thienyl)methyl]-6,7-dihydro-4H-spiro[furo[3,2- /]indolizine-8,3'-indole]-2',4(1'H)-dione
1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-6,7-dihydro-4H- spiro[furo[3,2-/]indolizine-8,3l-indole]-2l,4(1lH)-dione
Figure imgf000067_0002
Figure imgf000067_0003
7'-fluoro-1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H- spiro[furo[3,2-f]indolizine-8,3'-indole]-2',4(1Η)-dione
1'-[(1-isopropylpyrrolidin-3-yl)methyl]-6,7-dihydro-4H- spiro[furo[3,2-/]indolizine-8,3l-indole]-2l,4(1'H)-dione
Figure imgf000067_0004
Figure imgf000067_0005
3-[(2'14-dioxo-6,7-dihydro-4/-/-spiro[furo[3,2-/]indolizine-8,3'- indol]-1'(2'H)-yl)methyl]-Λ/-isopropylpyrrolidine-1-carboxamide
1'-[(1-isopropylpiperidin-4-yl)methyl]-6,7-dihydro-4/-/- spiro[furo[3,2-flindolizine-8,3'-indole]-2',4(1'H)-dione
1'-[(1-acetylpiperidin-4-yl)methyl]-6,7-dihydro-4H-spiro[furo[3,2- /]indolizine-8,3'-indole]-2',4(1'/-/)-dione
4-[(2',4-dioxo-6,7-dihydro-4/-/-spiro[furo[3,2-/]indolizine-8,31- indol]-1 '(2'/-/)-yl)methyl]-Λ/-isopropylpiperidine-1 -carboxamide
Figure imgf000068_0001
3-[(2',4-dioxo-6,7-dihydro-4H-spiro[furo[3,2-f]indolizine-8,3'- indol]-1 '(2'H)-yl)methyl]-Λ/-isopropylpiperidine-1 -carboxamide
3-methyl-1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H- spiro[furo[3,2-/]indolizine-8>3l-indole]-2',4(1l/-0-dione
Figure imgf000068_0002
2,3-dimethyl-1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro- 4H-spiro[furo[3,2-f]indolizine-8,3'-indole]-2\4(1Η)-diorιe
1 '-methyl-1 -{[5-(trifluoromethyl)-2-furyl]methyl}-6',7'- dihydrospiro[indole-3,8'-pyrrolo[3,2-f]indolizine]-2,4X1 H1I1H)- dione
1-{[5-(trifluoromethyl)-2-furyl]methyl}-6\7'-dihydro-4'H- spiro[indole-3,8'-thieno[3,2-/]indolizine]-2,4I(1H)-dione
1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H-spiro[1,3- dioxolo[4,5-/]indolizine-8,3'-indole]-2l,4(1lH)-dione
Figure imgf000069_0001
1 >3-oxazol-5-yl)methyl]-2'-thioxo-r,2l,6,7- piro[1 ,3-dioxolo[4,5-/]indolizine-8,3'-indol]-4-
1 >3-thiazol-5-yl)methyl]-2'-thioxo-ri2',6,7- piro[1 ,3-dioxolo[4,5-/]indolizine-8,3'-indol]-4-
Figure imgf000069_0002
Figure imgf000069_0003
Figure imgf000070_0001
r-Kδ-chloro-Σ-furyOmethyq^'-thioxo-r^'.β.y-tetrahydro^H-
Figure imgf000070_0002
r-[(5-chloro-2-thienyl)methyl]-2'-thioxo-r,2',6,7-tetrahydro-4H- spiro[1 ,3-dioxolo[4,5-/]indolizine-8,3'-indol]-4-one
Figure imgf000070_0003
Figure imgf000070_0004
1 -[(2-isopropyl-1.S-thiazol-δ-yOmethyll-δ'J'-dihydro-i H,4'H- spiro[2>1-benzisothiazole-3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4l-one
2-oxide
1 -{[5-(trifluoromethyl)-2-furyl]methyl}-6l,7'-dihydro-1 H,4'H- spiro[2,1-benzisothiazole-3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4'-one
2-oxide
Figure imgf000070_0005
ne
Figure imgf000070_0006
Figure imgf000071_0001
1 -[(5-chloro-2-thienyl)methyl]-6',7'-dihydro-1 H,4'tf-spiro[2, 1 - benzisothiazole-3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2-oxide
1 -[(2-isopropyl-1 ,3-oxazol-5-yl)methyl]-6',7'-dihydro-1 H ,4' H- spiro[2,1-benzisothiazole-3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4l-one
2,2-dioxide
1-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-6\7'-dihydro-1H,4'H- spiro[2,1-benzisothiazole-3,841 ,3]dioxolo[4,5-/]indolizin]-4'-one
2,2-dioxide
1 -{[5-(trifluoromethy!)-2-furyl]methyl}-6l,7l-dihydro-1 HA1H- spiro[2,1-benzisothiazole-3,8'-[1.3]dioxolo[4,5-f]indolizin]-4'-one
2,2-dioxide
Figure imgf000071_0002
ne
Figure imgf000071_0003
1-[(5-chloro-2-furyl)methyl]-6',7'-dihydro-1H,4'H-spiro[2,1- benzisothiazole-3,8'-[1 ,3]dioxolo[4,5-fjindolizin]-4'-one 2,2- dioxide
Figure imgf000071_0004
1 -[(5-chloro-2-thienyl)methyl]-6\7'-dihydro-1 H,4'H-spiro[2, 1 ■ benzisothiazole-3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2,2- dioxide
Figure imgf000072_0001
Another embodiment provides compounds of formula (I), wherein: v is 1 ;
each
Figure imgf000072_0002
independently a fused heterocyclic ring or a fused heteroaryl ring;
R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; and each R3 is alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name r-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H- spiro[furo[3,2-f]indolizine-8,3'-pyrrolo[2,3-ύ]pyridine]-2\4(1Η)- dione
r-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H- spiro[furo[3,2-/]indolizine-8,3'-pyrrolo[3,2-ib]pyridine]-2',4(1'H)- dione
Figure imgf000072_0003
Figure imgf000073_0001
In another aspect, the invention provides compounds of formula (II):
Figure imgf000073_0002
wherein: t, v and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000073_0003
a annHd
Figure imgf000073_0004
are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN; R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4,
-R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a and R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5,
-N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a and R2b may be independently optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; or two adjacent R2b together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. One embodiment provides compounds of formula (II), wherein: j is 0 and k is 1 ; Q is -O-;
Figure imgf000076_0001
a anntdλ
Figure imgf000076_0002
are each a fused aryl ring; R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5,
-R8-C(O)OR5, R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4,-R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; and two adjacent R3 together with the carbon ring atoms to which they are directly attached, form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl.
Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
10-{[5-(trifluoromethyl)-2-furyl]methyl}-10H-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
10-{[5-(trifluoromethyl)-2-thienyl]methyl}-10H-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
Figure imgf000077_0001
[(5-chloro-2-furyl)methyl]-10H-spiro[acridine-9,7'-furo[2,3- ,3]benzodioxole]
Figure imgf000077_0002
Figure imgf000077_0003
10-[(2-chloro-1 ,3-oxazol-5-yl)methyl]-10H-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
10-[(2-chloro-1 ,3-thiazol-5-yl)methyl]-10/-/-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
10-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-10/-/-spiro[acridine-9,71- furo[2,3-/][1 ,3]benzodioxole]
Figure imgf000077_0004
10-[(2-isopropyl-1 ,3-oxazol-5-yl)methyl]-10H-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
Figure imgf000078_0001
(2-thienylmethyl)-1 OH-spirotacridine-ΘJ'-furoP.S- ,3]benzodioxole]
(2-furylmethyl)-10H-spiro[acridine-9,7'-furo[2,3- ,3]benzodioxole]
Figure imgf000078_0002
Figure imgf000078_0003
5-(10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxol]-10- ylmethyl)-2-furonitrile
5-(10/-/-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxol]-10- ylmethyl)thiophene-2-carbonitrile N
10-benzyl-10/-/-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]
Figure imgf000078_0004
Figure imgf000079_0001
10-(pyridin-3-ylmethyl)-10H-spiro[acridine-9,7'-furo[2,3- /][1 ,3]benzodioxole]
10-[(1-methylpiperidin-4-yl)methyl]-10/-/-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
Figure imgf000079_0002
sopropyl-4-(10H-spiro[acridine-9,7'-furo[2,3- ,3]benzodioxol]-10-ylmethyl)piperidine-1 -carboxamide
Figure imgf000079_0003
ethyl-3-(10H-spiro[acridine-9,7'-furo[2,3- nzodioxol]-10-ylmethyl)piperidine-1 -carboxamide
Figure imgf000079_0004
10-[(1-acetylpiperidin-3-yl)methyl]-10/-/-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
10-[(1-isopropylpyrrolidin-3-yl)methyl]-10/-/-spiro[acridine-9,7'- furo[2,3-/][1 ,3]benzodioxole]
Figure imgf000079_0005
Another embodiment provides compounds of formula (II), wherein: j is 0 and k is 1 ; Q is -O-;
at least one
Figure imgf000080_0001
and
Figure imgf000080_0002
is a fused heterocyclic ring or a fused heteroaryl ring; R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5,
-R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4,
-R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R3 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; and each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000080_0003
Figure imgf000081_0001
10-[(5-chloro-2-thienyl)methyl]-5'-methoxy-10/-/-spiro[acridine- 9,3'-furo[3,2-ύ]pyridine]
5-[(5'-methoxy-10H-spiro[acridine-9,3'-furo[3,2-6]pyridin]-10- yl)methyl]thiophene-2-carbonitrile
5'-methoxy-10-[(5-methyl-2-thienyl)methyl]-10/-/-spiro[acridine- 9,3'-furo[3,2-jb]pyridine]
Figure imgf000081_0002
Figure imgf000081_0003
10-(2-furylmethyl)-5'-methoxy-10H-spiro[acridine-9>3'-furo[3>2- jb]pyridine]
2'-methoxy-10'-{[5-(trifluoromethyl)-2-furyl]methyl}-10'H-spiro[1- benzofuran-3,5'-benzo[d][1 ,8]naphthyridine]
10'-[(5-chloro-2-thienyl)methyl]-2'-methoxy-10'H-spiro[1 - benzofuran-3,5'-benzo[jb][1 ,8]naphthyridine]
Figure imgf000081_0004
Figure imgf000082_0001
In another aspect, the invention provides compounds of formula (III):
Figure imgf000082_0002
wherein: p and q are each independently 0, 1 , 2, 3 or 4; v is 0, 1 or 2; represents an optional double bond;
J, Q and E are each independently -N=, -CR2b=, -NR2b- or -C(R2b)2-; each D and X are independently N or C, provided when D is N, X is C, or when D is C,
X is N; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-;
Figure imgf000083_0001
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or
-R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5,
-R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4,
-R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3,
-R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4; -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)nR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. One embodiment provides compounds of formula (III), wherein: at least one of J and Q is -N=, and the other is -N=, -CR2b=, -NR2b- or -C(R2b)2-;
E is -N=, -CR2b=, -NR2b- or -C(R2b)2-;
D is C;
X is N; R1 is hydrogen, aikyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclylalkyl or the heteroarylalkyl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R2b is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4,
-N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3,
-R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain. A further embodiment provides compounds of formula (III), wherein: v is 1 ; X is N;
D is C;
Z is -C(O)- or -C(S)-;
E, Q and J are each independently -N= or -CH=; and
each
Figure imgf000089_0001
and are independently a fused aryl ring or a fused heteroaryl ring.
Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
line-
1 ■
Figure imgf000089_0002
1'-(pyridin-3-ylmethyl)spiro[1,3-dioxolo[4,5-Sf]tetrazolo[5,1- a]isoquinoline-6,3'-indol]-2'(1'H)-one
1 '-[(6-methoxypyridin-3-yl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'H)-one
1'-[(1-isopropylpiperidin-4-yl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'H)-one
1'-[(1-acetylpiperidin-4-yl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'H)-one
Λ/-isopropyl-4-[(2'-oxospiro[1 ,3-dioxolo[4,5-g]tetrazolo[5,1 ■ a]isoquinoline-6,3'-indol]-1 '(2l/-/)-yl)methyl]piperidine-1 - carboxamide
Figure imgf000090_0001
1'-[(1-isopropylpiperidin-3-yl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1Η)-one
Figure imgf000090_0002
Λ/-isopropyl-3-[(2'-oxospiro[1 ,3-dioxolo[4,5-g]tetrazolo[5,1- a]isoquinoline-6,3'-indol]-1 '(2'H)-yl)methyl]piperidine-1 - carboxamide
1'-[(1-acetylpiperidin-3-yl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'/-/)-one
1'-[(1-isopropylpyrrolidin-3-yl)methyl]spiro[1 ,3-dioxolo[4,5- gf]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'H)-one
Λ/-isopropyl-3-[(2'-oxospiro[1 ,3-dioxolo[4,5-g]tetrazolo[5,1- a]isoquinoline-6,3'-indol]-1 '(2'H)-yl)methyl]pyrrolidine-1 - carboxamide
Figure imgf000091_0001
,5-
Figure imgf000091_0002
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5>1-a]isoquinoline-6,3'-indol]-2'(1Η)-one
Figure imgf000091_0003
1'-{[5-(trifluoromethyl)-2-thienyl]methyl}spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'/-/)-one
14(5-chloro-2-thienyl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'H)-one
1 '-[(5-chloro-2-furyl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3l-indol]-2'(1'/-/)-one
1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1'/-/)-one
Figure imgf000092_0001
olo[4,5-
Figure imgf000092_0002
1 '-[(5-methyl-2-furyl)methyl]spiro[1 ,3-dioxolo[4,5- g]tetrazolo[5, 1 -a]isoquinoline-6,3'-indol]-2'( 1 '/-/)-one
Figure imgf000092_0003
Figure imgf000093_0001
1-[(5-chloro-2-furyl)methyl]-8'-methoxyspiro[indole-3,6'- tetrazolo[5,1-fl[1 ,6]naphthyridine]-2(1/-/)-thione
8'-methoxy-1-{[5-(trifluoromethyl)-2- furyl]methyl}spiro[indole-3,6'-tetrazolo[5, 1 - /][1 ,6]naphthyridine]-2(1H)-thione
8'-methoxy-1-{[5-(trifluoromethyl)-2- furyl]methyl}spiro[indole-3,6'-[1 ,2,3]triazolo[5, 1 ■ /][1 ,6]naphthyridine]-2(1 H)-thione
Figure imgf000094_0001
hoxyspiro[indole-3,6'- e]-2( 1 H)-thione
Figure imgf000094_0002
1 -[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-8'- methoxyspiro[indole-3,6'-[1 ,2,3]triazolo[5, 1 - /][1 ,6]naphthyridine]-2(1H)-thione
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[1 ,3-dioxolo[4,5- g][1 ,2,3]triazolo[5,1-a]isoquinoline-6,3'-indol]-2'(1l/-/)-one
Figure imgf000094_0003
1 '-[(5-chloro-2-thienyl)methyl]spiro[1 ,3-dioxolo[4,5- g][1,2,3]triazolo[5,1-a]isoquinoline-6,3'-indol]-2l(1l/-/)-one
1 '-[(5-methyl-2-furyl)methyl]spiiO[1 ,3-dioxolo[4,5- g][1 ,2,3]triazolo[5, 1 -a]isoquinoline-6,3'-indol]-2'(1 'H)-one
Figure imgf000095_0001
Figure imgf000095_0002
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[1 ,3-dioxolo[4,5- g][1 ,2,3]triazolo[5,1-a]isoquinoline-6,3'-pyrrolo[2,3- b]pyridin]-2'(rH)-one
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[1 ,3-dioxolo[4,5- g][1 ,2,3]triazolo[5, 1 -a]isoquinoline-6,3'-pyrrolo[3,2- b]pyridin]-2'(rH)-one
Figure imgf000095_0003
trifluoromethyl)-2-furyl]methyl}spiro[1 ,3- ,2,3]triazolo[5,1-a]isoquinoline-6,3'-indol]-
Figure imgf000095_0004
,3-
-
Figure imgf000096_0001
1 '-[(5-chloro-2-thienyl)methyl]spiro[1 ,3-dioxolo[4,5- g]imidazo[5,1-a]isoquinoline-6,3'-indol]-2'(1'H)-one
1 '-[(5-methyl-2-furyl)methyl]spiro[1 ,3-dioxolo[4,5- g]imidazo[5,1-a]isoquinoline-6,3'-indol]-2'(1'/-/)-one
5-[(2'-oxospiro[1 ,3-dioxolo[4,5-g]imidazo[5,1-a]isoquinoline- 6,3'-indol]-1'(2'H)-yl)methyl]-2-furonitrile
Figure imgf000096_0002
,3-thiazol-5-yl)methyl]-8- dazo[5,1-/][1 ,6]naphthyridine-6,3'-indol]-
Figure imgf000096_0003
piro[imidazo[5, 1 ■
Figure imgf000097_0001
1 '-[(5-chloro-2-thienyl)methyl]-8-methoxyspiro[imidazo[5, 1 ■ /][1 ,6]naphthyridine-6,3'-pyrrolo[2><b]pyridin]-2χiΗ)-one
Figure imgf000097_0002
Figure imgf000097_0003
l]-7'-fluoro-8- 1,6]naphthyridine-6,3'-indol]-
Figure imgf000097_0004
7'-fluoro-8-methoxy-1'-{[5-(trifluoromethyl)-2- furyl]methyl}spiro[imidazo[5,1-/][1 l6]naphthyridine-6,3'- indol]-2'(1'H)-one
Figure imgf000097_0005
)-2- thyridine-6,3'-
Figure imgf000097_0006
dazo[5,1-
-
1 -
Figure imgf000098_0001
Another embodiment provides compounds of formula (III), wherein: at least one of Q and E is -N=, and the other is -N=, -CR2b=, -NR2b- or -C(R2V;
J is -N=, -CR2b=, -NR2b- or -C(R2tV;
X is C;
D is N;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclylalkyl or the heteroarylalkyl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5JS(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R2b is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5,
-R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain.
A further embodiment provides compounds of formula (III), wherein: v is 1 ; X is C; D is N;
Z is -C(O)- or -C(S)-;
E, Q and J are each independently -N= or -CH=; and
each
Figure imgf000101_0001
and v — ' are independently a fused aryl ring or a fused heteroaryl ring. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
1 '-benzyl-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1Η)-one
1 '-(4-fluorobenzyl)-4/-/-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1'H)-one
1 '-(4-methoxybenzyl)-4H-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1'/-/)-one
Figure imgf000101_0002
1'-(1 ,3-benzodioxol-5-ylmethyl)-4/-/-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1'/-/)-one
Figure imgf000102_0001
Figure imgf000102_0002
1 '-[(6-methoxypyridin-3-yl)methyl]-4/-/-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3l-indol]-2'(1'/-/)-one
1'-[(1-isopropylpiperidin-4-yl)methyl]-4/-/-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2l(1'/-/)-one
1'-[(1-acetylpiperidin-4-yl)methyl]-4H-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1'H)-one
Λ/-isopropyl-4-[(2'-oxo-4/-/-spiro[1,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-1 '(2'H)- yl)methyl]piperidine-1-carboxamide
Figure imgf000102_0003
Figure imgf000103_0001
Λ/-isopropyl-3-[(2'-oxo-4H-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-1 '(2'H)- yl)methyl]piperidine-1-carboxamide
1'-[(1-acetylpiperidin-3-yl)methyl]-4H-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1Η)-one
1'-[(1-isopropylpyrrolidin-3-yl)methyl]-4H-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1'H)-one
Λ/-isopropyl-3-[(2'-oxo-4/-/-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-1 '(2'H)- yl)methyl]pyrrolidine-1-carboxamide
1'-[(1-acetylpyrrolidin-3-y!)methyl]-4H-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1'H)-one
Figure imgf000103_0002
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4H-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3I-indol]-2'(1lH)-one
1 '-{[5-(trifluoromethyl)-2-thienyl]methyl}-4/-/-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5)3'-indol]-2'(1'/-/)-one
1 '-[(5-chloro-2-furyl)methyl]-4H-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(17-/)-one
1 '-[(5-chloro-2-thienyl)methyl]-4/-/-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1'H)-one
1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-4/-/-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3l-indol]-2'(1l/-/)-one
Figure imgf000104_0001
Figure imgf000104_0002
1 '-[(5-methyl-2-furyl)methyl]-4H-spiro[1 ,3-dioxolo[4,5- g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2'(1'/-/)-one
Figure imgf000104_0003
,5-
Figure imgf000105_0001
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4H-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-pyrrolo[2,3-
6]pyridin]-2'(rH)-one
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4H-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-pyrrolo[3,2-
<b]pyridin]-2'(1'H)-one
Figure imgf000105_0002
H)-one
Figure imgf000105_0003
1-[(5-chloro-2-thienyl)methyl]-7'-methoxy-4Η-spiro[indole- 3,5'-tetrazolo[1 ,5-a][1 ,5]naphthyridin]-2(1H)-one
1-[(5-chloro-2-furyl)methyl]-7'-methoxy-4lH-spiro[indole-3,51- tetrazolo[1 ,5-a][1 ,5]naphthyridin]-2(1 H)-one
Figure imgf000105_0004
1-[(5-chloro-2-furyl)methyl]-7l-methoxy-4'H-spiro[indole-3,5l- tetrazolo[1 ,5-a][1 ,5]naphthyridine]-2(1H)-thione
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4H-spiro[1 ,3- dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indole]-2'(1'/-/)- thione
Figure imgf000106_0001
In another aspect, the invention provides compounds of formula (IV):
Figure imgf000106_0002
wherein: t and q are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3; Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
X, W, E are each independently -N= or -CH=;
Figure imgf000106_0003
a annHd are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2) -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4 -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
One embodiment provides compounds of formula (IV), wherein: j is 0; k is 1;
Q is -O-; and E, X and W are each -N=.
Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Sctructure Chemical Name spiro[furo[2,3-f][1,3]benzodioxole-7,91- tetrazolo[1 ,5-a]indole]
5-methoxyspiro[furo[3,2-/j]pyridine-3,9'- tetrazolo[1 ,5-a]indole]
8'-pyrimidin-5-ylspiro[furo[2,3-/][1 ,3]benzodioxole- 7,9'-tetrazolo[1 ,5-a]indole]
Figure imgf000109_0001
Another embodiment provides compounds of formula (IV), wherein: j is O; k is 1 ; Q is -O-;
E and W are each -N=; and X is -CH=.
Specific examples of this embodiment include, but are not limited to, the following compounds: Chemical Sctructure Chemical Name
Figure imgf000110_0001
Another embodiment provides compounds of formula (IV), wherein: j is O; k is 1 ; Q is -O-;
X and W are each -N=; and E is -CH=.
Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Sctructure Chemical Name
Figure imgf000110_0002
Figure imgf000111_0001
Another embodiment provides compounds of formula (IV), wherein: j is O; k is 1 ; Q is -O-;
E and X are each -CH=; and
W is -N=.
Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Sctructure Chemical Name spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'- pyrazolo[1 ,5-a]indole]
5-methoxyspiro[furo[3,2-jfc>]pyridine-3,4'- pyrazolo[1 ,5-a]indole]
5'-pyrimidin-5-ylspiro[furo[2,3-/][1 ,3]benzodioxole- 7,4'-pyrazolo[1 ,5-a]indole]
Figure imgf000111_0002
Another embodiment provides compounds of formula (IV), wherein: j is O; k is 1 ; Q is -O-; E and W are each -CH=; and X is -N=.
Chemical Sctructure Chemical Name ,5-
Figure imgf000112_0001
In another aspect, the invention provides compounds of formula (V):
Figure imgf000112_0002
wherein: t and p are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-
-OC(O)-, -C(O)N(R5)- or -N(R5)C(0)-; R1a is hydrogen or -OR5; X is hydrogen or halo;
Figure imgf000113_0001
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN; R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4, and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
One embodiment provides compounds of formula (V), wherein: j is O; k is O; p is 2; Q is -O- or -NH-;
X is hydrogen or fluoro;
each
Figure imgf000116_0001
and are independently a fused aryl ring;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; and two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl.
Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
H-
Figure imgf000116_0002
Figure imgf000117_0001
Figure imgf000118_0001
Another embodiment provides compounds of formula (V), wherein: j is O; k is O;
Q is -O-, -S(O)m- (m is 0 or 2) or -NH-;
X is hydrogen or fluoro;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN, or -R8-NO2;
is a fused aryl ring; and
Figure imgf000118_0002
is a fused heteroaryl ring. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name 10b-fluoro-9-methoxy-2-{[5-(trifluoromethyl)-2- thienyl]methyl}-2, 10b-dihydro-1 H- pyrido[2',3':5,6]pyrano[4,3,2-cc/]indol-1-one
Figure imgf000119_0001
-2-
Figure imgf000119_0002
9-methoxy-2-{[5-(trifluoromethyl)-2-furyl]methyl}- 2,1 Ob-dihydro-1
Figure imgf000119_0003
cc/]indol-1-one
Figure imgf000119_0004
oro-2-thienyl)methyl]-9-methoxy-2, 10b- 1 H-pyrido[2',3':5,6]pyrano[4,3,2-cαf]indol-1-
Figure imgf000119_0005
2-[(5-chloro-2-furyl)methyl]-9-methoxy-6, 10b- dihydroindolo[4,3-bc][1 ,5]naphthyridin-1 (2H)-one
Figure imgf000119_0006
oromethyl)-2-furyl]methyl}- ,3-ibc][1 ,5]naphthyridin-1 (2H)-
Figure imgf000119_0007
9-methoxy-2-{[5-(trifluoromethyl)-2-furyl]methyl}- 2,1 Ob-dihydro-1 H-pyrido[2',3':5,6]thiopyrano[4,3,2- cc/]indol-1-one
Figure imgf000119_0008
Figure imgf000120_0001
2-[(5-chloro-2-thienyl)methyl]-9-methoxy-2, 1 Ob- dihydro-1H-pyrido[2',3':5,6]thiopyrano[4,3,2-cc0indol- 1-one 6,6-dioxide
Figure imgf000120_0002
Another embodiment provides compounds of formula (V), wherein: j is O; k is O; P is 2;
Q is -O-, -S- or -NH-; X is hydrogen or fluoro;
is a fused aryl ring;
Figure imgf000120_0003
is a fused heteroaryl ring;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alky!, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; and two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl.
Specific examples of this embodiment include, but are not limited to, the following compounds: Chemical Structure Chemical Name
11 b-fluoro-2-{[5-(trifluoromethyl)-2-furyl]methyl}-
2,11 b-dihydro-1H-6,8,10-trioxa-2,3- diazacyclopenta[/c]aceanthrylen-1-one
2-[(5-chloro-2-thienyl)methyl]-11 b-fluoro-2, 11 b- dihydro-1 H-6,8, 10-trioxa-2,3- diazacyclopenta[/c]aceanthrylen-1-one
2-[(5-chloro-2-thienyl)methyl]-11 b-fluoro-6, 11 b- dihydro[1 ,3]benzodioxolo[5,6-b]pyrrolo[4,3,2- de][1 ,6]naphthyridin-1 (2/-/)-one
Figure imgf000121_0001
Another embodiment provides compounds of formula (V), wherein: j is O; k is O;
Q is -O-, -S- or -NH-;
X is hydrogen or fluoro;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; and
each
Figure imgf000121_0002
and are independently a fused heteroaryl ring.
Specific examples of this aspect include, but are not limited to, the following compounds: Chemical Structure Chemical Name
2-[(5-chloro-2-thienyl)methyl]-9-methoxy-2, 10b- dihydro-1 H-6-oxa-2,3, 10-triazaaceanthrylen-1 -one
2-[(5-chloro-2-furyl)methyl]-9-methoxy-2, 10b- dihydro-1 H-6-oxa-2,3, 10-triazaaceanthrylen-1 -one
Figure imgf000122_0001
loro-2-thienyl)methyl]-10b-fluoro-9-methoxy- ihydro-1 H-6-thia-2,3, 1 O-triazaaceanthrylen-
Figure imgf000122_0002
2-[(5-chloro-2-thienyl)methyl]-9-methoxy-2, 10b- dihydro-1 H-6-thia-2,3, 10-triazaaceanthrylen-1 -one
Figure imgf000122_0003
In another aspect, the invention provides compounds of formula (Vl):
Figure imgf000122_0004
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)1n- (where m is O1 1 or 2), -CF2-, -C(O)O-, -OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000123_0001
is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; Y is aryl, heterocyclic or heteroaryl ring; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is O, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl,
-R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R*)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
One embodiment provides compounds of formula (Vl), wherein: j is O; k is 2; Q is -O-; Z is -C(O)-;
Figure imgf000126_0001
is a fused aryl ring; and Y is aryl or heteroaryl.
Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000126_0002
2a-(1 ,3-benzodioxol-5-yl)-1-{[5-(trifluoromethyl)-2-furyl]methyl}- 1 ,2a,4,5-tetrahydro-2H-pyrano[2,3,4-cc/]indol-2-one
Figure imgf000126_0003
-benzodioxol-5-yl)-1-{[5-(trifluoromethyl)-2- methyl}-1,2a,4,5-tetrahydro-2H-pyrano[2,3,4-coφndol-2-
Figure imgf000126_0004
2a-(1 ,3-benzodioxol-5-yl)-1-[(5-chloro-2-thienyl)methyl]- 1 ,2a,4,5-tetrahydro-2H-pyrano[2,3,4-cof]indol-2-one
2a-(1 ,3-benzodioxol-5-yl)-1 -[(5-chloro-2-furyl)methyl]-1 ,2a,4,5- tetrahydro-2H-pyrano[2,3,4-cd]indol-2-one
2a-(1 ,3-benzodioxol-5-yl)-1 -(4-fluorobenzyl)-1 ,2a,4,5- tetrahydro-2H-pyrano[2,3,4-cc/]indol-2-one
Figure imgf000126_0005
Figure imgf000127_0001
2a-(1 ,3-benzodioxol-5-yl)-1-(pyridin-3-ylmethyl)-1 ,2a,4,5- tetrahydro-2H-pyrano[2,3,4-cc/]indol-2-one
Figure imgf000127_0002
Figure imgf000127_0003
1-[(5-chloro-2-thienyl)methyl]-2a-(6-methoxypyridin-2-yl)- 1 ,2a,4,5-tetrahydro-2/-/-pyrano[2,3,4-cd]indol-2-one
Figure imgf000127_0004
)methyl]-
Figure imgf000127_0005
1-[(1-acetylpiperidin-4-yl)methyl]-2a-(1 ,3-benzodioxol-5-yl)- 1 ,2a,4,5-tetrahydro-2H-pyrano[2,3,4-cc/]indol-2-one
4-{[2a-(1 ,3-benzodioxol-5-yl)-2-oxo-2,2a,4,5-tetrahydro-1H- pyrano[2,3,4-cc(]indol-1-yl]methyl}-Λ/-isopropylpiperidine-1- carboxamide
Figure imgf000127_0006
3-{[2a-(1 ,3-benzodioxol-5-yl)-2-oxo-2,2a,4,5-tetrahydro-1 H- pyrano[2,3,4-cc/]inclol-1 -yl]methyl}-Λ/-isopropylpiperidine-1 - carboxamide
1-[(1-acetylpiperidin-3-yl)methyl]-2a-(1 ,3-benzodioxol-5-yl)- 1 ,2a,4,5-tetrahydro-2/-/-pyrano[2,3,4-cc(]indol-2-one
1-[(1-acetylpyrrolidin-3-yl)methyl]-2a-(1 ,3-benzodioxol-5-yl)- 1 ,2a,4,5-tetrahydro-2H-pyrano[2,3,4-cc/Iindol-2-one
2a-(1 ,3-benzodioxol-5-yl)-1-[(1-isopropylpyrrolidin-3-yl)methyl]- 1 ,2a,4,5-tetrahydro-2H-pyrano[2,3,4-cc/]indol-2-one
3-{[2a-(1 ,3-benzodioxol-5-yl)-2-oxo-2,2a,4,5-tetrahydro-1/-/- pyrano[2,3,4-cc/]indol-1 -yl]methyl}-Λ/-isopropylpyrrolidine-1 - carboxamide
2a-(1 ,3-benzodioxol-5-yl)-1-pentyl-1 ,2a,4,5-tetrahydro-2H- pyrano[2,3,4-cc/]indol-2-one
2a-(1,3-benzodioxol-5-yl)-1-[(5-methyl-2-furyl)methyl]-1 ,2a,4,5- tetrahydro-2H-pyrano[2,3,4-cc/]indol-2-one
Figure imgf000128_0001
5-{[2a-(1,3-benzodioxol-5-yl)-2-oxo-2,2a,4,5-tetrahydro-1/-/- pyrano[2,3,4-ccdindol-1-yl]methyl}-2-furonitrile
5-{[2a-(6-methoxypyridin-2-yl)-2-oxo-2,2a,4,5-tetrahydro-1/-/- pyrano[2,3,4-cc(]indol-1-yl]methyl}-2-furonitrile
1-[(5-chloro-2-thienyl)methyl]-8-fluoro-2a-(6-methoxypyridin-2- yl)-1 ,2a,4,5-tetrahydro-2/-/-pyrano[2,3,4-cc/]indol-2-one
Figure imgf000129_0001
Another embodiment provides compounds of formula (Vl), wherein: j is O; k is 2; Q is -O-; Z is -C(O)-;
Figure imgf000129_0002
is a fused heteroaryl ring; and Y is aryl or heteroaryl.
Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000129_0003
1-[(5-chloro-2-thienyl)methyl]-2a-(6-methoxypyridin-2-yl)- 1 ,2a,4,5-tetrahydro-2H-3-oxa-1 ,8-diazaacenaphthylen-2-one
1-[(5-chloro-2-fui7l)methyl]-2a-(6-methoxypyridin-2-yl)-1 ,2a,4,5- tetrahydro-2H-3-oxa-1 ,8-diazaacenaphthylen-2-one
2a-(6-methoxypyridin-2-yl)-1-{[5-(trifluoromethyl)-2-furyl]methyl}- 1 ,2a,4,5-tetrahydro-2H-3-oxa-1 ,8-diazaacenaphthylen-2-one
Figure imgf000130_0001
In another aspect, the invention provides compounds of formula (VII):
Figure imgf000130_0002
wherein: t and q are each independently 0, 1, 2, 3 or 4; v is 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3; Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000130_0003
and v — ' are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl,
-R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyciyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
One embodiment provides compounds of formula (VII), wherein: j is 0; k is 1 ; v is 1 ; X is O or S;
is a fused aryl ring; and
Figure imgf000133_0001
is a fused heteroaryl ring or a fused aryl ring.
Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000134_0001
1 '-pentyl-5,6-dihydro-1 'H-spiro[benzo[1 ,2-b:5,4-b Idifuran-
Figure imgf000134_0003
Figure imgf000134_0002
r-pentyl-r/-/-spiro[1-benzofuran-3,4'-quinolin]-
Figure imgf000134_0004
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 Η-spiro[furo[2,3- f][1 ,3]benzodioxole-7,4'-quinolin]-2'(3'/-0-one
1 '-[(5-chloro-2-thienyl)methyl]-1 'H-spiro[furo[2,3- /][1 l3]benzodioxole-7,4'-quinolin]-2'(3'/-/)-one
Figure imgf000134_0005
1 '-(2-cyclopropylethyl)-1 Η-spiro[furo[2,3-/][1 ,3]benzodioxole- 7,4'-quinolin]-2'(3'H)-one
Figure imgf000135_0001
Figure imgf000135_0002
1 '-{[5-(trifluoromethyl)-2-furyi]methyl}-5,6-dihydro-11H- spiro[benzo[1 ,2-ib:5,4-jb]difuran-3,4'-quinolin]-2'(3Η)-one
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-5,6-dihydro-11H- spiro[benzo[1 ,2-b:5,4-b']difuran-3,4'-quinolin]-2l(3'H)-one
Figure imgf000135_0003
Figure imgf000136_0001
hione
Figure imgf000136_0002
1 '-[(5-chloro-2-thienyl)methyl]-1 'H-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-quinoline]-2'(3'/-/)-thione
5-methoxy-1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H- spiro[furo[3,2-/)]pyridine-3,4'-quinolin]-2'(3'H)-one
1 '-[(5-chloro-2-furyl)methyl]-5-methoxy-1 Η-spiro[furo[3,2- fc»]pyridine-3,4'-quinolin]-2'(3'/-/)-one
1 '-[(5-chloro-2-thienyl)methyl]-5-methoxy-1 Η-spiro[furo[3,2- 6]pyridine-3,4'-quinolin]-2'(3'H)-one
Figure imgf000136_0003
-i '-[(2-JSOPrOPyI-1 ,3-thiazol-5-yl)methyl]-5-methoxy-1 'H- spiro[furo[3,2-/b]pyridine-3,4'-quinolin]-21(3'/-/)-one
Figure imgf000137_0001
Another embodiment provides compounds of formula (VII), wherein: j is O; k is 1; v is 1 ; X is O or S;
is a fused heteroaryl ring; and
Figure imgf000137_0002
is a fused aryl ring or a fused heteroaryl ring. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name 3-
Figure imgf000137_0003
1 '-[(5-chloro-2-thienyl)methyl]-1 'H-spiro[furo[2,3-
/][1 ,3]benzodioxole-7,4'-[1 ,5]naphthyridin]-2'(3'H)-one
1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-1 'H-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-[1 ,5]naphthyridin]-2'(3'H)-one
Figure imgf000138_0001
Figure imgf000138_0002
[furo[3,2-
ro[furo[3,2-
Figure imgf000138_0003
Figure imgf000138_0004
In another aspect, the invention provides compounds of formula (VIII):
Figure imgf000139_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3; Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(0)-; R1a is hydrogen or -OR5; Z is -N(R5)- or -O-;
Figure imgf000139_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5, -N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
One embodiment provides compounds of formula (VIII), wherein: j is O; k is 1 ; Z is -O-; Q is -O-; X is O or S; and
Figure imgf000142_0001
and v — ' are each independently a fused aryl ring or a fused heteroaryl ring. Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
1-pentylspiro[3,1-benzoxazine-4,7'-furo[2,3- /][1 ,3]benzodioxol]-2(1H)-one
Figure imgf000142_0002
1 '-pentyl-5,6-dihydrospiro[benzo[1 ,2-6:5,4-6 ]difuran-3,4r- [3,1 ]benzoxazin]-2'( 1 'H)-one
5,6-difluoro-1'-pentylspiro[1-benzofuran-3,4'- [3,1 ]benzoxazin]-2'( 1 'H)-one
1-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[3,1-benzoxazine-
Figure imgf000143_0002
, 3]benzodioxol]-2(1H)-one
1-[(5-chloro-2-thienyl)methyl]spiro[3,1-benzoxazine-4,7'- furo[2,3-/][1 ,3]benzodioxol]-2(1 H)-one
1 '-[(5-chloro-2-thienyl)methyl]-5,6-dihydrospiro[benzo[1 ,2- b-.δA-bWtfuran-ZA'-foipenzoxaήnyZiVHyone
Figure imgf000143_0001
Figure imgf000144_0001
1'-[(5-chloro-2-furyl)methyl]spiro[furo[2,3-f][1 ,3]benzodioxole- 7,4'-pyrido[3,2-c/][1 ,3]oxazin]-2'(1 'H)-one
Figure imgf000144_0002
1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3- /][1 l3]benzodioxole-7,4'-pyrido[3,2-d][1 ,3]oxazin]-2l(1l/-/)-one
Figure imgf000145_0001
(2-isopropyl-1 ,3-thiazol-5-yl)methyl]spiro[furo[2,3- ,3]benzodioxole-7,4I-pyrido[3,2-c(][1 ,3]oxazin]-2'(r/-/)-one
Figure imgf000145_0002
1 -[(5-chloro-2-thienyl)methyl]-5'-methoxyspiro[3, 1 - benzoxazine-4,3'-furo[3,2-/3]pyridine]-2(1/-/)-thione
1-[(5-chloro-2-furyl)methyl]-5'-methoxyspiro[3,1-benzoxazine- 4,3'-furo[3,2-ib]pyridine]-2(1H)-thione
5'-methoxy-1-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[3,1- benzoxazine-4,3'-furo[3,2-ύ]pyridine]-2(1H)-thione
Figure imgf000145_0003
1-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-5'-methoxyspiro[3,1- benzoxazine-4,3'-furo[3,2-ύ]pyridine]-2(1H)-thione
1 -[(5-chloro-2-thienyl)methyl]spiro[3, 1 -benzoxazine-4,7'- furo[2,3-/][1 ,3]benzodioxole]-2(1 H)-thione
1-[(5-chloro-2-furyl)methyl]spiro[3,1-benzoxazine-4,7'- furo[2,3-/][1 ,3]benzodioxole]-2(1 H)-thione
1-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[3,1-benzoxazine- 4,7l-furo[2,3-f|[1 )3]benzodioxole]-2(1H)-thione
1-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]spiro[3,1-benzoxazine- 4,7'-furo[2,3-/][1 ,3]benzodioxole]-2(1 H)-thione
Figure imgf000146_0001
Another embodiment provides compounds of formula (VIII), wherein: j is O; k is 1 ; Z is -NH-; Q is -O-; X is O or S;
Figure imgf000147_0001
are each independently a fused aryl ring or a fused heteroaryl ring. Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Structure Chemical Name spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinazolin]-
Figure imgf000147_0002
1 '-pentyl-5,6-dihydro-1 'H-spiro[benzo[1 ,2-jb:5,4-jfc»]difuran-3,4'- quinazolin]-2'(3'H)-one
Figure imgf000147_0003
spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinazolin]-
Figure imgf000147_0004
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-quinazolin]-2'(3'/-/)-one
Figure imgf000147_0005
1 '-[(5-chloro-2-thienyl)methyl]-1 Η-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-quinazolin]-2'(3'H)-one
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-5,6-dihydro-1 'H- spiro[benzo[1 ,2-b:5,4-jb]difuran-3,4'-quinazolin]-2X3Η)-one
Figure imgf000148_0001
,2-
Figure imgf000148_0002
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-2,3-dihydro-1 'H- spiro[furo[2,3-g][1 ,4]benzodioxine-8,4'-quinazolin]-2'(3'/-/)-one
Figure imgf000148_0003
1 '-[(5-chloro-2-thienyl)methyl]-1 Η-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-pyrido[3,2-c/]pyrimidin]-2'(3'H)-one
1 '-[(5-chloro-2-furyl)methyl]-1 'H-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-pyrido[3,2-c0pyrimidin]-2X377)-one
1 ■-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3- f][1 ,3]benzodioxole-7,4'-pyrido[3,2-c/]pyrimidin]-2'(3'H)-one
1 '-[(2-isopropyM ,3-thiazol-5-yl)methyl]-1 'H-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-pyrido[3,2-c(]pyrimidin]-2'(3Η)-one
1 '-[(5-chloro-2-thienyl)methyl]-5-methoxy-1 '/-/-spiro[furo[3,2- ό]pyridine-3,4'-quinazoline]-2'(3Η)-thione
1 '-[(5-chloro-2-furyl)methyl]-5-methoxy-1 'H-spiro[furo[3,2- ib]pyridine-3,4'-quinazoline]-2'(3'H)-thione
Figure imgf000149_0001
5-methoxy-1'-{[5-(trifluoromethyl)-2-furyl]methyl}-11H- spiro[furo[3,2-6]pyridine-3,4'-quinazoline]-2X3'f/)-thione
1 '-[(2-JSOPrOPyI-1 ,3-thiazol-5-yl)methyl]-5-methoxy-1 'H- spiro[furo[3,2-jb]pyridine-3,4'-quinazoline]-2'(3'H)-thione
1 '-[(5-chloro-2-thienyl)methyl]-1 '/-/-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-quinazoline]-2'(3'H)-thione
1 '-[(5-chloro-2-furyl)methyl]-1 'H-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-quinazoline]-2'(3Η)-thione
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3- /][1,3]benzodioxole-7,4'-quinazoline]-2'(3'H)-thione
Figure imgf000150_0001
1 '-[(2-isopropyl-i ,3-thiazol-5-yl)methyl]-1 'H-spiro[furo[2,3- /][1 ,3]benzodioxole-7,4'-quinazoline]-2'(3l/-/)-thione
Figure imgf000151_0001
In another aspect, the invention provides compounds of formula (IX):
Figure imgf000151_0002
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1, 2 or 3; Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5; p is 1 , 2 or 3, wherein when p is 1 , v is 0, 1 , 2, 3, 4, 5 or 6, when p is 2, v is 0, 1 , 2, 3, 4, 5, 6, 7 or 8; and when p is 3, v is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10;
Figure imgf000151_0003
a anndd are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl, and wherein each of the fused ring may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy and aryl. each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. One embodiment provides compounds of formula (IX), wherein: j is 0; k is 1 ; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
-R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and
-N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5,
-N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and
Figure imgf000154_0001
and are each independently a fused aryl ring.
Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Structure Chemical Name 2,2',3,3l >4,5-hexahydrospiro[1 ,3-diazepino[1 ,2-a]indole- 11 ,8'-furo[2,3-g][1 ,4]benzodioxine]
2,3,4,5-tetrahydrospiro[1 ,3-diazepino[1 ,2-a]indole-11 ,T- furo[2,3-/3[1,3]benzodioxole]
Figure imgf000155_0001
101-
le-
Figure imgf000155_0002
3\4\5,6-tetrahydro-2'H-spiro[benzo[1 ,2-;b:5,4-ib]difuran- 3, 10'-pyrimido[1 ,2-a]indole]
(1 lZ)-3l I4I I5,5I I6,6l-hexahydro-2lH-spiro[benzo[1 ,2-6:5,4- <b]difuran-3, 12'-[1 ,3]diazocino[1 ,2-a]indole]
Figure imgf000156_0001
Another embodiment provides compounds of formula (IX), wherein: j is O; k is 1 ; p is 1; v is 2, 3 or 4; Q is -O-;
Figure imgf000156_0002
and are each independently a fused aryl ring or a fused heteroaryl ring; and two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl, and wherein each of the fused ring may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy and aryl. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000156_0003
2'-chloro-4'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7, 101- thieno[2\3':4,5]pyrimido[1 ,2-a]indole]
Figure imgf000157_0001
pyridine-3, 101-
uro[3,2-ib]pyridine-
Figure imgf000157_0002
2'-(trifluoromethyl)-4'/-/-spiro[furo[2,3-/][1 ,3]benzodioxole- 7, 10'-furo[2,3-c/]pyπdo[3',2':4,5]pyrrolo[1 ,2-a]pyrimidine]
Figure imgf000157_0003
,3]benzodioxole- ,2-a]pyrimidine]
Figure imgf000157_0004
,2-a]indole]
Figure imgf000157_0005
Figure imgf000157_0006
2'-(trifluoromethyl)-11 'H-spiro[furo[2,3-/][1 ,3]benzodioxole- 7,δl-furo[3',2':4,δ]pyrimido[1 ,2-a]indole]
Figure imgf000157_0007
1δ6 2'-chloro-11'/-/-spiro[furo[2,3-/][1 ,3]benzodioxole-7,5'- thieno[3',2':4,5]pyrimido[1 ,2-a]indole]
Figure imgf000158_0001
,2-b]pyridine-3,5'-
Figure imgf000158_0002
5-methoxy-2'-(trifluoromethyl)-11'/-/-spiro[furo[3,2-ib]pyridine- 3>5I-furo[3l,2l:4,5]pyrimido[1 ,2-a]indole]
Figure imgf000158_0003
ro[furo[3,2-ib]pyridine- ,2-a]pyrimidine]
Figure imgf000158_0004
dine-
Figure imgf000158_0005
In another aspect, the invention provides compounds of formula (X):
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000159_0001
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN; R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4,
-N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4,
-R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2l -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. One embodiment provides compounds of formula (X), wherein: j is O; k is 1 ;
X is O or S; Q is -O-; and
Figure imgf000162_0001
and are each independently a fused aryl ring. Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000162_0002
2'-{[5-(trifluoromethyl)-2-furyl]methyl}-r,2'-dihydro-3'H- spiro[furo[2,3-/][1>3]benzodioxole-7,4l-isoquinolin]-3l-one
21-[(5-chloro-2-thienyl)methyl]-r,2'-dihydro-31H- spiro[furo[2,3-/][1 >3]benzodioxole-7,4'-isoquinolin]-3I-one
Figure imgf000163_0001
piro[furo[2,3-
Figure imgf000163_0002
2'-(2-cyclopropylethyl)-r,2'-dihydro-31H-spiro[furo[2>3- /J[1 ,3]benzodioxole-7,4'-isoquinolin]-3'-one
Figure imgf000163_0003
Figure imgf000163_0004
2l-[(5-chloro-2-furyl)methyl]-1I,2'-dihydro-3'H- spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-isoquinoline]-3'- thione
Figure imgf000164_0001
Figure imgf000164_0002
Another embodiment provides compounds of formula (X), wherein: j is O; k is 1 ;
X is O or S; Q is -O-;
is a fused aryl ring; and
Figure imgf000164_0003
is a fused heteroaryl ring. Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000164_0004
Figure imgf000165_0001
2'-[(5-chloro-2-thienyl)methyl]-5-methoxy-1',2l-dihydro- 3'/-/-spiro[furo[3,2-j£>]pyridine-3,4'-isoquinoline]-3'-thione
Figure imgf000165_0002
In another aspect, the invention provides compounds of formula (Xl):
Figure imgf000165_0003
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000165_0004
is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -Ra-C(O)R5, -RS-C(O)OR5, -Rb-C(0)N(R4)Ra, -S(O)2-R3, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4,
-R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4 -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; or R1 and R2 together with the adjacent nitrogen atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4,
-N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
One embodiment provides compounds of formula (Xl), wherein: j is 0; k is 1 ; q is 1 ; Q is -O-; X is O or S
Figure imgf000168_0001
is a fused heteroaryl ring;
R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2.
Specific examples of this aspect include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
5-methoxy-1'-{[5-(trifluoromethyl)-2- fuιyl]methyl}spiro[furo[3,2-/b]pyridine-3,3'-pyrrolo[1 ,2-
<b]pyrazol]-2'(1'H)-one
3-methyl-1'-{[5-(trifluoromethyl)-2- furyl]methyl}spiro[furo[2,3-c]isoxazole-4,3'-pyrrolo[1 ,2-
*b]pyrazol]-2'(1'H)-one
Figure imgf000169_0001
Figure imgf000170_0001
Another embodiment provides compounds of formula (XIV), wherein: j is O; k is 1 ; Q is -O-; X is O or S; q is 2;
Figure imgf000170_0002
is a fused aryl ring; and two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl.
Specific examples of this embodiment include, but are not limited to, the following compounds:
Chemical Structure Chemical Name
Figure imgf000170_0003
Figure imgf000171_0001
1'-{[5-(trifluoromethyl)-2- thienyl]methyl}spiro[furo[2,3-/][1 )3]benzodioxole-7,3I- pyrrolo[1 ,2-b]pyrazol]-2'(1 Η)-one
Figure imgf000171_0002
iro[furo[2,3- 1 ,2-jb]pyrazol]-
Figure imgf000171_0003
-1 ,3-thiazol-5-yl)methyl]spiro[furo[2,3- xole-7,3'-pyrrolo[1 ,2-ύ]pyrazol]-
Figure imgf000171_0004
1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3- /][1 ,3]benzodioxole-7,3'-pyrrolo[1 ,2-ύ]pyrazole]- 2'(1'H)-thione
Figure imgf000171_0005
5-chloro-2-furyl)methyl]spiro[furo[2,3- 3]benzodioxole-7,3'-pyrrolo[1 ,2-/j]pyrazole]- 'H)-thione
Figure imgf000171_0006
Figure imgf000172_0001
One embodiment of the invention describes a method of treating or preventing hypercholesterolemia in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
Another embodiment of the invention describes a method of treating or preventing benign prostatic hyperplasia in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
Another embodiment of the invention describes a method of treating or preventing pruritis in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
Another embodiment of the invention describes a method of treating or preventing cancer in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I) to (Xl) as set forth above for the embodiments of the compounds of formula (I) to (Xl).
Specific embodiments of the compounds of formulae (I)- (Xl) are described in more detail below in the Preparation of the Compounds of the Invention. UTILITY AND TESTING OF THE COMPOUNDS OF THE INVENTION
The present invention relates to compounds, pharmaceutical compositions and methods of using the compounds and pharmaceutical compositions for the treatment of sodium channel-mediated diseases, preferably diseases related to pain, central nervous conditions such as epilepsy, anxiety, depression and bipolar disease; cardiovascular conditions such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular conditions such as restless leg syndrome and muscle paralysis or tetanus; neuroprotection against stroke, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome, by administering to a patient in need of such treatment an effective amount of a sodium channel blocker modulating, especially inhibiting, agent.
In general, the present invention provides a method for treating a patient for, or protecting a patient from developing, a sodium channel-mediated disease, especially pain, comprising administering to an animal, such as a mammal, especially a human patient in need thereof, a therapeutically effective amount of a compound of the invention or a pharmaceutical composition comprising a compound of the invention wherein the compound modulates the activity of one or more voltage-dependent sodium channels.
The general value of the compounds of the invention in mediating, especially inhibiting, the sodium channel ion flux can be determined using the assays described below in the Biological Assays section. Alternatively, the general value of the compounds in treating conditions and diseases may be established in industry standard animal models for demonstrating the efficacy of compounds in treating pain. Animal models of human neuropathic pain conditions have been developed that result in reproducible sensory deficits (allodynia, hyperalgesia, and spontaneous pain) over a sustained period of time that can be evaluated by sensory testing. By establishing the degree of mechanical, chemical, and temperature induced allodynia and hyperalgesia present, several physiopathological conditions observed in humans can be modeled allowing the evaluation of pharmacotherapies.
In rat models of peripheral nerve injury, ectopic activity in the injured nerve corresponds to the behavioural signs of pain. In these models, intravenous application of the sodium channel blocker and local anesthetic lidocaine can suppress the ectopic activity and reverse the tactile allodynia at concentrations that do not affect general behaviour and motor function (Mao, J. and Chen, L. L, Pain (2000), 87:7-17). Allimetric scaling of the doses effective in these rat models, translates into doses similar to those shown to be efficacious in humans (Tanelian, D. L. and Brose, W. G., Anesthesiology (1991 ), 74(5):949-951 ). Furthermore, Lidoderm®, lidocaine applied in the form of a dermal patch, is currently an FDA approved treatment for post-herpetic neuralgia (Devers, A. and Glaler, B.S., CHn. J. Pain (2000), 16(3):205-8). Sodium channel blockers have clinical uses in addition to pain. Epilepsy and cardiac arrhythmias are often targets of sodium channel blockers. Recent evidence from animal models suggest that sodium channel blockers may also be useful for neuroprotection under ischaemic conditions caused by stroke or neural trauma and in patients with multiple sclerosis (MS) (Clare, J.J. et al., op. cit. and Anger, T. et al., op. cit.).
The compounds of the invention modulate, preferably inhibit, ion flux through a voltage-dependent sodium channel in a mammal, especially in a human. Any such modulation, whether it be partial or complete inhibition or prevention of ion flux, is sometimes referred to herein as "blocking" and corresponding compounds as "blockers". In general, the compounds of the invention modulates the activity of a sodium channel downwards, inhibits the voltage-dependent activity of the sodium channel, and/or reduces or prevents sodium ion flux across a cell membrane by preventing sodium channel activity such as ion flux.
The compounds of the instant invention are sodium channel blockers and are therefore useful for treating diseases and conditions in humans and other organisms, including all those human diseases and conditions which are the result of aberrant voltage-dependent sodium channel biological activity or which may be ameliorated by modulation of voltage-dependent sodium channel biological activity.
As defined herein, a sodium channel-mediated disease or condition refers to a disease or condition which is ameliorated upon modulation of the sodium channel and includes, but is not limited to, pain, central nervous conditions such as epilepsy, anxiety, depression and bipolar disease; cardiovascular conditions such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular conditions such as restless leg syndrome and muscle paralysis or tetanus; neuroprotection against stroke, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome.
A sodium channel-mediated disease or condition also includes pain associated with HIV, HIV treatment induced neuropathy, trigeminal neuralgia, glossopharyngeal neuralgia, neuropathy secondary to metastatic infiltration, adiposis dolorosa, thalamic lesions, hypertension, autoimmune disease, asthma, drug addiction (e.g. opiate, benzodiazepine, amphetamine, cocaine, alcohol, butane inhalation), Alzheimer, dementia, age-related memory impairment, Korsakoff syndrome, restenosis, urinary dysfunction, incontinence, parkinson's disease, cerebrovascular ischemia, neurosis, gastrointestinal disease, sickle cell anemia, transplant rejection, heart failure, myocardial infarction, reperfusion injury, intermittant claudication, angina, convulsion, respiratory disorders, cerebral or myocardial ischemias, long-QT syndrome, Catecholeminergic polymorphic ventricular tachycardia, ophthalmic diseases, spasticity, spastic paraplegia, myopathies, myasthenia gravis, paramyotonia congentia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, alopecia, anxiety disorders, psychotic disorders, mania, paranoia, seasonal affective disorder, panic disorder, obsessive compulsive disorder (OCD), phobias, autism, Aspergers Syndrome, Retts syndrome, disintegrative disorder, attention deficit disorder, aggressivity, impulse control disorders, thrombosis, pre clampsia, congestive cardiac failure, cardiac arrest, Freidrich's ataxia, Spinocerebellar ataxia, myelopathy, radiculopathy, systemic lupus erythamatosis, granulomatous disease, olivo-ponto- cerebellar atrophy, spinocerebellar ataxia, episodic ataxia, myokymia, progressive pallidal atrophy, progressive supranuclear palsy and spasticity, traumatic brain injury, cerebral oedema, hydrocephalus injury, spinal cord injury, anorexia nervosa, bulimia, Prader-Willi syndrome, obesity, optic neuritis, cataract, retinal haemorrhage, ischaemic retinopathy, retinitis pigmentosa, acute and chronic glaucoma, macular degeneration, retinal artery occlusion, Chorea, Huntington's chorea, cerebral edema, proctitis, postherpetic neuralgia, eudynia, heat sensitivity, sarcoidosis, irritable bowel syndrome, Tourette syndrome, Lesch-Nyhan Syndrome, Brugado syndrome, Liddle syndrome, Crohns disease, multiple sclerosis and the pain associated with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), disseminated sclerosis, diabetic neuropathy, peripheral neuropathy, Charcot marie tooth syndrome, arthritic, rheumatoid arthritis, osteoarthritis, chondrocalcinosis, atherosclerosis, paroxysmal dystonia, myasthenia syndromes, myotonia, myotonic dystrophy, muscular dystrophy, malignant hyperthermia, cystic fibrosis, pseudoaldosteronism, rhabdomyolysis, mental handicap, hypothyroidism, bipolar depression, anxiety, schizophrenia, sodium channel toxin related illnesses, familial erythermalgia, primary erythermalgia, rectal pain, cancer, epilepsy, partial and general tonic seizures, febrile seizures, absence seizures (petit mal), myoclonic seizures, atonic seizures, clonic seizures, Lennox Gastaut, West Syndome (infantile spasms), multiresistant seizures, seizure prophylaxis (anti- epileptogenic), familial Mediterranean fever syndrome, gout, restless leg syndrome, arrhythmias, fibromyalgia, neuroprotection under ischaemic conditions caused by stroke or neural trauma, tachy-arrhythmias, atrial fibrillation and ventricular fibrillation and as a general or local anaesthetic.
As used herein, the term "pain" refers to all categories of pain and is recognized to include, but is not limited to, neuropathic pain, inflammatory pain, nociceptive pain, idiopathic pain, neuralgic pain, orofacial pain, burn pain, burning mouth syndrome, somatic pain, visceral pain, myofacial pain, dental pain, cancer pain, chemotherapy pain, trauma pain, surgical pain, post-surgical pain, childbirth pain, labor pain, reflex sympathetic dystrophy, brachial plexus avulsion, neurogenic bladder, acute pain (e.g. musculoskeletal and post-operative pain), chronic pain, persistent pain, peripherally mediated pain, centrally mediated pain, chronic headache, migraine headache, familial hemiplegic migraine, conditions associated with cephalic pain, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, pain following stroke, thalamic lesions, radiculopathy.HIV pain, post-herpetic pain, non- cardiac chest pain, irritable bowel syndrome and pain associated with bowel disorders and dyspepsia, and combinations thereof.
The compounds identified in the instant specification inhibit the ion flux through a voltage-dependent sodium channel. Preferably, the compounds are state or frequency dependent modifers of the sodium channels, having a low affinity for the rested/closed state and a high affinity for the inactivated state. These compounds are likely to interact with overlapping sites located in the inner cavity of the sodium conducting pore of the channel similar to that described for other state-dependent sodium channel blockers (Cestele, S., et al., op. cit). These compounds may also be likely to interact with sites outside of the inner cavity and have allosteric effects on sodium ion conduction through the channel pore.
Any of these consequences may ultimately be responsible for the overall therapeutic benefit provided by these compounds.
The present invention relates to compounds, pharmaceutical compositions and methods of using the compounds and pharmaceutical compositions for the treatment or prevention of diseaes or conditions such as benign prostatic hyperplasia (BPH)1 hypercholesterolemia, cancer and pruritis (itch).
Benign prostatic hyperplasia (BPH), also known as benign prostatic hypertrophy, is one of the most common diseases affecting aging men. BPH is a progressive condition which is characterized by a nodular enlargement of prostatic tissue resulting in obstruction of the urethra. Consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder, acute urinary retention and an increased incidence of urinary tract infection.
BPH has a high public health impact and is one of the most common reasons for surgical intervention among elderly men. Attempts have been made to clarify the etiology and pathogenesis and, to that end, experimental models have been developed. Spontaneous animal models are limited to the chimpanzee and the dog. BPH in man and the dog share many common features. In both species, the development of BPH occurs spontaneously with advanced age and can be prevented by early/prepubertal castration. A medical alternative to surgery is very desirable for treating BHP and the consequences.
The prostatic epithelial hyperplasia in both man and the dog is androgen sensitive, undergoing involution with androgen deprivation and resuming epithelial hyperplasia when androgen is replaced. Cells originating from the prostate gland have been shown to express high levels of voltage gated sodium channels, lmmunostaining studies clearly demonstrated evidence for voltage gated sodium channels in prostatic tissues (Prostate Cancer Prostatic Dis. 2005; 8(3):266-73).
Hypercholesterolemia, i.e., elevated blood cholesterol, is an established risk factor in the development of, e.g., atherosclerosis, coronary artery disease, hyperlipidemia, stroke, hyperinsulinemias, hypertension, obesity, diabetes, cardiovascular diseases (CVD), myocardial ischemia, and heart attack. Thus, lowering the levels of total serum cholesterol in individuals with high levels of cholesterol has been known to reduce the risk of these diseases. The lowering of low density lipoprotein cholesterol in particular is an essential step in the prevention of CVD. Although there are a variety of hypercholesterolemia therapies, there is a continuing need and a continuing search in this field of art for alternative therapies.
The invention provides compounds which are useful as antihypercholesterolemia agents and their related conditions. The present compounds may act in a variety of ways. While not wishing to be bound to any particular mechanism of action, the compounds may be direct or indirect inhibitors of the enzyme acyl CoA: cholesterol acyl transferase (ACAT) that results in inhibition of the esterification and transport of cholesterol across the intestinal wall. Another possibility may be that the compounds of the invention may be direct or indirect inhibitors of cholesterol biosynthesis in the liver. It is possible that some compounds of the invention may act as both direct or indirect inhibitors of ACAT and cholesterol biosynthesis.
Pruritus, commonly known as itch, is a common dermatological condition. While the exact causes of pruritis are complex and poorly understood, there has long been acknowledged to have interactions with pain. In particular, it is believed that sodium channels likely communicate or propagate along the nerve axon the itch signals along the skin. Transmission of the itch impulses results in the unpleasant sensation that elicits the desire or reflex to scratch.
From a neurobiology level, it is believed that there is a shared complexity of specific mediators, related neuronal pathways and the central processes of itch and pain and recent data suggest that there is a broad overlap between pain- and itch- related peripheral mediators and/or receptors (Ikoma et al., Nature Reviews
Neuroscience, 7:535-547, 2006). Remarkably, pain and itch have similar mechanisms of neuronal sensitization in the peripheral nervous system and the central nervous system but exhibits intriguing differences as well.
For example, the mildly painful stimuli from scratching are effective in abolishing the itch sensation. In contrast, analgesics such as opioids can generate severe pruritus. The antagonistic interaction between pain and itch can be exploited in pruritus therapy, and current research concentrates on the identification of common targets for future analgesic and antipruritic therapy.
Compounds of the present invention have been shown to have analgesic effects in a number of animal models at oral doses ranging from 1 mg/kg to 100 mg/kg. The compounds of the invention can also be useful for treating pruritus. The types of itch or skin irritation, include, but are not limited to: a) psoriatic pruritis, itch due to hemodyalisis, aguagenic pruritus, and itching caused by skin disorders (e.g., contact dermatitis), systemic disorders, neuropathy, psychogenic factors or a mixture thereof; b) itch caused by allergic reactions, insect bites, hypersensitivity (e.g., dry skin, acne, eczema, psoriasis), inflammatory conditions or injury; c) itch associated with vulvar vestibulitis; and d) skin irritation or inflammatory effect from administration of another therapeutic such as, for example, antibiotics, antivirals and antihistamines. The compounds of the invention are also useful in treating or preventing certain hormone sensitive cancers, such as prostate cancer (adenocarcinoma), breast cancer, ovarian cancer, testicular cancer, thyroid neoplasia. The voltage gated sodium channels have been demonstrated to be expressed in prostate and breast cancer cells. Up-regulation of neonatal Na(v)1.5 occurs as an integral part of the metastatic process in human breast cancer and could serve both as a novel marker of the metastatic phenotype and a therapeutic target (Clin. Cancer Res.2005, Aug. 1 ; 11(15): 5381-9). Functional expression of voltage-gated sodium channel alpha-subunits, specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Voltage-gated sodium channel alpha-subunits immunostaining, using antibodies specific to the sodium channel alpha subunit was evident in prostatic tissues and markedly stronger in CaP vs non-CaP patients (Prostate Cancer Prostatic Dis. 2005;8(3):266-73)
The compounds of the invention are also useful in treating or preventing symptoms associated with BPH such as, but not limited to, acute urinary retention and urinary tract infection.
The compounds of the invention are also useful in treating or preventing certain endocrine imbalances or endocrinopathies such as congenital adrenal hyperplasia , hyperthyroidism, hypothyroidism, osteoporosis, osteomalacia, rickets, Cushing's Syndrome, Conn's syndrome, hyperaldosteronism, hypogonadism, hypergonadism, infertility, fertility and diabetes.
The present invention readily affords many different means for identification of sodium channel modulating agents that are useful as therapeutic agents. Identification of modulators of sodium channel can be assessed using a variety of in vitro and in vivo assays, e.g. measuring current, measuring membrane potential, measuring ion flux, (e.g. sodium or guanidinium), measuring sodium concentration, measuring second messengers and transcription levels, and using e.g., voltage-sensitive dyes, radioactive tracers, and patch-clamp electrophysiology.
One such protocol involves the screening of chemical agents for ability to modulate the activity of a sodium channel thereby identifying it as a modulating agent. A typical assay described in Bean et al., J. General Physiology (1983), 83:613- 642, and Leuwer, M., et al., Br. J. Pharmacol (2004), 141(1 ):47-54, uses patch-clamp techniques to study the behaviour of channels. Such techniques are known to those skilled in the art, and may be developed, using current technologies, into low or medium throughput assays for evaluating compounds for their ability to modulate sodium channel behaviour.
A competitive binding assay with known sodium channel toxins such as tetrodotoxin, alpha-scorpion toxins, aconitine, BTX and the like, may be suitable for identifying potential therapeutic agents with high selectivity for a particular sodium channel. The use of BTX in such a binding assay is well known and is described in McNeal, E.T., et al., J. Med. Chem. (1985), 28(3):381-8; and Creveling, C.R., et al., Methods in Neuroscience, Vol.8: Neurotoxins (Conn PM Ed) (1992), pp. 25-37, Academic Press, New York.
These assays can be carried out in cells, or cell or tissue extracts expressing the channel of interest in a natural endogenous setting or in a recombinant setting. The assays that can be used include plate assays which measure Na+ influx through surrogate markers such as 14C-guanidine influx or determine cell depolarization using fluorescent dyes such as the FRET based and other fluorescent assays or a radiolabeled binding assay employing radiolabeled aconitine, BTX, TTX or STX. More direct measurements can be made with manual or automated electrophysiology systems. The guanidine influx assay is explained in more detail below in the Biological Assays section.
Throughput of test compounds is an important consideration in the choice of screening assay to be used. In some strategies, where hundreds of thousands of compounds are to be tested, it is not desirable to use low throughput means. In other cases, however, low throughput is satisfactory to identify important differences between a limited number of compounds. Often it will be necessary to combine assay types to identify specific sodium channel modulating compounds.
Electrophysiological assays using patch clamp techniques is accepted as a gold standard for detailed characterization of sodium channel compound interactions, and as described in Bean et al., op. tit. and Leuwer, M., et al., op. tit. There is a manual low-throughput screening (LTS) method which can compare 2-10 compounds per day; a recently developed system for automated medium-throughput screening (MTS) at 20-50 patches (i.e. compounds) per day; and a technology from Molecular Devices Corporation (Sunnyvale, CA) which permits automated high-throughput screening (HTS) at 1000-3000 patches (i.e. compounds) per day.
One automated patch-clamp system utilizes planar electrode technology to accelerate the rate of drug discovery. Planar electrodes are capable of achieving high- resistance, cells-attached seals followed by stable, low-noise whole-cell recordings that are comparable to conventional recordings. A suitable instrument is the PatchXpress 7000A (Axon Instruments Inc, Union City, CA). A variety of cell lines and culture techniques, which include adherent cells as well as cells growing spontaneously in suspension are ranked for seal success rate and stability. Immortalized cells (e.g. HEK and CHO) stably expressing high levels of the relevant sodium ion channel can be adapted into high-density suspension cultures.
Other assays can be selected which allow the investigator to identify compounds which block specific states of the channel, such as the open state, closed state or the resting state, or which block transition from open to closed, closed to resting or resting to open. Those skilled in the art are generally familiar with such assays.
Binding assays are also available, however these are of only limited functional value and information content. Designs include traditional radioactive filter based binding assays or the confocal based fluorescent system available from Evotec OAI group of companies (Hamburg, Germany), both of which are HTS. Radioactive flux assays can also be used. In this assay, channels are stimulated to open with veratridine or aconitine and held in a stabilized open state with a toxin, and channel blockers are identified by their ability to prevent ion influx. The assay can use radioactive 22[Na] and 14[C] guanidinium ions as tracers. FlashPlate & Cytostar-T plates in living cells avoids separation steps and are suitable for HTS. Scintillation plate technology has also advanced this method to HTS suitability.
Because of the functional aspects of the assay, the information content is reasonably good.
Yet another format measures the redistribution of membrane potential using the FLIPR system membrane potential kit (HTS) available from Molecular Dynamics (a division of Amersham Biosciences, Piscataway, NJ). This method is limited to slow membrane potential changes. Some problems may result from the fluorescent background of compounds. Test compounds may also directly influence the fluidity of the cell membrane and lead to an increase in intracellular dye concentrations. Still, because of the functional aspects of the assay, the information content is reasonably good.
Sodium dyes can be used to measure the rate or amount of sodium ion influx through a channel. This type of assay provides a very high information content regarding potential channel blockers. The assay is functional and would measure Na+ influx directly. CoroNa Red, SBFI and/or sodium green (Molecular Probes, Inc. Eugene OR) can be used to measure Na influx; all are Na responsive dyes. They can be used in combination with the FLIPR instrument. The use of these dyes in a screen has not been previously described in the literature. Calcium dyes may also have potential in this format.
In another assay, FRET based voltage sensors are used to measure the ability of a test compound to directly block Na influx. Commercially available HTS systems include the VIPR™ Il FRET system (Aurora Biosciences Corporation, San Diego, CA, a division of Vertex Pharmaceuticals, Inc.) which may be used in conjunction with FRET dyes, also available from Aurora Biosciences. This assay measures sub-second responses to voltage changes. There is no requirement for a modifier of channel function. The assay measures depolarization and hyperpolarizations, and provides ratiometric outputs for quantification. A somewhat less expensive MTS version of this assay employs the FLEXstation™ (Molecular Devices Corporation) in conjunction with FRET dyes from Aurora Biosciences. Other methods of testing the compounds disclosed herein are also readily known and available to those skilled in the art. These results provide the basis for analysis of the structure-activity relationship
(SAR) between test compounds and the sodium channel. Certain substituents on the core structure of the test compound tend to provide more potent inhibitory compounds. SAR analysis is one of the tools those skilled in the art may now employ to identify preferred embodiments of the compounds of the invention for use as therapeutic agents.
Modulating agents so identified are then tested in a variety of in vivo models so as to determine if they alleviate pain, especially chronic pain or other conditions such as arrhythmias, epilepsy, benign prostatic hyperplasia (BPH), hypercholesterolemia, cancer and pruritis (itch) with minimal adverse events. The assays described below in the Biological Assays Section are useful in assessing the biological activity of the instant compounds.
Typically, a successful therapeutic agent of the present invention will meet some or all of the following criteria. Oral availability should be at or above 20%. Animal model efficacy is less than about 0.1 μg to about 100 mg/Kg body weight and the target human dose is between 0.1 μg to about 100 mg/Kg body weight, although doses outside of this range may be acceptable ("mg/Kg" means milligrams of compound per kilogram of body mass of the subject to whom it is being administered). The therapeutic index (or ratio of toxic dose to therapeutic dose) should be greater than 100. The potency (as expressed by IC50 value) should be less than 10 μM, preferably below 1 μM and most preferably below 50 nM. The IC50 ("Inhibitory Concentration - 50%") is a measure of the amount of compound required to achieve 50% inhibition of ion flux through a sodium channel, over a specific time period, in an assay of the invention. Compounds of the present invention in the guanidine influx assay have demonstrated IC-50s ranging from less than a nanomolar to less than 10 micromolar.
In an alternative use of the invention, the compounds of the invention can be used in in vitro or in vivo studies as exemplary agents for comparative purposes to find other compounds also useful in treatment of, or protection from, the various diseases disclosed herein. Another aspect of the invention relates to inhibiting Nav1.1, Na/1.2, Na1/! .3,
Na/1.4, Nay1.5, Nayi .6, Nav1.7, Nav1.8, or Na^I .9 activity in a biological sample or a patient, which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound. The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
Inhibition of Nav1.1 , Na/I .2, Nav1.3, Na/I .4, Nav1.5, Na/I .6, Na/I .7, Na*/I .8, or Na/I .9 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
PHARMACEUTICAL COMPOSITIONS OF THE INVENTION AND ADMINISTRATION
Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration of agents for serving similar utilities. The pharmaceutical compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. Typical routes of administering such pharmaceutical compositions include, without limitation, oral, topical, transdermal, inhalation, parenteral, sublingual, rectal, vaginal, and intranasal. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Pharmaceutical compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this invention.
A pharmaceutical composition of the invention may be in the form of a solid or liquid. In one aspect, the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) may be liquid, with the compositions being, for example, an oral syrup, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.
When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
As a solid composition for oral administration, the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition will typically contain one or more inert diluents or edible carriers. In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
When the pharmaceutical composition is in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil. The pharmaceutical composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.
The liquid pharmaceutical compositions of the invention, whether they be solutions, suspensions or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile.
A liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained. Typically, this amount is at least 0.01% of a compound of the invention in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition. Preferred oral pharmaceutical compositions contain between about 4% and about 50% of the compound of the invention. Preferred pharmaceutical compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10% by weight of the compound prior to dilution of the invention.
The pharmaceutical composition of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a pharmaceutical composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device. Topical formulations may contain a concentration of the compound of the invention from about 0.1 to about 10% w/v (weight per unit volume). The pharmaceutical composition of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and polyethylene glycol. The pharmaceutical composition of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients may be encased in a gelatin capsule.
The pharmaceutical composition of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound. Suitable agents that may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome. The pharmaceutical composition of the invention may consist of dosage units that can be administered as an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One skilled in the art, without undue experimentation may determine preferred aerosols. The pharmaceutical compositions of the invention may be prepared by methodology well known in the pharmaceutical art. For example, a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution. A surfactant may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy. Generally, a therapeutically effective daily dose is (for a 70 kg mammal) from about 0.001 mg/kg (Ae., 0.7 mg) to about 100 mg/kg (Ae., 7.0 gm); preferaby a therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg/kg (Ae., 7 mg) to about 50 mg/kg (Ae., 3.5 gm); more preferably a therapeutically effective dose is (for a 70 kg mammal) from about 1 mg/kg (Ae., 70 mg) to about 25 mg/kg (Ae., 1.75 gm).
The ranges of effective doses provided herein are not intended to be limiting and represent preferred dose ranges. However, the most preferred dosage will be tailored to the individual subject, as is understood and determinable by one skilled in the relevant arts, (see, e.g., Berkowet al., eds., The Merck Manual, 16th edition, Merck and Co., Rahway, NJ. , 1992; Goodmanetna., eds.,Goodman and Oilman's The Pharmacological Basis of Therapeutics, 10th edition, Pergamon Press, Inc., Elmsford, N.Y., (2001 ); Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD. (1987), Ebadi, Pharmacology, Little, Brown and Co., Boston, (1985); Osolci al., eds., Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, PA (1990); Katzung, Basic and Clinical Pharmacology, Appleton and Lange, Norwalk, CT (1992)).
The total dose required for each treatment can be administered by multiple doses or in a single dose over the course of the day, if desired. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. The diagnostic pharmaceutical compound or composition can be administered alone or in conjunction with other diagnostics and/or pharmaceuticals directed to the pathology, or directed to other symptoms of the pathology. The recipients of administration of compounds and/or compositions of the invention can be any vertebrate animal, such as mammals. Among mammals, the preferred recipients are mammals of the Orders Primate (including humans, apes and monkeys), Arteriodactyla (including horses, goats, cows, sheep, pigs), Rodenta (including mice, rats, rabbits, and hamsters), and Carnivora (including cats, and dogs). Among birds, the preferred recipients are turkeys, chickens and other members of the same order. The most preferred recipients are humans. For topical applications, it is preferred to administer an effective amount of a pharmaceutical composition according to the invention to target area, e.g., skin surfaces, mucous membranes, and the like, which are adjacent to peripheral neurons which are to be treated. This amount will generally range from about 0.0001 mg to about 1 g of a compound of the invention per application, depending upon the area to be treated, whether the use is diagnostic, prophylactic or therapeutic, the severity of the symptoms, and the nature of the topical vehicle employed. A preferred topical preparation is an ointment, wherein about 0.001 to about 50 mg of active ingredient is used per cc of ointment base. The pharmaceutical composition can be formulated as transdermal compositions or transdermal delivery devices ("patches"). Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive. Such transdermal patches may be used to provide continuous pulsatile, or on demand delivery of the compounds of the present invention as desired.
The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art. Controlled release drug delivery systems include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770 and 4,326,525 and in P. J. Kuzma et al, Regional Anesthesia 22 (6): 543-551 (1997), all of which are incorporated herein by reference.
The compositions of the invention can also be delivered through intra-nasal drug delivery systems for local, systemic, and nose-to-brain medical therapies. Controlled Particle Dispersion (CPD)™ technology, traditional nasal spray bottles, inhalers or nebulizers are known by those skilled in the art to provide effective local and systemic delivery of drugs by targeting the olfactory region and paranasal sinuses.
The invention also relates to an intravaginal shell or core drug delivery device suitable for administration to the human or animal female. The device may be comprised of the active pharmaceutical ingredient in a polymer matrix, surrounded by a sheath, and capable of releasing the compound in a substantially zero order pattern on a daily basis similar to devises used to apply testosterone as desscribed in PCT Patent No. WO 98/50016.
Current methods for ocular delivery include topical administration (eye drops), subconjunctival injections, periocular injections, intravitreal injections, surgical implants and iontophoresis (uses a small electrical current to transport ionized drugs into and through body tissues). Those skilled in the art would combine the best suited excipients with the compound for safe and effective intra-occular administration.
The most suitable route will depend on the nature and severity of the condition being treated. Those skilled in the art are also familiar with determining administration methods (oral, intravenous, inhalation, sub-cutaneous, rectal etc.), dosage forms, suitable pharmaceutical excipients and other matters relevant to the delivery of the compounds to a subject in need thereof.
COMBINATION THERAPY
The compounds of the invention may be usefully combined with one or more other compounds of the invention or one or more other therapeutic agent or as any combination thereof, in the treatment of sodium channel-mediated diseases and conditions. For example, a compound of formula (I) may be administered simultaneously, sequentially or separately in combination with other therapeutic agents, including, but not limited to: • opiates analgesics, e.g. morphine, heroin, cocaine, oxymorphine, levorphanol, levallorphan, oxycodone, codeine, dihydrocodeine, propoxyphene, nalmefene, fentanyl, hydrocodone, hydromorphone, meripidine, methadone, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine and pentazocine; • non-opiate analgesics, e.g. acetomeniphen, salicylates (e.g. aspirin);
• nonsteroidal antiinflammatory drugs (NSAIDs), e.g. ibuprofen, naproxen, fenoprofen, ketoprofen, celecoxib, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin and zomepirac;
• anticonvulsants, e.g. carbamazepine, oxcarbazepine, lamotrigine, valproate, topiramate, gabapentin and pregabalin;
• antidepressants such as tricyclic antidepressants, e.g. amitriptyline, clomipramine, despramine, imipramine and nortriptyline;,
• COX-2 selective inhibitors, e.g. celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, and lumiracoxib;
• alpha-adrenergics, e.g. doxazosin, tamsulosin, clonidine, guanfacine, dexmetatomidine, modafinil, and 4-amino-6,7-dimethoxy-2-(5- methane sulfonamido-1 ,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline;
• barbiturate sedatives, e.g. amobarbital, aprobarbital, butabarbital, butabital, mephobarbital, metharbital, methohexital, pentobarbital, phenobartital, secobarbital, talbutal, theamylal and thiopental; • tachykinin (NK) antagonist, particularly an NK-3, NK-2 or NK-1 antagonist, e.g.
(aR, 9R)-7-[3I5-bis(trifluoiOmβthyl)benzyl)]-8I9,10,11-tetrahydro-9-methyl-5-(4- methylphenyl)-7H-[1 ,4]diazocino[2, 1 -g][1 ,7]-naphthyridine-6-13-dione (TAK- 637), 5-[[2R,3S)-2-[(1 R)-1-[3,5-bis(trifluoromethylphenyl]ethoxy-3-(4- fluorophenyl)-4-morpholinyl]-methyl]-1 ,2-dihydro-3H-1 ,2,4-triazol-3-one (MK- 869), aprepitant, lanepitant, dapitant or 3-[[2-methoxy5-
(trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine (2S,3S);
• coal-tar analgesics, in particular paracetamol;
• serotonin reuptake inhibitors, e.g. paroxetine, sertraline, norfluoxetine (fluoxetine desmethyl metabolite), metabolite demethylsertraline, "3 fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine, trazodone and fluoxetine;
• noradrenaline (norepinephrine) reuptake inhibitors, e.g. maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, buproprion, buproprion metabolite hydroxybuproprion, nomifensine and viloxazine (Vivalan®)), especially a selective noradrenaline reuptake inhibitor such as reboxetine, in particular (S,S)-reboxetine, and venlafaxine duloxetine neuroleptics sedative/anxiolytics; • dual serotonin-noradrenaline reuptake inhibitors, such as venlafaxine, venlafaxine metabolite O- desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine, milnacipran and imipramine;
• acetylcholinesterase inhibitors such as donepezil;
• 5-HT3 antagonists such as ondansetron; • metabotropic glutamate receptor (mGluR) antagonists;
• local anaesthetic such as mexiletine and lidocaine;
• corticosteroid such as dexamethasone;
• antiarrhythmics, e.g. mexiletine and phenytoin; • muscarinic antagonists, e.g., tolterodine, propiverine, tropsium t chloride, darifenacin, solifenacin, temiverine and ipratropium;
• cannabinoids;
• vanilloid receptor agonists (e.g. resinferatoxin) or antagonists (e.g. capsazepine); • sedatives, e.g. glutethimide, meprobamate, methaqualone, and dichloralphenazone;
• anxiolytics such as benzodiazepines,
• antidepressants such as mirtazapine,
• topical agents (e.g. lidocaine, capsacin and resiniferotoxin); • muscle relaxants such as benzodiazepines, baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol and orphrenadine;
• anti-histamines or H1 antagonists;
• NMDA receptor antagonists;
• 5-HT receptor agonists/antagonists; • PDEV inhibitors;
• Tramadol®;
• cholinergic (nicotine) analgesics;
• alpha-2-delta ligands;
• prostaglandin E2 subtype antagonists; • leukotriene B4 antagonists;
• 5-lipoxygenase inhibitors; and
• 5-HT3 antagonists.
Sodium channel-mediated diseases and conditions that may be treated and/or prevented using such combinations include but not limited to, pain, central and peripherally mediated, acute, chronic, neuropathic as well as other diseases with associated pain and other central nervous disorders such as epilepsy, anxiety, depression and bipolar disease; or cardiovascular disorders such as arrhythmias, atrial fibrillation and ventricular fibrillation; neuromuscular disorders such as restless leg syndrome and muscle paralysis or tetanus; neuroprotection against stroke, neural trauma and multiple sclerosis; and channelopathies such as erythromyalgia and familial rectal pain syndrome.
As used herein "combination" refers to any mixture or permutation of one or more compounds of the invention and one or more other compounds of the invention or one or more additional therapeutic agent. Unless the context makes clear otherwise, "combination" may include simultaneous or sequentially delivery of a compound of the invention with one or more therapeutic agents. Unless the context makes clear otherwise, "combination" may include dosage forms of a compound of the invention with another therapeutic agent. Unless the context makes clear otherwise, "combination" may include routes of administration of a compound of the invention with another therapeutic agent. Unless the context makes clear otherwise, "combination" may include formulations of a compound of the invention with another therapeutic agent. Dosage forms, routes of administration and pharmaceutical compositions include, but are not limited to, those described herein.
KITS-OF-PARTS
The present invention also provides kits that contain a pharmaceutical composition which includes one or more compounds of the above formulae. The kit also includes instructions for the use of the pharmaceutical composition for modulating the activity of ion channels, for the treatment of pain, as well as other utilities as disclosed herein. Preferably, a commercial package will contain one or more unit doses of the pharmaceutical composition. For example, such a unit dose may be an amount sufficient for the preparation of an intravenous injection. It will be evident to those of ordinary skill in the art that compounds which are light and/or air sensitive may require special packaging and/or formulation. For example, packaging may be used which is opaque to light, and/or sealed from contact with ambient air, and/or formulated with suitable coatings or excipients.
PREPARATION OF THE COMPOUNDS OF THE INVENTION The following Reaction Schemes illustrate methods to make compounds of the invention, e.g., compounds of formula (I): wherein
Figure imgf000193_0001
, t, v, Z, R1- R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof. It is understood that in the following description, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds.
It will also be appreciated by those skilled in the art that in the process described below the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (e.g., f-butyldimethylsilyl, f-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include f-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or arylalkyl), p-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.
Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P. G. M.
Wuts, Greene's Protective Groups in Organic Synthesis (2006), 4th Ed., Wiley. The protecting group may also be a polymer resin such as a Wang resin or a 2-chlorotrityl- chloride resin.
It will also be appreciated by those skilled in the art, although such protected derivatives of compounds of this invention may not possess pharmacological activity as such, they may be administered to a mammal and thereafter metabolized in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds of this invention are included within the scope of the invention.
The following Reaction Schemes illustrate methods to make compounds of this invention. It is understood that one skilled in the art would be able to make these compounds by similar methods or by methods known to one skilled in the art. It is also understood that one skilled in the art would be able to make in a similar manner as described below other compounds of formula (I) not specifically illustrated below by using the appropriate starting components and modifying the parameters of the synthesis as needed. In general, starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, e.g., Smith, M. B. and J. March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described herein.
In the following Reaction Schemes, R1, R2 and R3 are defined as in the Specification unless specifically defined otherwise. X is Cl or Br. R" is an alkyl group. In general, the compounds of formula (I) of the invention where v is 1 , Z is
-C(O)-, -C(S)-, -S(O)- or -S(O)2-, one v-—-' is a fused aryl ring and the
other v — J is a fused furan ring and can be synthesized following the general procedure as described in REACTION SCHEME 1.1.
REACTION SCHEME 1.1
Figure imgf000195_0001
Treatment of compound (1.1-1) (where Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-) with an alkylating reagent (1.1-2) and a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, Λ/,Λ/-dimethylformamide provides compound (1.1-3). Compound (1.1-3) can be treated with a lithium base such as, but not limited to, n-butyllithium, sec-butyllithium or te/t-butyllithium at low temperature (0 0C or -78 0C) followed by reaction with zinc chloride to form the zinc intermediate (1.1-4) in situ. The coupling of intermediate (1.1- 4) and a halo compound (1.1-5) can be achieved in the presence of a palladium catalyst such as, but not limited to, tetrakis(triphenylphosphine)palladium(0), palladium acetate, or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'- bis(diphenylphosphino)ferrocene or 2-(di-terf-butylphosphino)biphenyl, in a solvent such as, but not limited to, dimethoxyethane, dioxane, or tetrahydrofuran to provide the coupled product (1.1-6). Compound (1.1-6) is treated with a base, such as, but not limited to, cesium carbonate or potassium carbonate in the presence of dihaloethane (1.1-7) such as, but not limited to, 1 ,2-diiodoethane to produce compound (1.1-8) as the formula (I) of the invention. In general, the compounds of formula (II) of the invention where
Figure imgf000196_0001
are each fused phenyl ring, Q is -O-, j is 0 and k is 1 can be synthesized following the general procedure as described in REACTION SCHEME 2.1.
REACTION SCHEME 2.1
Figure imgf000196_0002
Figure imgf000196_0003
Formula Il
Reaction of the acridone compound (2.1-1) with an electrophile (2.1-2) in the presence of a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, Λ/,Λ/-dimethylformamide provides compound (2.1-3). Treatment of sesamol (2.1-4) with a Grignard reagent (2.1-5) at low temperature (0 0C) generates an anion at the ortho position of the phenol hydroxyl group that reacts with the keto-carbonyl group of the compound (2.1-3) in a solvent, such as, but not limited to, tetrahydrofuran or dichloromethane to afford the compound (2.1-6). The removal of the hydroxyl group at the C-9 position can be achieved by treating compound (2.1-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (2.1-6) with thionyl chloride and triethylamine then reduction with zinc dust to give compound (2.1-7). Compound (2.1-7) is treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide, sodium hydride or sodium hydroxide followed by reaction with paraformaldehyde to generate the hydroxymethyl intermediate (2.1-8). Intramolecular cyclization of compound (2.1-8) via Mitsunobu reaction employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate or di- terf-butyl azodicarboxylate in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate affords compound (2.1-9) as formula (II) of the invention.
In general, the compounds of formula (III) of the invention where
Figure imgf000197_0001
Figure imgf000197_0002
are each fused phenyl ring, v is 1, D is N, X is C and J, Q, E are each -N=, can be synthesized following the general procedure as described in REACTION SCHEME 3.1.
REACTION SCHEME 3.1
Figure imgf000197_0003
(3.1 -11) Fromula I Reaction of the isatin compound (3.1-1) with an electrophile (3.1-2) in the presence of a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, Λ/,Λ/-dimethylformamide provides compound (3.1-3). Treatment of the dibromo compound (3.1-4) with one equivlent of Grignard reagent or alkyl lithium, such as, but not limited to, isopropylmagnesium chloride or n-butyllithium (3.1-5) at low temperature (0 0C or -78 0C) allows the selective mono metal-halogen exchange to take place to form an anion that reacts with the keto-carbonyl group of the isatin compound (3.1-3) in a solvent, such as, but not limited to, tetrahydrofuran to afford the oxindole compound (3.1-6). The removal of the hydroxyl group at the C-3 position can be achieved by treating compound (3.1-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (3.1-6) with thionyl chloride and triethylamine then reduction with zinc dust to give compound (3.1-7). Compound (3.1-7) is treated with a base such as, but not limited to, sodium hydroxide, lithium hydroxide or Λ/,Λ/-diisopropylethylamine followed by reaction with α-halo acetonitrile (3.1-8) to generate the cyano intermediate (3.1-9). Furthermore, treatment of compound (3.1-9) with an azide such as, but not limited to sodium azide provides the tetrazole compound (3.1-10). Intramolecular cyclization of compound (3.1-10) via Buchwald amination reaction employing a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-terf-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, sodium terf-butoxide or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofuran provides the cyclized product (3.1-11) as the folrmula (III) of the invention.
In general, the compounds of formula (III) of the invention where
Figure imgf000198_0001
Figure imgf000198_0002
are each fused phenyl ring, v is 1 , X is N, D is C, and J, Q, E are -N= can be synthesized following the general procedure as described in Reaction Scheme 3.2. REACTION SCHEME 3.2
Figure imgf000199_0002
(3.2-1)
Figure imgf000199_0001
Figure imgf000199_0003
Reaction of the isatin compound (3.2-1) with an electrophile (3.2-2) in the presence of a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, Λ/,Λ/-dimethylformamide provides compound (3.2-3). Treatment of the dibromo compound (3.2-4) with 1 equivlent of Grignard reagent or alkyl lithium, such as, but not limited to, isopropylmagnesium chloride or n-butyllithium (3.2-5) at low temperature (0 0C or -78 0C) allows the mono metal-halogen exchange to take place to form an anion that reacts with the keto-carbonyl group of the isatin compound (3.2-3) in a solvent, such as, but not limited to, tetrahydrofuran affords the oxindole compound (3.2-6). The removal of the hydroxyl group at the C-3 position can be achieved by treating compound (3.2-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (3.2-6) with thionyl chloride and triethylamine then reduction with zinc dust to give compound (3.2-7). Compound (3.2-7) is treated with a base such as, but not limited to, sodium hydroxide, lithium hydroxide or Λ/, Λ/-diisopropylethylamine followed by reaction with formaldehyde to generate the hydroxymethyl intermediate (3.2-8). Reaction of compound (3.2-8) with tetrazole under Mitsunobu conditions employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-terf-butyl azodicarboxylate or tetramethyl diazenedicarboxamide, in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate affords compound (3.2-9). Treatment of compound (3.2-9) with a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-tert-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofuran provides the cyclized product (3.2-10) as the formula (III) of the invention.
In general, the compounds of formula (IV) of the invention where
Figure imgf000200_0001
Figure imgf000200_0002
are each fused aryl ring, Q is -O-, j is 0, k is 1 , X is -CH= and W, E are -N= and can be synthesized following the general procedure as described in REACTION SCHEME 4.1.
REACTION SCHEME 4.1
Figure imgf000201_0001
Treatment of a protected phenol compound (4.1-2) such as, but not limited to, O- benzylsesamol with ortho-fluorobenzoyl chloride (4.1-1) in the presence of a Lewis acid catalyst such as, but not limited to, aluminum chloride in a solvent such as, but not limited to, carbon disulfide generates the o-fluorobenzophenone compound (4.1- 3).Treatment of compound (4.1-3) with 1 ,2,4-triazole (4.1-4) in the presence of a base such as, but not limited to, potassium carbonate in a solvent such as, but not limited to, dimethyl sulfoxide (See Rosevear, J. et al. Aust. J. Chem. 1991 , 44, 1097) provides the alcohol compound (4.1-5). The removal of the hydroxyl group can be achieved by treating compound (4.1-5) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. Deprotection of the benzylic group can be achieved by carrying out a catalytic hydrogenation to afford compound (4.1-7). Compound (4.1-7) is treated with a dihalomethane (4.1-8) such as, but not limited to, iodochloromethane in the presence of a base such as, but not limited to, cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran or acetonitrile to afford the compound (4.1-9) as formula (IV) of the invention. In general, the compounds of formula (IV) of the invention where
Figure imgf000202_0001
Figure imgf000202_0002
are each fused aryl ring, Q, is -O-, j is 0, k is 1 and X, W, E are -N= and can be synthesized following the general procedure as described in REACTION SCHEME 4.2.
REACTION SCHEME 4.2
Figure imgf000202_0003
Figure imgf000202_0004
(4.2-5)
Figure imgf000202_0005
(4.2-6) (4.2-7) (4.2-8)
Figure imgf000202_0006
Reaction of the phenol compound (4.2-2) with a Grignard reagent (4.2-3) at low temperature (0 0C) allows the formation of a phenoxymagnesium halide intermediate that can react with the keto-carbonyl group of the isatin compound (4.2-1) in a solvent, such as, but not limited to, tetrahydrofuran or dichloromethane to afford the oxindole compound (4.2-4). The removal of the hydroxyl group at the C-3 position can be achieved by treating compound (4.2-4) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (4.2-4) with SOCI2/NEt3 then reduction with Zn dust to give compound (4.2-5). Compound (4.2-5) is treated with a silyl compound, such as, but not limited to, trimethylsilyl chloride, to generate the silyl ether intermediate which is treated with a metal reagent such as, but not limited to, ytterbium (III) trifluoromethanesulfonate or scandium (III) trifluoromethanesulfonate and formaldehyde to afford compound (4.2-6).AIternatively, compound (4.2-5) can be treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide or sodium hydroxide followed by reaction with formaldehyde to generate compound (4.2-6). Intramolecular cyclization of compound (4.2-6) via Mitsunobu reaction employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-terf-butyl azodicarboxylate or tetramethyl diazenedicarboxamide, in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate provides compound (4.2-7). Treatment of the spiro-compound (4.2-7) with phosphorous pentachloride in a solvent, such as, but not limited to, toluene affords chloroimine compound (4.2-8). Compound (4.2-8) is treated with an azide reagent such as, but not limited to, hydrogen azide in a solvent such as, but not limited to, benzene to afford compound (4.2-9) as formula (IV) of the invention.
In general, the compounds of formula (IV) of the invention where
Figure imgf000203_0001
Figure imgf000203_0002
are each fused aryl ring, Q, is -O-, j is 0, k is 1 and R" is an aryl or heteroaryl ring and can be synthesized following the general procedure as described in REACTION SCHEME 4.3.
REACTION SCHEME 4.3
Figure imgf000203_0003
(4.3-1) (4.3-3) Formula IV Compounds of formula (4.3-1) can react with an aryl or heteroaryl boronic acid (4.3-2) in the presence of a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine)palladium(0), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'- bis(diphenylphosphino)ferrocene or 2-(di-ter£-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, or tetrahedrofuran to provide the coupled product of formula (4.3-3) as compounds of formula (IV) (see Kotha, S., et al, Tetrahedron (2002), 58:9633 and Miyaura, N., et al, Chem. Rev. (1995), 95:2457).
In general, the compounds of formula (IV) of the invention where
Figure imgf000204_0001
Figure imgf000204_0002
are each fused aryl ring, Q is -O-, j is 0, k is 1 , X and W are -CH= and E is -N= and can be synthesized following the general procedure as described in REACTION SCHEME 4.4.
REACTION SCHEME 4.4
Figure imgf000205_0001
(4.4-7) (4.4-8) Formula IV
Treatment of an aldehyde compound of formula (4.4-1) with imidazole (4.4-2) in the presence of a base such as, but not limited to, potassium carbonate in a solvent such as, but not limited to, dimethyl sulfoxide affords compound (4.4-3) (See Rosevear, J. et al. Aust. J. Chem. 1991, 44, 1097). Reaction of (4.4-3) with the in situ generated intermediate (4.4-4), from the corresponding phenol with a Grignard reagent, provides the alcohol compound of formula (4.4-5). The removal of the hydroxyl group can be achieved by treating the compound (4.4-5) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid to generate the compound of formula (4.4-6). Compound (4.4-6) can be treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide or sodium hydroxide followed by reaction with formaldehyde to generate compound (4.4-7). Intramolecular cyclization of compound (4.4-7) via Mitsunobu reaction employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-terf-butyl azodicarboxylate or tetramethyl diazenedicarboxamide, in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate provides compound (4.4-8) as formula (IV) of the invention.
In general, the compounds of formula (V) of the invention where
Figure imgf000206_0001
Figure imgf000206_0002
are each fused aryl ring, Q, is -O-, j is 0, k is 0 and Z is -C(O)- or -C(S)-,, and can be synthesized following the general procedure as described in REACTION SCHEME 5.1.
REACTION SCHEME 5.1
Figure imgf000206_0003
Reaction of the bromo compound (5.1-1) with an electrophile (5.1-2) in the presence of a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, Λ/,Λ/-dimethylformamide provides compound (5.1-3). Reaction of an anion, generated from compound (5.1-4) and a base (5.1-5), with compound (5.1-3) in a solvent, such as, but not limited to, tetrahydrofuran gives compound (5.1-6). When Q is -O- or -S-, the corresponding anion can be generated by treating compound (5.1-4) with a Grignard reagent such as, but not limited to, isopropylmagnesium chloride or phenylmagnesium chloride (5.1-5) at low temperature (0 0C or -78 0C). When Q is NBoc, the ortho anion can be generated by treating compound (5.1-4) with an alkyllithium reagent (5.1-5) such as, but not limited to, terf-butyllithium or n-butyllithium. The removal of the hydroxyl group at the C-3 position can be achieved by treating compound (5.1-6) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (5.1-6) with thionyl chloride and triethylamine followed by reduction with zinc dust to give compound (5.1-7). Intramolecular cyclization of compound (5.1-7) via Buchwald etherification reaction employing a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o- tolyl)phosphine, 1,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-ferf- butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, sodium terf-butoxide or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofuran provides the cyclized product (5.1-8) as the formula (V) of the invention. In compound (5.1-8), when Q is - NBoc-, the compound can be treated with an acid such as, but not limited to, trifluoroacetic acid to generate the compound with Q being -NH-.
In compound (5.1-8), when Q is -S-, an oxidation with a reagent such as, but not limited to, 3-chloroperbenzoic acid leads to the formation of the compound with Q being -S(O)2-. Treatment of compound of formula (5.1-8) with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4- disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide, converts the C=O group in the compound of formula (5.1-8) to the C=S group to generate a compound (5.1-9) as the formula (V) of the invention.
In general, the compounds of formula (Vl) of the invention where
Figure imgf000207_0001
is a
fused aryl ring,
Figure imgf000207_0002
is fused aryl ring, Q is -O-, j is 0, k is 2 and Z is -C(O)-, or -C(S)-, and can be synthesized following the general procedure as described in REACTION SCHEME 6.1.
REACTION SCHEME 6.1
Figure imgf000208_0001
Figure imgf000208_0002
(6.1-6)
Figure imgf000208_0003
Reaction of the 4-bromo isatin compound (6.1-1) with an electrophile (6.1-2) in the presence of a base such as, but not limited to, sodium hydride or cesium carbonate in a solvent such as, but not limited to, tetrahydrofuran, acetone, N, N- dimethylformamide provides compound (6.1-3). Treatment of the bromo compound (6.1-4) (i.e., X is Br) with a Grignard reagent or alkyl lithium reagent, such as, but not limited to, isopropylmagnesium chloride or n-butyllithium (6.1-5) at low temperature (0 0C or -78 0C) forms an anion that reacts with the keto-carbonyl group of the isatin compound (6.1-3) in a solvent, such as, but not limited to, tetrahydrofuran to afford the compound oxindole (6.1-6). The hydroxyl group at C-3 position of compound (6.1-6) is protected with a protecting group (PG1 ) by employment of, such as, but not limited to, tert-butyl(chloro) dimethyl silane, chlorotrimethylsilane or chloromethyl methyl ether with a base, such as, but not limited to, imidazole, triethylamine or sodium hydride to give compound (6.1-7). When compound (6.1-7) is treated with an alkyl lithium reagent, such as, but not limited to, n-butyllithium, sec-butyllithium or tert-butyllithium at low temperature (0 0C or -78 0C), the anion is formed by metal-halogen exchange, which reacts with an alkyl halide (6.1-8), to afford compound (6.1-9). When the protecting group, PG1 and PG2 are silyl group, they can be removed by treating with a fluoride reagent, such as, but not limited to, tetrabutylammonium fluoride or cesium fluoride to form compound (6.1-10). Intramolecular cyclization of compound (6.1-10) via Mitsunobu reaction employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate or di-te/t-butyl azodicarboxylate in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate affords compound (6.1-11) as formula (Vl) of the invention. Furthermore, compound (6.1-11) can be treated with a sulfur reagent such as, but not limited to, 2,4- bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (6.1-12) as formula (Vl) of the invention.
In general, the compounds of formula (VII) of the invention where Q is -O-, j is 0, k is 1 and X is O or S and can be synthesized following the general procedure as described in REACTION SCHEME 7.1.
REACTION SCHEME 7.1
Figure imgf000210_0001
Formula VII
Figure imgf000210_0002
Formula VII
Treatment of compound (7.1-2) with a Grignard reagent (7.1-3) at low temperature (O 0C) gives an anion which reacts with the keto-carbonyl group of compound (7.1-1) in a solvent, such as, but not limited to, methylene chloride, tetrahydrofuran or toluene to afford compound (7.1-4). The removal of the hydroxyl group can be achieved by treating compound (7.1-4) with a silane reagent such as, but not limited to, triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (7.1-4) with SOCI2/NEt3 followed by reduction with Zn dust. The treatment of compound (7.1-5) with a dihalomethylene reagent such as, but not limited to, chloroiodomethane in the presence of a base such as, but not limited to, cesium carbonate provides compound (7.1-6) in a solvent, such as, but not limited to, acetone or tetrahydrofuran. Compound (7.1-7) can be reduced to the corresponding alcohol using a reducing agent such as, but not limited to, diisobutylaluminum hydride, then oxidized to the aldehyde compound (7.1-8) with an oxidant such as, but not limited to, 1 ,1,1-tris(acetyloxy)1 ,1-dihydro-1,2- benziodoxol-3-(1f/)-one in a solvent, such as, but not limited to, methylene chloride. Reaction of compound (7.1-8) with a Wittig reagent (7.1-10) in a solvent, such as, but not limited to, methylene chloride, tetrahydrofuran or toluene provides compound (7.1- 11) after acidic hydrolysis. The aldehyde compound (7.1-11) can be oxidized with an oxidant such as, but not limited to, pyridinium chlorochromate in a solvent, such as, but not limited to, methylene chloride or tetrahydrofuran. The acid (7.1-12) can couple with an amine (7.1-13) under reaction conditions known to those skilled in the art to form the amide (7.1-14). Intramolecular cyclization of compound (7.1-14) via Buchwald amination reaction employing a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-terf-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, sodium terf-butoxide or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofuran affords compound (7.1-15) as formula (VII) of the invention. Furthermore, compound (7.1-15) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (7.1-16) as formula (VII) of the invention.
In general, the compounds of formula (VIII) of the invention where Q is -O-, j is 0, k is 1 , Z is -O- , and X is O or S and can be synthesized following the general procedure as described in REACTION SCHEME 8.1.
REACTION SCHEME 8.1
Figure imgf000212_0001
Formula VlIl Formula VIII
Treatment of compound (8.1-2, where Xa is bromo or iodo) with a Grignard reagent or alkyl lithium reagent (8.1-3) at low temperature (O 0C or -78 0C) allows the formation of an anion after metal-halogen exchange, which reacts with the keto- carbonyl group of compound (8.1-1) in a solvent, such as, but not limited to, methylene chloride, tetrahydrofuran or toluene to afford compound (8.1-4). Compound (8.1-6) can be obtained by the treatment of compound (8.1-4) with an isocyanate reagent (8.1-5) in the presence of a base such as, but not limited to, trientyl amine in a solvent, such as, but not limited to, methylene chloride or tetrahydrofuran. Intramolecular cyclization of compound (8.1-6) via Buchwald amination reaction employing a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-tert-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, sodium fert-butoxide or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofuran provides compound (8.1-7). The ester in compound (8.1-7) is reduced to the alcohol to generate compound (8.1-8) using a reducing reagent, such as, but not limited to, sodium boron hydride in a solvent, such as, but not limited to, methanol. Compound (8.1-8) is further deprotected to afford compound (8.1-9) via method known to the skilled in the art depending the type of protecting group. Intramolecular cyclization of compound (8.1-9) via Mitsunobu reaction employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate or di-terf-butyl azodicarboxylate in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate affords compound (8.1-10) as the formula (VIII) of the invention. Furthermore, compound (8.1-10) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (8.1-11) as the formula (VIII) of the invention.
In general, the compounds of formula (VIII) of the invention where Q is -O-, j is 0, k is 1, Z is -NH-, and X is O or S and can be synthesized following the general procedure as described in REACTION SCHEME 8.2.
REACTION SCHEME 8.2
Figure imgf000214_0001
8.2-14 Formula VIII
Treatment of compound (8.2-2) with a Grignard reagent (8.2-3) at low temperature (O 0C) gives an anion which reacts with the keto-carbonyl group of compound (8.2-1) in a solvent, such as, but not limited to, methylene chloride, tetrahydrofuran or toluene to afford compound (8.2-4). The removal of the hydroxyl group can be achieved by treating compound (8.2-4) with a silane reagent such as, but not limited to, triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (8.2-4) with SOCI2/NEt3 followed by reduction with Zn dust. The treatment of compound (8.2-5) with a dihalomethylene reagent (8.2-6) such as, but not limited to, chloroiodomethane in the presence of a base such as, but not limited to, cesium carbonate provides compound (8.2-7) in a solvent, such as, but not limited to, acetone or tetrahydrofuran. Compound (8.2-7) can be hydrolyzed under reaction conditions known to the skilled in the art to give compound (8.2-8). The acid (8.2-8) can undergo Curtius rearrangement with diphenyl phosphoryl azide and terf-butanol to afford compound (8.2-9). Reaction of the bromo compound (8.2-9) with an amine (8.2-10) under the Buchwald amination reaction conditions employing a palladium catalyst such as, but not limited to, palladium acetate, tetrakis(triphenylphosphine) palladium(O), or tris(dibenzylideneacetone)dipalladium(0), with or without a ligand such as, but not limited to, triphenylphosphine, tri(o-tolyl)phosphine, 1 ,1'-bis(diphenyl phosphino)ferrocene, S-Phos or 2-(di-terf-butylphosphino)biphenyl, a base such as, but not limited to, sodium carbonate, cesium carbonate, sodium terf-butoxide or sodium bicarbonate, in a solvent such as, but not limited to, dimethoxyethane, dioxane, toluene or tetrahydrofuran affords compound (8.2-11). The protecting group tert- butyloxyl in compound (8.2-11) can be removed under conditions known to the skilled in the art to give compound (8.2-12). Intramolecular cyclization of compound (8.2-12) employing a reagent, such as, but not limited to, 1 ,1'-carbonyldiimidazole in a solvent such as, but not limited to, tetrahydrofuran, or methylene chloride affords compound (8.2-13) as the formula (VIII) of the invention. Furthermore, compound (8.2-13) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)- 1 ,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (8.2-14) as formula (VIII) of the invention.
In general, the compounds of formula (IX) of the invention where
Figure imgf000215_0001
Figure imgf000215_0002
are each fused aryl ring, Q is -O-, p is 1 , j is 0 and k is 1 and can be synthesized following the general procedure as described in REACTION SCHEME 9.1.
REACTION SCHEME 9.1
Figure imgf000216_0001
Figure imgf000216_0002
Reaction of the phenol compound (9.1-2) with a Grignard reagent (9.1-3) at low temperature (0 0C) allows the formation of a phenoxymagnesium halide intermediate that can react with the keto-carbonyl group of the isatin compound (9.1-1) in a solvent, such as, but not limited to, tetrahydrofuran or dichloromethane to afford the oxindole compound (9.1-4). The removal of the hydroxyl group at the C-3 position can be achieved by treating compound (9.1-4) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid. It can also be achieved by treating compound (9.1-4) with SOCI2/N Et3 followed by reduction with Zn dust to give compound (9.1-5). Compound (9.1-5) is treated with a silyl compound, such as, but not limited to, trimethylsilyl chloride, to generate the silyl ether intermediate which is treated with a metal reagent such as, but not limited to, ytterbium (III) trifluoromethanesulfonate or scandium (III) trifluoromethanesulfonate and formaldehyde to afford compound (9.1-6). Alternatively, compound (9.1-5) can be treated with a base such as, but not limited to, diisopropylamine, lithium diisopropylamide, lithium hydroxide or sodium hydroxide followed by reaction with formaldehyde to generate compound (9.1-6). Intramolecular cyclization of compound (9.1-6) via Mitsunobu reaction employing a phosphine reagent such as, but not limited to, triphenylphosphine or tributylphosphine and an azo reagent such as, but not limited to, diethyl azodicarboxylate, diisopropyl azodicarboxylate, di-tert-butyl azodicarboxylate or tetramethyl diazenedicarboxamide, in a solvent such as, but not limited to, tetrahydrofuran, dichloromethane or ethyl acetate provides compound (9.1-7).
N-alkylation of compound (9.1-7) is achieved by the treatment of compound (9-1-7) with a base such as, but not limited to, sodium hydride or cesium carbonate and a bromoalkyl phthalimide (9.1-8) in a solvent such as, but not limited to, tetrahydrofuran, acetonitrile, acetone. The removal of the phthalimide protecting group can be achieved by treating compound (9.1-9) with hydrazine in a solvent, such as, but not limited to, ethanol or methanol provides compound (9.1-10). Intramolecular cyclization of compound (9.1-10) is achieved by refluxing compound (9.1-10) with catalytic amount of an acid such as, but not limited to, p-toluenesulfonic acid in a solvent, such as, but not limited to, xylene to produce the cyclized amidine compound (9.1-11) as the formula (IX) of the invention.
In general, the compounds of formula (X) of the invention where
Figure imgf000217_0001
Figure imgf000217_0002
are each fused aryl ring, Q is -O-, X is O or S, j is 0 and k is 1 and can be synthesized following the general procedure as described in REACTION SCHEME 10.1.
REACTION SCHEME 10.1
Figure imgf000218_0001
Formula X
Treatment of compound (10.1-1) with trichloromethane under basic conditions in a solvent, such as, but not limited to, ethanol, leads to the formation of formylation intermediate. The hydroxy group of the formylation intermediate is then protected by a protecting group (e.g., MOM) in a solvent, such as, but not limited to, tetrahydronfuran to provide compound (10.1-2) (see Kamara, B., et al, Tetrahedron (1999), 55:861 ). The preparation of compound (10.1-3) can be achieved by treating compound (10.1-2) with bromoform in the presence of a base such as, but not limited to, potassium hydroxide in a solvent, such as, but not limited to, water. The hydroxy group in compound (10.1-3) is then protected with an acyl protecting group to afford compound (10.1-4). Compound (10.1-4) is then coupled with an amine (10.1-5) to give the amide compound (10.1-6) using HOBt and a coupling reagent such as, but not limited to, EDCI, in a solvent, such as, but not limited to, tetrahydrofuran under conditions known to those skilled in the art. The removal of the acyl protecting group can be achieved by treating compound (10.1-6) with a base such as sodium hydroxide in a solvent, such as, but not limited to, ethanol to generate an alcohol intermediate, which can then be converted to compound (10.1-7) using thionyl chloride. Intramolecular cyclization of compound (10.1-7) via Friedel-Crafts reaction employing a Lewis acid reagent such as, but not limited to, zinc chloride in a solvent such as, but not limited to, tetrahydrofuran, or dichloromethane affords compound (10.1-8). The removal of the MOM protecting group can be achieved by treating compound (10.1-8) with an acid such as but not limited to, acetic acid. Furthermore, compound (10.1-9) is then treated with a dihalomethane such as, but not limited to, chloroiodomethane in the presence of a base such as, but not limited to, cesium carbonate to provide compound (10.1-10) as formula (X) of the invention where X is O. Compound (10.1-10) can be further treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (10.1-11) of formula (X) of the invention where X is S.
In general, the compounds of formula (Xl) of the invention where
Figure imgf000219_0001
is a fused aryl ring, Q is -O-, j is 0, k is 1 and X is O or S and can be synthesized following the general procedure as described in Reaction Scheme 11.1.
REACTION SCHEME 11.1
Figure imgf000220_0001
(11.1-7) (11.1-8) (11.1-9) Formula Xl
Figure imgf000220_0002
(14.1-10) Formula Xl
Treatment of the 1-aminopyrrole (11.1-1) with an electrophile (11.1-2), in the presence of a base such as, but not limited to, cesium carbonate in a solvent such as, but not limited to tetrahydrofuran or Λ/,Λ/-dimethylformamide to afford the alkylated 1- aminopyrrole compound (11.1-3). The compound (11.1-3) is treated with oxalyl chloride in a solvent such as, but not limited to, ether, at -10 0C to afford isatin compound (11.1-4). Treatment of an aryl or heteroaryl hydroxy compound (11.1-5) (e.g., sesamol) with a Grignard reagent (11.1-6) at low temperature (0 0C) provides the aryloxymagnesium halide intermediate, which reacts with the keto-carbonyl group of the isatin compound (11.1-4) in a solvent, such as, but not limited to, methylene chloride to afford the oxindole compound (11.1-7). The removal of the tertiary hydroxyl group at C-3 position can be achieved by treating compound (11.1-7) with a silane reagent such as triethylsilane in the presence of an acid such as, but not limited to, trifluoroacetic acid to afford the compound (11.1-8). The compound (11.1-8) is treated with a dihalomethylene reagent such as, but not limited to, iodochloroiodomethane, in the presence of a base such as, but not limited to, cesium carbonate, in a solvent such as, but not limited to, tetrahydrofuran, to afford compound (11.1-9) as Formula (Xl) of the invention where X is O. Furthermore, compound (11.1-9) can be treated with a sulfur reagent such as, but not limited to, 2,4-bis(4-methoxyphenyl)-1 ,3,2,4- dithiadiphosphetane 2,4-disulfide (Lawesson reagent) or bis(tricyclohexyltin) sulfide to provide compound (11.1-10) as formula (Xl) of the invention where X is S.
SYNTHETIC PREPARATION 1 Synthesis of 9-(6-hydroxy-1 ,3-benzodioxol-5-yl)-9H-imidazo[1 ,2-a]indol-9-ol
To a solution of 3,4-methylenedioxyphenol (sesamol) (0.49 g, 3.53 mmol) in tetrahydrofuran (12 mL) was added /so-propylmagnesium chloride (1.80 ml_, 2 M THF solution, 3.60 mmol) slowly at 0 0C. The mixture was stirred at 0 0C for 45 min and concentrated in vacuo. Dichloromethane (9 mL) was added, followed by the addition of a solution of 9H-imidazo[1 ,2-a]indol-9-one (0.50 g, 2.94 mmol) in dichloromethane (9 mL) at -5 0C. The mixture was stirred at ambient temperature for 16 h, and quenched with saturated aqueous ammonium chloride (5 mL). After stirring at 0 0C for 30 min, water (5 mL) was added to the mixture and the stirring was continued for an additional 20 min at 0 0C. The precipitate was filtered, washed with water (2 x 8 mL) and diethyl ether (2 x 15 mL), dried under vacuum to give 9-(6-hydroxy-1 ,3-benzodioxol-5-yl)-9H- imidazo[1 ,2-a]indol-9-ol (0.67 g, 74%) as a white solid: MS (ES+) m/z 309.2 (M + 1 ).
SYNTHETIC EXAMPLE 1 Synthesis of spiro[furo[2,3-/][1 ,3]benzodioxole-7,9'-imidazo[1 ,2-a]indole]
Figure imgf000221_0001
A. Synthesis of 6-(9/-/-imidazoπ .2-a1indol-9-yl)-1 ,3-benzodioxol-5-ol
To a solution of 9-(6-hydroxy-1 ,3-benzodioxol-5-yl)-9/-/-imidazo[1 ,2-a]indol-9-ol (0.69 g, 2.23 mmol) in trifluoroacetic acid (11 mL) was added triethylsilane (1.4 mL, 8.72 mmol) dropwise at -5 0C. The reaction mixture was stirred at ambient temperature for 5 h, concentrated and dried in vacuo to dryness to give 6-(9H-imidazo[1 ,2-a]indol-9- yl)-1 ,3-benzodioxol-5-ol (1.54 g, crude): MS (ES+) m/z 293.2 (M + 1 ). B. Synthesis of 6-r9-(hydroxymethyl)-9/-/-imidazof 1 ,2-a1indol-9-vn-1 ,3-benzodioxol- 5-QI
To a mixture of 6-(9H-imidazo[1 ,2-a]indol-9-yl)-1,3-benzodioxol-5-ol (1.54 g, 2.23 mmol) and paraformaldehyde (0.67 g, 22.35 mmol) in tetrahydrofuran (20 ml.) was added diisopropylamine (1.00 ml_, 0.72 g, 7.15 mmol) at 5 to 10 0C. The reaction mixture was stirred at 5 0C to 10 0C for 1 h and ambient temperature for 18 h. The reaction was quenched with saturated aqueous ammonium chloride (30 ml_). The mixture was extracted with ethyl acetate (200 mL), washed with water and brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and dried in vacuo to give 6-[9-(hydroxymethyl)-9H-imidazo[1 ,2-a]indol-9-yl]-1 ,3-benzodioxol-5-ol (0.71 g, crude): MS (ES+): m/z 323.2 (M + 1).
C. Synthesis of spiroffuror2,3-firi ,31benzodioxole-7,9'-imidazoH ,2-alindolel To a solution of 6-[9-(hydroxymethyl)-9H-imidazo[1 ,2-a]indol-9-yl]-1 ,3- benzodioxol-5-ol (0.71 g, 2.23 mmol) in tetrahydrofuran (50 mL) was added tributylphosphine (0.66 mL, 0.54 g, 2.68 mmol) and diethyl azodicarboxalate (0.48 mL, 0.53 g, 3.06 mmol) at -78 0C. The mixture was stirred at -78 0C for 1 h and ambient temperature for 16 h. The reaction was quenched with saturated aqueous ammonium chloride (50 mL) at 0 0C, and concentrated to remove most of tetrahydrofuran. The residue was extracted with ethyl acetate (180 mL), washed with water and brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated in vacuo, and the residue was purified by column chromatography to give spiro[furo[2,3- /][1 ,3]benzodioxole-7,9'-imidazo[1 ,2-a]indole] (0.11 g, 11% for three steps) as a white powder: mp 195-197 0C; 1H NMR (300 MHz, CDCI3) δ 7.39-7.17 (m, 6H), 6.54 (s, 1H), 6.12 (s, 1 H), 5.85-5.82 (m, 2H), 4.99 (d, J = 9 Hz), 4.73 (d, J = 8.7 Hz, 1 H); 13C NMR (75 MHz, DMSOd6) δ 156.9, 155.8, 148.8, 142.5, 141.6, 136.9, 134.0, 128.9, 125.8, 125.2, 119.5, 111.2, 111.0, 103.4, 101.5, 93.7, 81.0, 53.8; MS (ES+) m/z 305.2 (M + 1 ).
BIOLOGICAL ASSAYS
Various techniques are known in the art for testing the activity of compounds of the invention. In order that the invention described herein may be more fully understood, the following biological assays are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner. BIOLOGICAL EXAMPLE 1 Guanidine Influx Assay (in vitro assay)
This example describes an in vitro assay for testing and profiling test agents against human or rat sodium channels stably expressed in cells of either an endogenous or recombinant origin. The assay is also useful for determining the IC-50 of a sodium channel blocking compound. The assay is based on the guanidine flux assay described by Reddy, N. L., et al., J Med Chem (1998), 41(17):3298-302.
The guanidine influx assay is a radiotracer flux assay used to determine ion flux activity of sodium channels in a high-throughput microplate-based format. The assay uses 14C-guanidine hydrochloride in combination with various known sodium channel modulators, to assay the potency of test agents. Potency is determined by an IC-50 calculation. Selectivity is determined by comparing potency of the compound for the channel of interest to its potency against other sodium channels (also called 'selectivity profiling1). Each of the test agents is assayed against cells that express the channels of interest. Voltage gated sodium channels are either TTX sensitive or insensitive. This property is useful when evaluating the activities of a channel of interest when it resides in a mixed population with other sodium channels. The following Table 1 summarizes cell lines useful in screening for a certain channel activity in the presence or absence of TTX.
TABLE 1
Figure imgf000223_0001
Figure imgf000224_0001
It is also possible to employ recombinant cells expressing these sodium channels. Cloning and propagation of recombinant cells are known to those skilled in the art (see, for example, Klugbauer, N, et al., EMBO J. (1995), 14(6): 1084-90; and Lossin, C, et al., Neuron (2002), 34, pp. 877-884)
Cells expressing the channel of interest are grown according to the supplier or in the case of a recombinant cell in the presence of selective growth media such as G418 (Gibco/lnvitrogen). The cells are disassociated from the culture dishes with an enzymatic solution (1X) Trypsin/EDTA (Gibco/lnvitrogen) and analyzed for density and viability using haemocytometer (Neubauer). Disassociated cells are washed and resuspended in their culture media then plated into Scintiplates (Beckman Coulter Inc.) (approximately 100,000 cells/ well) and incubated at 37 °C/5 % CO2. for 20-24 hours. After an extensive wash with Low sodium HEPES-buffered saline solution (LNHBSS) (150 mM Choline Chloride, 20 nM HEPES (Sigma), 1mM Calcium Chloride, 5mM Potassium Chloride, 1 mM Magnesium Chloride, 10 mM Glucose) agents diluted with LNHBSS are added to each well. (Varying concentrations of test agent may be used). The activation/radiolabel mixture contains aconitine (Sigma), and 14C-guanidine hydrochloride (ARC).
After loading the cells with test agent and activation/radiolabel mixture, the Scintiplates are incubated at ambient temperature. Following the incubation, the Scintplates are extensively washed with LNHBSS supplemented with guanidine (Sigma). The Scintiplates are dried and then counted using a Wallac MicroBeta TriLux (Perkin-Elmer Life Sciences). The ability of the test agent to block sodium channel activity is determined by comparing the amount of 14C-guanidine present inside the cells expressing the different sodium channels. Based on this data, a variety of calculations, as set out elsewhere in this specification, may be used to determine whether a test agent is selective for a particular sodium channel.
IC-50 value of a test agent for a specific sodium channel may be determined using the above general method. IC-50 may be determined using a 3, 8, 10, 12 or 16 point curve in duplicate or triplicate with a starting concentration of 1 , 5 or 10μM diluted serially with a final concentration reaching the sub-nanomolar, nanomolar and low micromolar ranges. Typically the mid-point concentration of test agent is set at 1 μM, and sequential concentrations of half dilutions greater or smaller are applied (e.g. 0.5 μM; 5 μM and 0.25 μM; 10 μM and 0.125 μM; 20 μM etc.). The IC-50 curve is calculated using the 4 Parameter Logistic Model or Sigmoidal Dose-Response Model formula (fit = (A+((B-A)/(1 +((C/x)ΛD)))).
The fold selectivity, factor of selectivity or multiple of selectivity, is calculated by dividing the IC-50 value of the test sodium channel by the reference sodium channel, for example, Nav1.5.
Synthetic Example 1 , when tested in the above assay using a known cell line that expresses a sodium channel, demonstrated an IC50 (nM) activity level from 10 nM to 10O nM.
BIOLOGICAL EXAMPLE 2 Electrophysiological Assay {In vitro assay)
Cells expressing the channel of interest are cultured in DMEM growth media (Gibco) with 0.5mg/mL G418, +/-1% PSG, and 10% heat-inactivated fetal bovine serum at 37C° and 5% CO2. For electrophysiological recordings, cells are plated on 10mm dishes.
Whole cell recordings are examined by established methods of whole cell voltage clamp (Bean et al., op. cit.) using an Axopatch 200B amplifier and Clampex software (Axon Instruments, Union City, CA). All experiments are performed at ambient temperature. Electrodes are fire-polished to resistances of 2-4 Mohms Voltage errors and capacitance artifacts are minimized by series resistance compensation and capacitance compensation, respectively. Data are acquired at 40 kHz and filtered at 5 kHz. The external (bath) solution consists of: NaCI (140 mM), KCI (5 mM), CaCI2 (2 mM), MgCI2 (1 mM), HEPES (10 mM) at pH 7.4. The internal (pipette) solution consists of (in mM): NaCI (5), CaCI2 (0.1 ) MgCI2 (2), CsCI (10), CsF (120), HEPES (10), EGTA (10), at pH 7.2.
To estimate the steady-state affinity of compounds for the resting and inactivated state of the channel (Kr and K1, respectively), 12.5 ms test pulses to depolarizing voltages from -60 to +90 m V from a holding potential of -110 mV is used to construct current-voltage relationships (\-V curves). A voltage near the peak of the I V-curve (-30 to 0 m V) is used as the test pulse throughout the remainder of the experiment. Steady-state inactivation (availability) curves are then constructed by measuring the current activated during a 8.75 ms test pulse following 1 second conditioning pulses to potentials ranging from -110 to -10 mV. To monitor channels at steady-state, a single "diary" protocol with a holding potential of -11OmV is created to record the resting state current (10ms test pulse), the current after fast inactivation (5 ms pre-pulse of -80 to -50 m V follow by a 10 ms test pulse), and the current during various holding potentials (35 ms ramp to test pulse levels). Compounds are applied during the "diary" protocol and the block is monitored at 15 s intervals.
After the compounds equilibrated, the voltage-dependence of the steady-state inactivation in the presence of the compound is determined. Compounds that block the resting state of the channel decrease the current elicited during test pulses from all holding potentials, whereas compounds that primarily block the inactivated state decrease the current elicited during test pulses at more depolarized potentials. The currents at the resting state (lrest) and the currents during the inactivated state (lιnactιvated) are used to calculate steady-state affinity of compounds. Based on the Michaelis- Menton model of inhibition, the Kr and K1 are calculated as the concentration of compound needed to cause 50% inhibition of the lrest or the lιnactιvated> respectively.
% inhibition = Vmav *rDruq1h
[Drug]h + Km h
Vmax is the rate of inhibition, h is the Hill coefficient (for interacting sites), Km is
Michaelis-Menten constant, and [Drug] is the concentration of the test compound. At 50% inhibition (/4Vmax) of the lrest or lιnactιvated, the drug concentration is numerically equal to Km and approximates the Kr and K1, respectively. BIOLOGICAL EXAMPLE 3 Analgesia Induced by sodium channel Blockers Heat Induced Tail Flick Latency Test
In this test, the analgesia effect produced by administering a compound of the invention is observed through heat-induced tail-flick in mice. The test includes a heat source consisting of a projector lamp with a light beam focused and directed to a point on the tail of a mouse being tested. The tail-flick latencies, which are assessed prior to drug treatment, and in response to a noxious heat stimulus, i.e., the response time from applying radiant heat on the dorsal surface of the tail to the occurrence of tail flick, are measured and recorded at 40, 80, 120 and 160 minutes.
For example, a study can be designed wherein in the first part of the study, a certain number of animals undergo assessment of baseline tail flick latency once a day over two consecutive days. . These animals are then randomly assigned to one of the several different treatment groups (depending on how many compounds are tested) including a vehicle control, a morphine control, and compounds are administered intramuscularly at 30 mg/kg. Following dose administration, the animals are closely monitored for signs of toxicity including tremor or seizure, hyperactivity, shallow, rapid or depressed breathing and failure to groom. The optimal incubation time for each compound is determined via regression analysis. The analgesic activity of the test compounds is expressed as a percentage of the maximum possible effect (%MPE) and is calculated using the following formula:
Postdrug latency - Predrug latency
% MPE X 100% Cut-off time (1O s) - Predrug latency where:
Postdrug latency= the latency time for each individual animal taken before the tail is removed (flicked) from the heat source after receiving drug. Predrug latency= the latency time for each individual animal taken before the tail is flicked from the heat source prior to receiving drug.
Cut-off time (10 s)= is the maximum exposure to the heat source. Acute Pain (Formalin Test)
The formalin test is used as an animal model of acute pain. In the formalin test, animals are briefly habituated to the plexiglass test chamber on the day prior to experimental day for 20 minutes. On the test day, animals are randomly injected with the test articles. At 30 minutes after drug administration, 50 μl_ of 10% formalin is injected subcutaneously into the plantar surface of the left hind paw of the rats. Video data acquisition began immediately after formalin administration, for duration of 90 minutes. The images are captured using the Actimetrix Limelight software which stores files under the Mlii extension, and then converts it into the MPEG-4 coding. The videos are then analyzed using behaviour analysis software "The Observer 5.1", (Version 5.0, Noldus Information Technology, Wageningen, The Netherlands). The video analysis is done by watching the animal behaviour and scoring each according to type, and defining the length of the behaviour (Dubuisson and Dennis, 1977). Scored behaviours include: (1) normal behaviour, (2) putting no weight on the paw, (3) raising the paw, or (4) licking/biting or scratching the paw. Elevation, favoring, or excessive licking, biting and scratching of the injected paw indicate a pain response. Analgesic response or protection from compounds is indicated if both paws are resting on the floor with no obvious favoring, excessive licking, biting or scratching of the injected paw.
Analysis of the formalin test data is done according to two factors: (1) Percent Maximal Potential Inhibitory Effect (%MPIE) and (2) pain score. The %MPIEs can is calculated by a series of steps, where the first is to sum the length of non-normal behaviours (behaviours 1 ,2,3) of each animal. A single value for the vehicle group is obtained by averaging all scores within the vehicle treatment group. The following calculation yields the MPIE value for each animal:
MPIE (%) = 100 - [ (treatment sum/average vehicle value) X 100% ]
The pain score is calculated from a weighted scale as described above. The duration of the behaviour is multiplied by the weight (rating of the severity of the response), and divided by the total length of observation to determine a pain rating for each animal. The calculation is represented by the following formula:
Pain rating = [ 0(To) + 1(T1 ) + 2(T2) + 3(T3) ] / ( To + T1 + T2 + T3 ) CFA Induced Chronic Inflammatory Pain
In this test, tactile allodynia are assessed with calibrated von Frey filaments. Following a full week of acclimatization to the vivarium facility, 150 μL of the "Complete Freund's Adjuvant" (CFA) emulsion (CFA suspended in an oil/saline (1 :1 ) emulsion at a concentration of 0.5 mg/mL) is injected subcutaneously into the plantar surface of the left hind paw of rats under light isoflurane anaesthesia. Animals are allowed to recover from the anaesthesia and the baseline thermal and mechanical nociceptive thresholds of all animals are assessed one week after the administration of CFA. All animals are habituated to the experimental equipment for 20 minutes on the day prior to the start of the experiment. The test and control articles are administrated to the animals, and the nociceptive thresholds measured at defined time points after drug administration to determine the analgesic responses to each of the six available treatments. The time points used are previously determined to show the highest analgesic effect for each test compound.
Thermal nociceptive thresholds of the animals are assessed using the Hargreaves test. Animals are placed in a Plexiglas enclosure set on top of an elevated glass platform with heating units. The glass platform is thermostatically controlled at a temperature of approximately 30 °C for all test trials. Animals are allowed to accommodate for 20 minutes following placement into the enclosure until all exploration behaviour ceases. The Model 226 Plantar/Tail Stimulator Analgesia Meter (UTC, Woodland Hills, CA) is used to apply a radiant heat beam from underneath the glass platform to the plantar surface of the hind paws. During all test trials, the idle intensity and active intensity of the heat source are set at 1 and 45 respectively, and a cut off time of 20 seconds is employed to prevent tissue damage.
The response thresholds of animals to tactile stimuli are measured using the Model 2290 Electrovonfrey anesthesiometer (MTC Life Science, Woodland Hills, CA) following the Hargreaves test. Animals are placed in an elevated Plexiglas enclosure set on a mire mesh surface. After 10 minutes of accommodation, pre-calibrated Von Frey hairs are applied perpendicularly to the plantar surface of both paws of the animals in an ascending order starting from the 0.1 g hair, with sufficient force to cause slight buckling of the hair against the paw. Testing continues until the hair with the lowest force to induce a rapid flicking of the paw is determined or when the cut off force of approximately 20 g is reached. This cut off force is used because it represent approximately 10% of the animals' body weight and it serves to prevent raising of the entire limb due to the use of stiffer hairs, which would change the nature of the stimulus.
Postoperative Models of Nociception In this model, the hypealgesia caused by an intra-planar incision in the paw can be measured by applying increased tactile stimuli to the paw until the animal withdraws its paw from the applied stimuli. While animals are anaesthetized under 3.5% isofluorane, which is delivered via a nose cone, a 1 cm longitudinal incision was made using a number 10 scalpel blade in the plantar aspect of the left hind paw through the skin and fascia, starting 0.5 cm from the proximal edge of the heel and extending towards the toes. Following the incision, the skin is apposed using 2, 3-0 sterilized silk sutures. The injured site is covered with Polysporin and Betadine. Animals are returned to their home cage for overnight recovery.
The withdrawal thresholds of animals to tactile stimuli for both operated (ipsilateral) and unoperated (contralateral) paws can be measured using the Model 2290 Electro vo nfrey anesthesiometer (HTC Life Science, Woodland Hills, CA). Animals are placed in an elevated Plexiglas enclosure set on a mire mesh surface. After at least 10 minutes of acclimatization, pre-calibrated Von Frey hairs are applied perpendicularly to the plantar surface of both paws of the animals in an ascending order starting from the 10 g hair, with sufficient force to cause slight buckling of the hair against the paw. Testing continues until the hair with the lowest force to induce a rapid flicking of the paw is determined or when the cut off force of approximately 20 g is reached. This cut off force is used because it represent approximately 10% of the animals' body weight and it serves to prevent raising of the entire limb due to the use of stiffer hairs, which would change the nature of the stimulus. Neuropathic pain model; Chronic Constriction Injury
Briefly, an approximately 3 cm incision was made through the skin and the fascia at the mid thigh level of the animals' left hind leg using a no. 10 scalpel blade. The left sciatic nerve was exposed via blunt dissection through the biceps femoris with care to minimize haemorrhagia. Four loose ligatures were tied along the sciatic nerve using 4-0 non-degradable sterilized silk sutures at intervals of 1 to 2 mm apart. The tension of the loose ligatures was tight enough to induce slight constriction of the sciatic nerve when viewed under a dissection microscope at a magnification of 4 fold. In the sham-operated animal, the left sciatic nerve was exposed without further manipulation. Antibacterial ointment was applied directly into the wound, and the muscle was closed using sterilized sutures. Betadine was applied onto the muscle and its surroundings, followed by skin closure with surgical clips.
The response thresholds of animals to tactile stimuli were measured using the Model 2290 Electrovonfrey anesthesiometer (HTC Life Science, Woodland Hills, CA). Animals were placed in an elevated Plexiglas enclosure set on a mire mesh surface. After 10 minutes of accommodation, pre-calibrated Von Frey hairs were applied perpendicularly to the plantar surface of both paws of the animals in an ascending order starting from the 0.1 g hair, with sufficient force to cause slight buckling of the hair against the paw. Testing continues until the hair with the lowest force to induce a rapid flicking of the paw is determined or when the cut off force of approximately 20 g is reached. This cut off force is used because it represents approximately 10% of the animals' body weight and it serves to prevent raising of the entire limb due to the use of stiffer hairs, which would change the nature of the stimulus. Compounds of the present invention were shown to be efficacious within a range of 30 mg/kg and 0.1 mg/Kg.
Thermal nociceptive thresholds of the animals were assessed using the Hargreaves test. Following the measurement of tactile thresholds, animals were placed in a Plexiglass enclosure set on top of an elevated glass platform with heating units. The glass platform is thermostatically controlled at a temperature of approximately 24 to 26 0C for all test trials. Animals were allowed to accommodate for 10 minutes following placement into the enclosure until all exploration behaviour ceases. The Model 226 Plantar/ Tail Stimulator Analgesia Meter (HTC, Woodland Hills, CA) was used to apply a radiant heat beam from underneath the glass platform to the plantar surface of the hind paws. During all test trials, the idle intensity and active intensity of the heat source were set at 1 and 55 respectively, and a cut off time of 20 seconds was used to prevent tissue damage.
BIOLOGICAL EXAMPLE 4 Aconitine Induced Arrhythmia Test
The antiarrhythmic activity of compounds of the invention is demonstrated by the following test. Arrhythmia is provoked by intravenous administration of aconitine(2.0μg/Kg) dissolved in physiological saline solution. Test compounds of the invention are intravenously administered 5 minutes after the administration of aconitine. Evaluation of the anti-arrhythmic activity is conducted by measuring the time from the aconitine administration to the occurrence of extrasystole (ES) and the time from the aconitine administration to the occurrence of ventricular tachycardia (VT).
In rates under isoflurane anaesthesia (1/4 to 1/3 of 2%), a tracheotomy is performed by first creating an incision in the neck area, then isolating the trachea and making a 2 mm incision to insert tracheal tube 2 cm into the trachea such that the opening of the tube is positioned just on top of the mouth. The tubing is secured with sutures and attached to a ventilator for the duration of the experiment.
Incisions (2.5 cm) are then made into the femoral areas and using a blunt dissection probe, the femoral vessels are isolated. Both femoral veins are cannulated, one for pentobarbital anaesthetic maintenance (0.02-0.05 mL) and one for the infusion and injection of drug and vehicle. The femoral artery is cannulated with the blood pressure gel catheter of the transmitter.
The ECG leads are attached to the thoracic muscle in the Lead Il position (upper right/above heart - white lead and lower left/below heart - red lead). The leads are secured with sutures. All surgical areas are covered with gauze moistened with 0.9% saline. Saline
(1-1.5 mL of a 0.9% solution) is supplied to moisten the areas post-surgery. The animals' ECG and ventillation are allowed to equilibrate for at least 30 minutes.
The arrhythmia is induced with a 2 μg/Kg/min aconitine infusion for 5 minutes. During this time the ECG is recorded and continuously monitoired.
BIOLOGICAL EXAMPLE 5
Ischemia Induced Arrhythmia Test
Rodent models of ventricular arrhythmias, in both acute cardioversion and prevention paradigms have been employed in testing potential therapeutics for both atrial and ventricular arrhythmias in humans. Cardiac ischemia leading to myocardial infarction is a common cause of morbidity and mortality. The ability of a compound to prevent ischemia-induced ventricular tachycardia and fibrillation is an accepted model for determining the efficacy of a compound in a clinical setting for both atrial and ventricular tachycardia and fibrillation.
Anaesthesia is first induced by pentobarbital (i.p.), and maintained by an i.v. bolus infusion. Male SD rats have their trachea cannulated for artificial ventilation with room air at a stroke volume of 10 ml/Kg, 60 strokes/minute. The right femoral artery and vein are cannulated with PE50 tubing for mean arterial blood pressure (MAP) recording and intravenous administration of compounds, respectively.
The chest is opened between the 4th and 5th ribs to create a 1.5 cm opening such that the heart is visible. Each rat is placed on a notched platform and metal restraints are hooked onto the rib cage opening the chest cavity. A suture needle is used to penetrate the ventricle just under the lifted atrium and exited the ventricle in a downward diagonal direction so that a >30% to <50% occlusion zone (OZ) would be obtained. The exit position is -0.5 cm below where the aorta connects to the left ventricle. The suture is tightened such that a loose loop (occluder) is formed around a branch of the artery. The chest is then closed with the end of the occluder accessible outside of the chest.
Electrodes were placed in the Lead Il position (right atrium to apex) for ECG measurement as follows: one electrode inserted into the right forepaw and the other electrode inserted into the left hind paw.
The body temperature, MAP, ECG and heart rate are constantly recorded throughout the experiment. Once the critical parameters has stabilized, a 1-2 minute recording is taken to establish the baseline values. Infusion of a compound of the invention or control substance is initiated once baseline values are established. After a 5-minute infusion of compound or control, the suture is pulled tight to ligate the LCA and create ischemia in the left ventricle. The critical parameters are recorded continuously for 20 minutes afterjgation, unless the MAP reached the critical level of 20-30 mmHg for at least 3 minutes, in which case the recording is stopped because the animal would be declared deceased and is then sacrificed. The ability of compounds of the invention to prevent arrhythmias and sustain near-normal MAP and HR is scored and compared to control.
* * * * *
All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety.
From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims

WHAT IS CLAIMED IS
1. A compound of formula (I):
Figure imgf000234_0001
wherein: each t is independently 0, 1, 2, 3 or 4; v is 1 , 2 or 3;
each
Figure imgf000234_0002
independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2) -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2) -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4 -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4 -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
2. The compound of claim 1 wherein: v is 1 ;
one
Figure imgf000237_0001
is a fused aryl ring and the other is a fused heterocyclic ring or a fused heteroaryl ring;
R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; and each R3 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy.
3. The compound of Claim 2 selected from the group consisting of the following: 1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4/-/-spiro[furo[3,2-^indolizine-8,3'- indole]-2',4(1'H)-dione; 1'-{[5-(trifluoromethyl)-2-thienyl]methyl}-6,7-dihydro-4H-spiro[furo[3,2-/]indolizine-8,31- indole]-2\4(rH)-dione; I'-KS-chloro^-furyOmethylJ-e.Z-dihydro^H-spiroIfuroIS^-flindolizine-δ.a'-indole]-
2',4(1'H)-dione; 1'-[(5-chloro-2-thienyl)methyl]-6,7-dihydro-4/-/-spiro[furo[3,2-/lindolizine-8,3l-indole]-
2\4(1'H)-dione; 1'-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-6,7-dihydro-4/-/-spiro[furo[3,2-/]indolizine-8,3'- indole]-2',4(1'H)-dione; '-fluoro-r-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H-spiro[furo[3,2-
/Jindolizine-8,3'-indole]-2',4(rH)-dione; 7'-fluoro-r-{[5-(trifluoronnethyl)-2-furyl]methyl}-6,7-dihydro-4/-/-spiro[furo[3,2-
/]indolizine-8,3'-indole]-2',4(rH)-dione; 1'-[(1-isopropylpyrrolidin-3-yl)methyl]-6>7-dihydro-4H-spiro[furo[3,2-/]indolizine-8,3l- indole]-2\4(1'H)-dione; r-[(1-acetylpyrrolidin-3-yl)methyl]-6,7-dihydro-4H-spiro[furo[3,2-/]indolizine-8,3l-indole]-
2',4(1'H)-dione; 3-[(2',4-dioxo-6,7-dihydro-4H-spiro[furo[3,2-f]indolizine-8>3'-indol]-1'(2Η)-yl)methyl]-Λ/- isopropylpyrrolidine-1-carboxamide; 1'-[(1-isopropylpiperidin-4-yl)methyl]-6,7-dihydro-4/-/-spiro[furo[3,2-/]indolizine-8,3'- indole]-2\4(1'H)-dione; 1'-[(1-acetylpiperidin-4-yl)methyl]-6,7-dihydro-4/-/-spiro[furo[3,2-/]indolizine-8,3l-indole]-
2'F4(1'H)-dione; 4-[(2',4-dioxo-6,7-dihydro-4H-spiro[furo[3,2-/]indolizine-8,31-indol]-r(21H)-yl)methyl]-/V- isopropylpiperidine-1-carboxamide; 3-[(21,4-dioxo-6,7-dihydro-4H-spiro[furo[3,2-/]indolizine-8>3'-indol]-r(2Η)-yl)methyl]-Λ/- isopropylpiperidine-1-carboxamide; 3-methyl-1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H-spiro[furo[3,2-
/jindolizine-δ.S'-indolel^'^CI'HJ-dione; 2,3-dimethyl-1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H-spiro[furo[3,2-
/]indolizine-8>3'-indole]-2',4(r/-/)-dione; r-methyl-i-lfδ-CtrifluoromethyO^-furyπmethylJ-e'J'-dihydrospiroCindole-S.δ'-pyrrolotS^-
/JindolizineJ^ΛXIH.rHJ-dione; ^{[δ-CtrifluoromethyO^-furyllmethylJ-e'J'-dihydro^'H-spirotindole-S.δ'-thienotS^-
/]indolizine]-2,4'(1/-0-dione; 1l-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4/-/-spiro[1 >3-dioxolo[4,5-/]indolizine-
8,3'-indole]-2',4(rH)-dione; 1 '-[(2-isopropyl-1 ,3-oxazol-5-yl)methyl]-2'-thioxo-1 ',2',6,7-tetrahydro-4/-/-spiro[1 ,3- dioxolo[4,5-f]indolizine-8,3'-indol]-4-one; 1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-2'-thioxo-1 ',2',6,7-tetrahydro-4H-spiro[1 ,3- dioxolo[4,5-/]indolizine-813l-indol]-4-one; 2'-thioxo-1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 ',2',6,7-tetrahydro-4H-spiro[1 ,3- dioxolo[4,5-/]indolizine-8,3'-indol]-4-one; 2'-thioxo-1 '-{[5-(trifluoromethyl)-2-thienyl]methyl}-1 ',2',6,7-tetrahydro-4H-spiro[1 ,3- dioxolo[4,5-/]indolizine-8,3'-inclol]-4-one; I'-Kδ-chloro^-furyOmethyll-Z-thioxo-r^'.βJ-tetrahydrO^W-spiroII.S-dioxolo^.δ-
/]indolizine-8,3'-indol]-4-one; 1'-[(5-chloro-2-thienyl)methyl]-2'-thioxo-r,2',6,7-tetrahydro-4H-spiro[1 ,3-dioxolo[4,5-
/]indolizine-8,3'-indol]-4-one; 1-[(2-isopropyl-1 ,3-oxazol-5-yl)methyl]-6l,7'-dihydro-1H,4'/-/-spiro[2,1-benzisothiazole-
3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2-oxide; 1-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-6',7'-dihydro-1H,4'/-/-spiro[2,1-benzisothiazole-
3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2-oxide; 1 -{[5-(trifluoromethyl)-2-furyl]methyl}-6',7'-dihydro-1 H,4'/-/-spiro[2, 1 -benzisothiazole-
3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2-oxide; 1-{[5-(trifluoromethyl)-2-thienyl]methyl}-6',7'-dihydro-1/-/,4Η-spiro[2,1-benzisothiazole-
3,8'-[1 ^Jdioxolo^.S-ZJindolizinH'-one 2-oxide; i-fCδ-chloro^-furyOmethyπ-e'J'-dihydro-IH^'H-spirop.i-benzisothiazole-S.δ1-
[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2-oxide; 1 -[(5-chloro-2-thienyl)methyl]-6\7'-dihydro-1 H,4'H-spiro[2, 1 -benzisothiazole-3,8'-
[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2-oxide; 1-[(2-isopropyl-1 >3-oxazol-5-yl)methyl]-6',7l-dihydro-1/-/,4'H-spiro[2,1-benzisothiazole-
3,8'-[1.SJdioxoloμ.δ-flindolizinl-^-one 2,2-dioxide; 1 -[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-6',7'-dihydro-1 /-/,4'H-spiro[2, 1 -benzisothiazole-
3,8'-[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2,2-dioxide; 1-{[5-(trifluoromethyl)-2-furyl]methyl}-6',7'-dihydro-1/-/,4l/-/-spiro[2,1-benzisothiazole-
3,8'-[1 ^Jdioxolo^.S-Zjindolizinl^'-one 2,2-dioxide; 1-{[5-(trifluoromethyl)-2-thienyl]methyl}-6',7'-dihydro-1H,4'/-/-spiro[2,1-benzisothiazole-
3,8'-[1 ,3]dioxolo[4,5-f]indolizin]-4'-one 2,2-dioxide; i-Kδ-chloro^-furyOmethylJ-e'J'-dihydro-IH^'H-spiro^.i-benzisothiazole-S.δ1-
[1.SJdioxolo^.δ-fjindolizinJ-^-one 2,2-dioxide; and 1-[(5-chloro-2-thienyl)methyl]-6',7'-dihydro-1H,4'H-spiro[2,1-benzisothiazole-3,8'-
[1 ,3]dioxolo[4,5-/]indolizin]-4'-one 2,2-dioxide.
4. The compound of claim 1 , wherein: v is 1 ; each
Figure imgf000240_0001
is independently a fused heterocyclic ring or a fused heteroaryl ring;
R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; and each R3 is alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy.
5. The compound of Claim 4 selected from the group consisting of the following: 1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H-spiro[furo[3>2-/]indolizine-8,31- pyrrolo[2,3-b]pyridine]-2',4(1'/-/)-dione; 1'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4/-/-spiro[furo[3,2-/]indolizine-8,31- pyrrolo[3,2-b]pyridine]-2',4(17-/)-dione; and 5'-{[5-(trifluoromethyl)-2-furyl]methyl}-6,7-dihydro-4H-spiro[furo[3,2-/]indolizine-8,7'- pyrrolo[2,3-jb]pyrazine]-4,6'(5Η)-dione.
6. A compound of formula (II):
Figure imgf000240_0002
wherein: t, v and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O- -OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000241_0001
and
Figure imgf000241_0002
are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5,
-R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or
-R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R6 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a and R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a and R2b may be independently optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; or two adjacent R2b together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4 -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
7. The compound of claim 6, wherein: j is 0 and k is 1 ; Q is -O-;
Figure imgf000244_0001
and
Figure imgf000244_0002
are each independently a fused aryl ring;
R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; and two adjacent R3 together with the carbon ring atoms to which they are directly attached, form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl.
8. The compound of claim 7 selected from the group consisting of the following: ^-{[δ-CtrifluoromethyO^-furyllmethylJ-IOH-spirofacridine-Θ.Z'-furoP.S-
/][1 ,3]benzodioxole]; 10-{[5-(trifluoromethyl)-2-thienyl]methyl}-10/-/-spiro[acridine-9,7'-furo[2,3- f][1 ,3]benzodioxole];
10-[(5-chloro-2-furyl)methyl]-10/-/-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]; 10-[(5-chloro-2-thienyl)methyl]-10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]; 10-[(2-chloro-1 ,3-oxazol-5-yl)methyl]-10/-/-spiro[acridine-9,7'-furo[2,3-
/][1 ,3]benzodioxole]; 10-[(2-chloro-1 ,3-thiazol-5-yl)methyl]-10H-spiro[acridine-9,7'-furo[2,3-
/][1 ,3]benzodioxole]; 10-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-10H-spiro[acridine-9,7'-furo[2,3-
/][1 ,3]benzodioxole]; 10-[(2-isopropyl-1 ,3-oxazol-5-yl)methyl]-10/-/-spiro[acridine-9,7'-furo[2,3-
/][1 ,3]benzodioxole];
10-(2-thienylmethyl)-10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]; 10-(2-furylmethyl)-10/-/-spiro[acridine-9,7'-furo[2,3-f][1 ,3]benzodioxole]; 10-[(5-methyl-2-furyl)methyl]-10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]; 5-(10/-/-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzoclioxol]-10-ylmethyl)-2-furonitrile; 5-(10/-/-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxol]-10-ylmethyl)thiophene-2- carbonitrile;
10-benzyl-10/-/-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]; 10-(3,4-difluorobenzyl)-10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]; 10-(pyridin-3-ylmethyl)-10H-spiro[acridine-9,7'-furo[2,3-fl[1 ,3]benzodioxole]; 10-[(1-methylpiperidin-4-yl)methyl]-10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxole]; /V-isopropyl-4-(10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxol]-10- ylmethyl)piperidine-1-carboxamide; Λ/,Λ/-dimethyl-3-(10H-spiro[acridine-9,7'-furo[2,3-/][1 ,3]benzodioxol]-10- ylmethyl)piperidine-1-carboxamide; lO-KI-acetylpiperidin-S-yOmethylj-IOH-spirotacridine-ΘJ'-furo^.S-flfi .Slbenzodioxole]; and 10-[(1-isopropylpyrrolidin-3-yl)methyl]-10H-spiro[acridine-9,7'-furo[2,3-
/][1 ,3]benzodioxole].
9. The compound of claim 6, wherein: j is 0 and k is 1 ; Q is -O-;
at least one of
Figure imgf000245_0001
and
Figure imgf000245_0002
is a fused heterocyclic ring or a fused heteroaryl ring;
R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R3 is independently alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; and each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl or haloalkoxy.
10. The compound of claim 9 selected from the group consisting of the following: 5'-methoxy-10-{[5-(trifluoromethyl)-2-furyl]methyl}-10H-spiro[acridine-9,3'-furo[3,2- b]pyridine]; 5'-methoxy-10-{[5-(trifluoromethyl)-2-thienyl]methyl}-10H-spiro[acridine-9,3'-furo[3,2-
£>]pyridine];
10-[(5-chloro-2-furyl)methyl]-5'-methoxy-10/-/-spiro[acridine-9,3'-furo[3,2-ϋ]pyridine]; lO-^δ-chloro^-thienyOmethylJ-δ'-methoxy-IOH-spirofacridine-Θ.S'-furoIS^-όJpyridine]; 5-[(5'-methoxy-10H-spiro[acridine-9,3'-furo[3,2-jb]pyridin]-10-yl)methyl]thiophene-2- carbonitrile;
5'-methoxy-10-[(5-methyl-2-thienyl)methyl]-10H-spiro[acridine-9,3'-furo[3,2-b]pyridine]; 5l-methoxy-10-[(5-methyl-2-furyl)methyl]-10/-/-spiro[acridine-9,3l-furo[3,2-ifc)]pyridine]; 10-(2-furylmethyl)-5'-methoxy-10H-spiro[acridine-9,3I-furo[3,2-ib]pyridine]; 2l-methoxy-10'-{[5-(trifluoromethyl)-2-furyl]methyl}-10'/-/-spiro[1-benzofuran-3,5'- benzo[fo][1 ,8]naphthyridine]; 10'-[(5-chloro-2-thienyl)methyl]-2'-methoxy-10Η-spiro[1 -benzofuran-3,5'- benzo[έ>][1 ,8]naphthyridine]; 10-[(5-chloro-2-thienyl)methyl]-2-methoxy-10H-spiro[benzo[b][1 ,8]naphthyridine-5,7'- furo[2,3-/][1 ,3]benzodioxole]; 10-[(5-chloro-2-thienyl)methyl]-10H-spiro[benzo[6][1 ,8]naphthyridine-5,7'-furo[2,3-
/][1 ,3]benzodioxole]; and 5l-[(5-chloro-2-thienyl)methyl]-5lH-spiro[furo[2,3-/][1 ,3]benzodioxole-7,10l-pyrido[2,3- ό][1 ,5]naphthyridine].
11. A compound of formula (III):
Figure imgf000247_0001
wherein: p and q are each independently 0, 1 , 2, 3 or 4; v is O, 1 or 2; represents an optional double bond;
J, Q and E are each independently -N=, -CR2b=, -NR2b- or -C(R2b)2-; each D and X are independently N or C, provided when D is N, X is C, or when D is C,
X is N; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-;
Figure imgf000247_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently O, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, . heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5JS(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
12. The compound of claim 11 wherein: at least one of J and Q is -N=, and the other is -N=, -CR2b=, -NR2b- or -C(R2b)2-; E is -N=, -CR2b=, -NR2b- or -C(R2b)2-;
D is C;
X is N;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclylalkyl or the heteroarylalkyl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R2b is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4; -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, araikyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R\ -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alky!, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, araikyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain.
13. The compound of claim 12 wherein: v is 1 ;
X is N;
D is C;
Z is -C(O)- or -C(S)-;
E, Q and J are each independently -N= or -CH=; and
each
Figure imgf000253_0001
and v — ' are independently a fused aryl ring or a fused heteroaryl ring.
14. The compound of claim 13 selected from the group consisting of the following:
I'-benzylspirofi .S-dioxolo^.δ-gltetrazolotδ.i-aJisoquinoline-β.S'-indolJ^XIΗJ-one; I'^ΦfluorobenzyOspiroti .S-dioxolo^.δ-gltetrazolotδ.i-alisoquinoline-δ.S'-indoπ^XI'H)- one; 1'-(4-methoxybenzyl)spiro[1 ,3-dioxolo[4,5-g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]- 2'(1'H)-one; IXI.S-benzodioxol-S-ylmethyOspiroti.S-dioxolo^.S-gJtetrazolotδ.i-alisoquinoline-β.S'- indol]-2'(1'H)-one; 1'-(pyridin-3-ylmethyl)spiro[1 ,3-dioxolo[4,5-g]tetrazolo[5,1-a]isoquinoline-6,3'-indol]-
2'(1'H)-one; I'-fiδ-methoxypyridin-S-yOmethyljspiroti .S-dioxolo^.δ-gltetrazolotδ.i-aJisoquinoline- δ.S'-indoll-ZCI'HJ-one; I'-^i-isopropylpiperidin^-yOmethylJspiroCI .S-dioxolo^.δ-gltetrazolofδ.i-aJisoquinoline-
6,3'-\ndo\]-2'(VH)-one; I'-^i-acetylpiperidin-ΦyOmethylJspiroti .S-dioxolo^.δ-gKetrazoloIδ.i-alisoquinoline-
Figure imgf000254_0001
Λ/-isopropyl-4-[(2'-oxospiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ,1-a]isoquinoline-6,3'-indol]-
1 '(2'H)-yl)methyl]piperidine-1 -carboxamide; 1'-[(1-isopropylpiperidin-3-yl)methyl]spiro[1 ,3-dioxolo[4,6-g]tetrazolo[6,1-a]isoquinoline-
Figure imgf000254_0002
Λ/-isopropyl-3-[(2'-oxospiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ, 1 -a]isoquinoline-6,3'-indol]-
1 '(2'/-/)-yl)methyl]piperidine-1 -carboxamide; 1 '-[( 1 -acetylpiperidin-3-yl)methyl]spiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ, 1 -ajisoquinoline- δ.S'-indo^^Xr^O-one; 1'-[(1-isopropylpyrrolidin-3-yl)methyl]spiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ,1- a]isoquinoline-6,3'-indol]-2'(1'/-/)-one; Λ/-isopropyl-3-[(2'-oxospiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ, 1 -a]isoquinoline-6,3'-indol]-
1 '(2'H)-yl)methyl]pyrrolidine-1 -carboxamide; I'-^i-acetylpyrrolidin-S-yOmethyQspiroti .S-dioxolo^.δ-gKetrazoloIδ.i-aJisoquinoline- δ.S'-indol^XrfO-one; ^-{[δ-CtrifluoromethyO^-furyllmethylJspiroti .S-dioxolo^.δ-gltetrazoloIδ.i- a]isoquinoline-6,3'-indol]-2'(1'H)-one; 1 '-{[δ-(trifluoromethyl)-2-thienyl]methyl}spiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ, 1 - a]isoquinoline-6,3'-indol]-2'(1'/-/)-one; 1 '-[(δ-chloro-2-thienyl)methy!]spiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ, 1 -a]isoquinoline-6,3'- indol]-2'(1'H)-one; 1 '-[(δ-chloro-2-furyl)methyl]spiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ, 1 -a]isoquinoline-6,3'- indol]-2'(1'H)-one; 1 '-[(2-isopropyl-1 ,3-thiazol-δ-yl)methyl]spiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ, 1 - a]isoquinoline-6,3'-indol]-2'(1lH)-one;
2δ3 1'-[(2-isopropyl-1 ,3-oxazol-δ-yl)methyl]spiro[1 ,3-dioxolo[4,δ-g]tetrazolo[δ,1- a]isoquinoline-6,3'-indol]-2'(1'/-/)-one; 1'-[(5-methyl-2-furyl)methyl]spiro[1 ,3-dioxolo[4,5-g]tetrazolo[5,1-a]isoquinoline-6,3'- indol]-2'(1'H)-one; 5-[(2'-oxospiro[1 ,3-dioxolo[4,5-g]tetrazolo[5, 1 -a]isoquinoline-6,3'-indol]-1 '(2'H)- yl)methyl]-2-furonitrile; r-^δ-Ctrifluoromethyl^-furyllmethylJspiroti .S-dioxolo^.δ-gJtetrazolotδ.i- a]isoquinoline-6,3'-pyrrolo[2,3-ib]pyridin]-2'(1'H)-one; "''-{[δ-CtrifluoromethyO^-furyOmethylJspiroti .S-dioxolo^.δ-gltetrazolotδ.i- a]isoquinoline-6,3'-pyrrolo[3,2-6]pyridin]-2'(1'H)-one; 8'-methoxy-1-{[δ-(trifluoromethyl)-2-furyl]methyl}spiro[indole-3,6'-tetrazolo[δ,1- f\[\ ,6]naphthyridin]-2(1 H)-one; 1 -[(δ-chloro-2-thienyl)methyl]-8'-methoxyspiro[indole-3,6'-tetrazolo[δ, 1 - f\[\ ,6]naphthyridin]-2(1 H)-one; 1 -[(δ-chloro-2-furyl)methyl]-8'-methoxyspiro[indole-3,6'-tetrazolo[δ, 1 -
/][1 ,6]naphthyridin]-2(1 H)-one; 1 -[(δ-chloro-2-furyl)methyl]-8'-methoxyspiro[indole-3,6'-tetrazolo[δ, 1 - f][1 ,6]naphthyridine]-2(1H)-thione; 8'-methoxy-1 -{[δ-(trifluoromethyl)-2-furyl]methyl}spiro[indole-3,6'-tetrazolo[δ, 1 -
/][1 ,6]naphthyridine]-2(1 H)-thione; δ'-methoxy-I^Cδ-Ctrifluoromethyl^-furyllmethylJspirotindole-S.Θ'-ti ^.Sltriazolotδ.i-
/][1 ,6]naphthyridine]-2(1H)-thione; 1 -[(6-chloro-2-thienyl)methyl]-8'-methoxyspiro[indole-3,6'-[1 ,2,3]triazolo[δ, 1 - f\[\ ,6]naphthyridine]-2(1 H)-thione; 1-[(2-isopropyl-1 ,3-thiazol-δ-yl)methyl]-8'-methoxyspiro[indole-3,6'-[1 ,2,3]triazolo[δ,1-
/][1 ,6]naphthyridine]-2(1H)-thione; 1 '-{[δ-(trifluoromethyl)-2-furyl]methyl}spiro[1 ,3-dioxolo[4,δ-g][1 ,2,3]triazolo[δ, 1 - a]isoquinoline-6,3'-indol]-2'(1Η)-one; I'-^δ-chloro^-thienyOmethylJspiroti ^-dioxolo^.δ^fi ^.SJtriazolotδ.i-alisoquinoline-
6,3'-indol]-2'(1'H)-one; 1 '-[(δ-methyl-2-furyl)methyl]spiro[1 ,3-dioxolo[4,δ-g][1 ,2,3]triazolo[δ, 1 -a]isoquinoline-
6,3'-indol]-2'(1'H)-one; δ-[(2'-oxospiro[1 ,3-dioxolo[4,δ-g][1 ,2,3]triazolo[δ>1-a]isoquinoline-6,3'-indol]-1'(2'H)- yl)methyl]-2-furonitrile; 1 '-{[δ-(trifluoromethyl)-2-furyl]methyl}spiro[1 ,3-dioxolo[4,δ-g][1 ,2,3]triazolo[δ, 1 -
2δ4 a]isoquinoline-6,3'-pyrrolo[2,3-/fc>]pyridin]-2'(1'H)-one; r-^S-Ctrifluoromethyl^-furyπmethylJspiroti .a-dioxolo^.δ-glti ^.SJtriazolo^.i- a]isoquinoline-6,3'-pyrrolo[3,2-jb]pyridin]-2'(1Η)-one; ^-fluoro-r-ltδ-^rifluoromethyO^-furyllmethylϊspiroIi .a-dioxolo^.δ-glti ^^ltriazolotδ.i- a]isoquinoline-6,3'-indol]-2'(1'/-0-one; 7'-fluoro-1 '-{[δ-(trifluoromethyl)-2-furyl]methyl}spiro[1 ,3-dioxolo[4,δ-g][1 ,2,3]triazolo[δ, 1 - a]isoquinoline-6,3'-indol]-2'(1'H)-one; I'-^δ-Ctrifluoromethyl^-furyllmethylJspiroti.S-dioxolo^.δ-glimidazotδ.i-alisoquinoline-
6,3'-indol]-2'(rH)-one; I'-fCδ-chloro^-thienyOmethyOspiroti .S-dioxolo^.δ-gjimidazotδ.i-alisoquinoline-Θ.S'- indol]-2'(1'H)-one; r-[(δ-methyl-2-furyl)methyl]spiro[1 ,3-dioxolo[4,δ-g]imidazo[δ,1-a]isoquinoline-6,3'- indol]-2'(1'H)-one; δ-[(2'-oxospiro[1 ,3-dioxolo[4,δ-g]imidazo[δ, 1 -a]isoquinoline-6,3'-indol]-1 '(2'H)- yl)methyl]-2-furonitιϊle; 1'-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-8-methoxyspiro[imidazo[5,1-
/][1 ,6]naphthyridine-6,3'-indol]-2'(1 'H)-one; 1 '-[(δ-chloro-2-thienyl)methyl]-8-methoxyspiro[imidazo[δ, 1 -f\{\ ,6]naphthyridine-6,3'- indol]-2'(1'H)-one; 1'-[(δ-chloro-2-thienyl)methyl]-8-methoxyspiro[imidazo[δ,1-/][1 ,6]naphthyridine-6,31- pyrrolo[2,3-t»]pyridin]-2'(1'H)-one; 1'-[(δ-chloro-2-thienyl)methyl]-8-methoxyspiro[imidazo[δ,1-/][1 ,6]naphthyridine-6,3'- pyrrolo[3,2-/b]pyridin]-2l(1lH)-one; 1 '-[(δ-chloro-2-thienyl)methyl]-7'-fluoro-8-methoxyspiro[imidazo[δ, 1 - f\{\ ,6]naphthyridine-6,3'-indol]-2'(1 'H)-one; 7'-fluoro-8-methoxy-r-{[δ-(trifluoromethyl)-2-furyl]methyl}spiro[imidazo[δ,1-
/J[1 ,6]naphthyridine-6,3'-indol]-2'(rH)-one; 4'-fluoro-8-methoxy-r-{[δ-(trifluoromethyl)-2-furyl]methyl}spiro[imidazo[δ,1-
^[i .θlnaphthyridine-e.S'-indolJ^XrHJ-one; 8-methoxy-1 '-[(δ-methyl-2-furyl)methyl]spiro[imidazo[δ, 1 -f\[\ ,6]naphthyridine-6,3'- indol]-2'(1'H)-one; 8-methoxy-r-(2-thienylmethyl)spiro[imidazo[δ,1-/][1 ,6]naphthyridine-6,3'-indol]-2'(11/-/)- one; and 1 '-(2-furylmethyl)-8-methoxyspiro[imidazo[δ, 1 -f\[\ ,6]naphthyridine-6,3'-indol]-2'(1 'H)- one.
2δδ
15. The compound of claim 11 wherein: at least one of Q and E is -N=, and the other is -N=, -CR2b=, -NR2b- or -C(R2b)2-; J is -N=, -CR2b=, -NR2b- or -C(R2V; X is C; D is N; v is 1 ; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)m-R5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclylalkyl or the heteroarylalkyl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R2b is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain.
16. The compound of claim 15 selected from the group consisting of the following:
1'-benzyl-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-2l(1'/-/)-one; 1 '-(4-fluorobenzyl)-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-
2'(1'H)-one; 1 '-(4-methoxybenzyl)-4H-spiro[1.S-dioxolo^.δ-gJtetrazoloti ,5-a]quinoline-5,3'-indol]-
2'(1'H)-one; 1 '-(1 ,3-benzodioxol-5-ylmethyl)-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-
5,3'-indol]-2'(rH)-one; 1 '-(pyridin-3-ylmethyl)-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-
2'(1'H)-one; 1 '-[(6-methoxypyridin-3-yl)methyl]-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline- δ.S'-indoll^i'HJ-one; 1'-[(1-isopropylpiperidin-4-yl)methyl]-4/-/-spiro[1 ,3-dioxolo[4,5-gf]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1Η)-one; 1 '-[(1 -acetylpiperidin-4-yl)methyl]-4/-/-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-
5,3'-indol]-2'(1'H)-one; Λ/-isopropyl-4-[(2'-oxo-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5>3'-indol]-
1 '(2'/-/)-yl)methyl]piperidine-1 -carboxamide; I'-tCI-isopropylpiperidin-S-yOmethylHH-spiroCI .S-dioxolo^.δ-gltetrazoloIi .δ- a]quinoline-5,3'-indol]-2'(1'/-/)-one; Λ/-isopropyl-3-[(2'-oxo-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-
1 l(2'/-/)-yl)methyl]piperidine-1 -carboxamide; 1'-[(1-acetylpiperidin-3-yl)methyl]-4/-/-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-
5,3'-indol]-2'(1'H)-one; 1'-[(1-isopropylpyrrolidin-3-yl)methyl]-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1Η)-one; Λ/-isopropyl-3-[(2'-oxo-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'-indol]-
1 '(2'H)-yl)methyl]pyrrolidine-1 -carboxamide; I'-^i-acetylpyrrolidin-S-ylJmethyll^H-spiroti .S-dioxolo^.δ-gJtetrazoloti .δ-alquinoline-
5,3'-indol]-2'(rH)-one; 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1'/-/)-one; 1 '-{[5-(trifluoromethyl)-2-thienyl]methyl}-4/-/-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1'H)-one; 1 '-[(5-chloro-2-furyl)methyl]-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'- indol]-2'(1'H)-one; 1 '-[(5-chloro-2-thienyl)methyl]-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'- indol]-2'(1'H)-one; 1l-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-4H-spiro[1,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1'/-/)-one; 1 '-[(2-isopropyl-1 ,3-oxazol-5-yl)methyl]-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indol]-2'(1'/-/)-one; 1 '-[(5-methyl-2-furyl)methyl]-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quinoline-5,3'- indol]-2"(1'H)-one; 5-[(2'-oxo-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5-a]quino!ine-5,3'-indol]-1 '(21H)- yl)methyl]thiophene-2-carbonitrile; 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-pyrrolo[2,3-6]pyridin]-2'(1'H)-one; 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4H-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-pyrrolo[3,2-<fc>]pyridin]-2'(1'H)-one; 7'-methoxy-1-{[5-(trifluoromethyl)-2-furyl]methyl}-4'/-/-spiro[indole-3,5'-tetrazolo[1 ,5- a][1 ,5]naphthyridin]-2(1/-/)-one; 1-[(5-chloro-2-thienyl)methyl]-7'-methoxy-4'/-/-spiro[indole-3,5'-tetrazolo[1 ,5- a][1 ,5]naphthyridin]-2(1 H)-one; 1-[(5-chloro-2-furyl)methyl]-7'-methoxy-4l/-/-spiro[indole-3,5'-tetrazolo[1 ,5- a][1 ,5]naphthyridin]-2(1 H)-one; 1-[(5-chloro-2-furyl)methyl]-7'-methoxy-4Η-spiro[indole-3,5'-tetrazolo[1 ,5- a][1 ,5]naphthyridine]-2(1H)-thione; and 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-4/-/-spiro[1 ,3-dioxolo[4,5-g]tetrazolo[1 ,5- a]quinoline-5,3'-indole]-2'(1l/-/)-thione.
17. A compound of formula (IV):
Figure imgf000261_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; p is 0, 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5; X, W and E are each independently -N= or -CH=;
Figure imgf000261_0002
a anndd
Figure imgf000261_0003
each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
18. The compound of claim 17, wherein: j is O; k is 1;
Q is -O-; and
E, X and W are each -N=.
19. The compound of claim 18 selected from the group consisting of the following: spiro[furo[2,3-/][1 ,3]benzodioxole-7,9'-tetrazolo[1 ,5-a]indole]; 5-methoxyspiro[furo[3,2-jb]pyridine-3,9'-tetrazolo[1 ,5-a]indole]; and 8'-pyrimidin-5-ylspiro[furo[2,3-/][1 ,3]benzodioxole-7,9'-tetrazolo[1 ,5-a]indole].
20. The compound of claim 17, wherein: j is O; k is 1 ;
Q is -O-;
E and W are each -N=; and
X is -CH=.
21. The compound of claim 20 selected from the group consisting of the following: spiro[furo[2,3-/][1 ,3]benzodioxole-7,9'-[1 ,2,4]triazolo[1 ,5-a]indole]; 5-methoxyspiro[furo[3,2-6]pyridine-3,9'-[1 ,2,4]triazolo[1 ,5-a]indole]; and 8'-pyrimidin-5-ylspiro[furo[2,3-/][1 ,3]benzodioxole-7,9'-[1 ,2,4]triazolo[1 ,5-a]indole].
22. The compound of claim 17, wherein: j is O; k is 1 ; Q is -O-;
X and W are each -N=; and
E is -CH=.
23. The compound of claim 22 selected from the group consisting of the following: spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-[1 ,2,3]triazolo[1 ,5-a]indole]; 5-methoxyspiro[furo[3,2-ib]pyridine-3,4'-[1 ,2,3]triazolo[1 ,5-a]indole]; and 5'-pyrimidin-5-ylspiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-[1 ,2,3]triazolo[1 ,5-a]indole].
24. The compound of claim 17, wherein: j is O; k is 1 ;
Q is -O-;
E and X are each -CH=; and
W is -N=.
25. The compound of claim 24 selected from the group consisting of the following: spiro[furo[2,3-f][1 ,3]benzodioxole-7,4'-pyrazolo[1 ,5-a]indole]; 5-methoxyspiro[furo[3,2-ib]pyridine-3,4'-pyrazolo[1 ,5-a]indole]; and 5'-pyrimidin-5-ylspiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-pyrazolo[1 ,5-a]indole].
26. The compound of claim 17, wherein: j is O; k is 1 ;
Q is -O-;
E and W are each -CH=; and
X is -N=.
27. The compound of claim 26 selected from the group consisting of the following: spiro[furo[2,3-f|[1 ,3]benzodioxole-7,9'-imidazo[1 ,5-a]indole]; 5-methoxyspiro[furo[3,2-b]pyridine-3,9'-imidazo[1 ,2-a]indole]; and δ'-pyrimidin-δ-ylspiro^urop.S-flfi .SJbenzodioxole^.θ'-imidazoti ^-alindole.
28. A compound of formula (V):
Figure imgf000266_0001
wherein: t and p are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5; X is hydrogen or halo;
Figure imgf000266_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is O1 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8- C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is O1 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently O, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4, and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)πN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
29. The compound of claim 28, wherein: j is O; k is O; p is 2;
Q is -O- or -NH-; X is hydrogen or fluoro;
each
Figure imgf000269_0001
and are independently a fused aryl ring;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; and two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl.
30. The compound of claim 29 selected from the group consisting of the following:
2-{[5-(trifluoromethyl)-2-furyl]methyl}-2, 11 b-dihydro-1 H-
[1 ,3]dioxolo[6,7]chromeno[4,3,2-cc/]indol-1-one; 2-{[5-(trifluoromethyl)-2-thienyl]methyl}-2, 11 b-dihydro-1 H-
[1.SJdioxolotejlchromenol^.S^-ccflindol-i -one; 2-[(5-chloro-2-thienyl)methyl]-2, 11 b-dihydro-1 /-/-[1 ,3]dioxolo[6,7]chromeno[4,3,2- ccφndol-1-one; 2-[(5-chloro-2-furyl)methyl]-2,11 b-dihydro-1 H-ti .SldioxolotejJchromeno^.S^-ccdindol-
1-one; 2-[(5-chloro-2-furyl)methyl]-11 b-fluoro-2,11 b-dihydro-1 H-
[1.SJdioxolotθ.yjchromeno^.S^-ccdindol-i -one; 2-[(5-chloro-2-thienyl)methyl]-11 b-fluoro-2,11 b-dihydro-1 H-
[1 ,3]dioxolo[6,7]chromeno[4,3,2-cc/]indol-1 -one; 11b-fluoro-2-{[5-(trifluoromethyl)-2-furyl]methyl}-2, 11 b-dihydro-1 H-
[1.SJdioxolo^JJchromeno^.S^-ccdindol-i -one; 11 b-fluoro-2-{[5-(trifluoromethyl)-2-thienyl]methyl}-2, 11 b-dihydro-1 H-
[1 ,3]dioxolo[6,7]chromeno[4,3,2-cc(Jindol-1 -one; 2-[(5-chloro-2-thienyl)methyl]-11b-fluoro-6,11b-dihydro[1 ,3]dioxolo[4,5-jb]pyrrolo[2,3,4-
/c/]acridin-1(2H)-one; 2-[(5-chloro-2-thienyl)methyl]-6,11 b-dihydro[1 ,3]dioxolo[4>5-6]pyrrolo[2,3,4-/f/]acridin-
1(2H)-one; and 2-{[5-(trifluoromethyl)-2-furyl]methyl}-6, 11 b-dihydro[1 ,3]dioxolo[4,5-ib]pyrrolo[2,3,4-
/c/]acridin-1(2H)-one.
31. The compound of claim 28, wherein: j is O; k is O;
Q is -O-, -S(O)m- (m is 0 or 2) or -NH-;
X is hydrogen or fluoro;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; is a fused aryl ring; and
Figure imgf000271_0001
is a fused heteroaryl ring.
32. The compound of claim 31 selected from the group consisting of the following: 10b-fluoro-9-methoxy-2-{[5-(trifluoromethyl)-2-thienyl]methyl}-2,10b-dihydro-1/-/- pyrido^'.S'iδ.θJpyrano^.S^-cc/lindol-i-one; 10b-fluoro-9-methoxy-2-{[5-(trifluoromethyl)-2-furyl]methyl}-2,10b-dihydro-1/-/- pyrido^'.S'iδ.δJpyrano^.S^-CGflindol-i-one; 9-methoxy-2-{[5-(trifluoromethyl)-2-furyl]methyl}-2,10b-dihydro-1H- pyrido[2',3':5,6]pyrano[4,3,2-cc/]indol-1-one; 2-[(5-chloro-2-thienyl)methyl]-9-methoxy-2, 10b-dihydro-1 H- pyridoP'.S'iδ.θtøyranorAS^-ccφndol-i-one; 2-[(5-chloro-2-furyl)methyl]-9-methoxy-6,10b-dihydroindolo[4,3-bc][1 ,5]naphthyridin-
1(2H)-one; 9-methoxy-2-{[5-(trifluoromethyl)-2-furyl]methyl}-6,10b-dihydroindolo[4,3- όc][1 ,5]naphthyridin-1 (2H)-one; 9-methoxy-2-{[5-(trifluoromethyl)-2-furyl]methyl}-2,10b-dihydro-1/-/- pyrido[2',3':5,6]thiopyrano[4,3,2-cd]indol-1-one; 10b-fluoro-9-methoxy-2-{[5-(trifluoromethyl)-2-furyl]methyl}-2, 10b-dihydro-1 H- pyrido[2',3':5,6]thiopyrano[4,3,2-cc/]indol-1 -one; and 2-[(5-chloro-2-thienyl)methyl]-9-methoxy-2, 10b-dihydro-1 H- pyrido^'.S'iδ.eithiopyranoK.S^-ccdindol-i-one e.e-dioxide.
33. The compound of claim 28, wherein: j is O; k is O;
P is 2;
Q is -O-, -S- or -NH-;
X is hydrogen or fluoro; is a fused aryl ring;
Figure imgf000272_0001
is a fused heteroaryl ring;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; and two adjacent R3 together with the carbon ring atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl.
34. The compound of claim 33 selected from the group consisting of the following:
11 b-fluoro-2-{[5-(trifluoromethyl)-2-furyl]methyl}-2, 11 b-dihydro-1 H-6,8, 10-trioxa-2,3- diazacyclopenta[/f]aceanthrylen-1-one; 2-[(5-chloro-2-thienyl)methyl]-11 b-fluoro-2, 11 b-dihydro-1 H-6,8, 10-trioxa-2,3- diazacyclopenta[/(]aceanthrylen-1 -one; and 2-[(5-chloro-2-thienyl)methyl]-11b-fluoro-6,11b-dihydro[1 ,3]benzodioxolo[5,6-
<fc>]pyrrolo[4,3,2-cte][1 ,6]naphthyridin-1 (2/-/)-one.
35. The compound of claim 28, wherein: j is O; k is O;
Q is -O-, -S- or -NH-;
X is hydrogen or fluoro;
R1 is heteroarylalkyl where the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-C(O)R5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; and
each
Figure imgf000273_0001
and are independently a fused heteroaryl ring.
36. The compound of claim 35 selected from the group consisting of the following: 2-[(5-chloro-2-thienyl)methyl]-9-methoxy-2, 10b-dihydro-1 H-6-oxa-2,3, 10- triazaaceanthrylen-1 -one; 2-[(5-chloro-2-furyl)methyl]-9-methoxy-2, 10b-dihydro-1 H-6-oxa-2,3, 10- triazaaceanthrylen-1 -one; 2-[(5-chloro-2-thienyl)methyl]-10b-fluoro-9-methoxy-2, 10b-dihydro-1 H-6-thia-2,3, 10- triazaaceanthrylen-1-one; and 2-[(5-chloro-2-thienyl)methyl]-9-methoxy-2, 1 Ob-dihydro-1 H-6-thia-2,3, 10- triazaaceanthrylen-1 -one.
37. A compound of formula (Vl):
Figure imgf000273_0002
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000273_0003
is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; Y is aryl, heterocyclic or heteroaryl ring; Z is -C(O)-, -C(S)-, -S(O)- or -S(O)2-;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5,
-R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or
-R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R6 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyi groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyi, -R8-CN, -R8-NO2) -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyi; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
38. The compound of claim 37, wherein: j is O; k is 2; Q is -O-; Z is -C(O)-;
Figure imgf000276_0001
is a fused aryl ring; and Y is aryl or heteroaryl.
39. The compound of claim 38 selected from the group consisting of the following:
2a-(1 ,3-benzodioxol-5-yl)-1-benzyl-1 ,2a,4,5-tetrahydro-2/-/-pyrano[2,3,4-cc(]indol-2-one; 2a-(1 ,3-benzodioxol-5-yl)-1-{[5-(trifluoromethyl)-2-furyl]methyl}-1 >2a,4,5-tetrahydro-2H- pyrano[2,3,4-cd]indol-2-one; 2a-(1 ,3-benzodioxol-5-yl)-1-{[5-(trifluoromethyl)-2-thienyl]methyl}-1 ,2a,4,5-tetrahydro-
2H-pyrano[2,3,4-cc0indol-2-one; 2a-(1 ,3-benzodioxol-5-yl)-1 -[(5-chloro-2-thienyl)methyl]-1 ,2a,4,5-tetrahydro-2W- pyrano[2,3,4-cc/]indol-2-one; 2a-(1,3-benzodioxol-5-yl)-1-[(5-chloro-2-furyl)methyl]-1 ,2a,4,5-tetrahydro-2H- pyrano[2,3,4-cc/]indol-2-one; 2a-(1 ,3-benzodioxol-5-yl)-1-(4-fluorobenzyl)-1 ,2a,4,5-tetrahydro-2H-pyrano[2,3,4- ccflindol-2-one; 2a-(1 ,3-benzodioxol-5-yl)-1-[(6-methoxypyridin-3-yl)methyl]-1 ,2a,4,5-tetrahydro-2H- pyrano[2,3,4-cc/]indol-2-one; 2a-(1 ,3-benzodioxol-5-yl)-1-(pyridin-3-ylmethyl)-1 ,2a,4,5-tetrahydro-2/-/-pyrano[2,3,4- cc/]indol-2-one; 2a-(6-methoxypyridin-2-yl)-1-{[5-(trifluoromethyl)-2-furyl]methyl}-1 ,2a,4,5-tetrahydro-
2H-pyrano[2,3,4-cc/]indol-2-one; i-^δ-chloro^-thienyOmethyO^a-CΘ-methoxypyridin^-yO-i ^a^.δ-tetrahydro^/-/- pyrano[2,3,4-cc(]indol-2-one; 2a-(1 ,3-benzodioxol-5-yl)-1-[(1-isopropylpiperidin-4-yl)methyl]-1 ,2a,4,5-tetrahydro-2H- pyrano[2,3,4-cc/]indol-2-one; i-^i-acetylpiperidin^-yOmethylJ^a-CI .S-benzodioxol-δ-yO-i ^a^.δ-tetrahydro^/-/- pyrano[2,3,4-cc/]indol-2-one; 4-{[2a-(1 ,3-benzodioxol-δ-yl)-2-oxo-2,2a,4,δ-tetrahydro-1 H-pyrano[2,3,4-cc/]indol-1 - yl]methyl}-Λ/-isopropylpiperidine-1-carboxamide; 3-{[2a-(1 ,3-benzodioxol-δ-yl)-2-oxo-2,2a>4,δ-tetrahydro-1H-pyrano[2,3,4-cc/lindol-1- yl]methyl}-Λ/-isopropylpiperidine-1-carboxamide; i-fCI-acetylpiperidin-S-yOmethylJ^a-CI .S-benzodioxol-δ-yO-i ^a^.δ-tetrahydro^H- pyrano[2,3,4-cc/]indol-2-one; i-KI-acetylpyrrolidin-S-yOmethyO^a-CI .S-benzodioxol-δ-yO-i ^a^.δ-tetrahydro^H- pyrano[2,3,4-cc/]indol-2-one; 2a-(1,3-benzodioxol-δ-yl)-1-[(1-isopropylpyrrolidin-3-yl)methyl]-1 ,2a,4,δ-tetrahydro-2H- pyrano[2,3,4-cc/]indol-2-one; 3-{[2a-(1 ,3-benzodioxol-5-yl)-2-oxo-2,2a,4,5-tetrahydro-1 /-/-pyrano[2,3,4-cc/]indol-1 - yl]methyl}-Λ/-isopropylpyrrolidine-1-carboxamide;
2a-(1 ,3-benzodioxol-5-yl)-1-pentyl-1 >2a,4,5-tetrahydro-2/-/-pyrano[2,3,4-co0indol-2-one; 2a-(1,3-benzodioxol-5-yl)-1-[(5-methyl-2-furyl)methyl]-1 ,2a,4,5-tetrahydro-2/-/- pyrano[2,3,4-cc(]indol-2-one; δ-pa-CI.S-benzodioxol-δ-yO^-oxo^^aΛ.δ-tetrahydro-IAV-pyrano^.S^-cc/lindol-i- yl]methyl}-2-furonitrile; δ-^a^e-methoxypyridin^-yl^-oxo^^a^.δ-tetrahydro-IH-pyranop.S^-cc/lindol-i- yl]methyl}-2-furonitrile; and i-^δ-chloro^-thienyOmethyll-δ-fluoro^a^δ-methoxypyridin^-yO-i ^a^.δ-tetrahydro-
2H-pyrano[2,3,4-cc/]indol-2-one.
40. The compound of claim 37, wherein: j is O; k is 2; Q is -O-;
Z is -C(O)-;
Figure imgf000278_0001
is a fused heteroaryl ring; and Y is aryl or heteroaryl.
41. The compound of claim 40 selected from the group consisting of the following: 2a-(1 ,3-benzodioxol-δ-yl)-1-{[δ-(trifluoromethyl)-2-furyl]methyl}-1 ,2a,4,δ-tetrahydro-2/-/-
3-oxa-1 ,8-diazaacenaphthylen-2-one; 2a-(1 ,3-benzodioxol-δ-yl)-1-[(δ-chloro-2-thienyl)methyl]-1 ,2a,4,δ-tetrahydro-2/-/-3-oxa-
1 ,8-diazaacenaphthylen-2-one; 1-[(δ-chloro-2-thienyl)methyl]-2a-(6-methoxypyridin-2-yl)-1 ,2a,4,δ-tetrahydro-2/-/-3-oxa-
1 ,8-diazaacenaphthylen-2-one; 1-[(δ-chloro-2-furyl)methyl]-2a-(6-methoxypyridin-2-yl)-1 ,2a,4,δ-tetrahydro-2H-3-oxa-
1 ,8-diazaacenaphthylen-2-one; and 2a-(6-methoxypyridin-2-yl)-1-{[δ-(trifluoromethyl)-2-furyl]methyl}-1 ,2a,4,δ-tetrahydro-
2H-3-oxa-1 ,8-diazaacenaphthylen-2-one.
42. A compound of formula (VII):
Figure imgf000279_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; v is 1 , 2 or 3; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000279_0002
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where: R6 is hydrogen, alkyl, aryl or aralkyl; and R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R\ -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
43. The compound of claim 42, wherein: j is O; k is 1 ; n is 1 ;
X is O or S;
Figure imgf000282_0001
is a fused aryl ring; and Y is fused heteroaryl or fused aryl.
44. The compound of claim 43 selected from the group consisting of the following:
1'-pentyl-1'/-/-spiro[furo[2,3-/][1 ,3]benzodioxole-7>4'-quinolin]-2'(3lH)-one; I'-pentyl-δ.e-dihydro-IΗ-spiroCbenzoti ^-ib^^-jbldifuran-S^'-quinolinl^'CSΗVone; 5,6-difluoro-1'-pentyl-1Η-spiro[1-benzofuran-3,4'-quinolin]-2'(3'H)-one;
1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3-/][1 ^benzodioxole^^1- quinolin]-2'(3'/-/)-one; 1 '-[(5-chloro-2-thienyl)methyl]-1 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinolin]-
2'(3'H)-one;
1l-(2-cyclopropylethyl)-1'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinolin]-2'(3lH)-one; 1 '-[(5-chloro-1 ,3-thiazol-2-yl)methyl]-1 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'- quinolin]-2'(3'H)-one; 1 '-[(5-chloro-2-thienyl)methyl]-5,6-dihydro-1 'H-spiro[benzo[1 ,2-b:5,4-b]difuran-3,4'- quinolin]-2'(3'H)-one;
Figure imgf000283_0001
3A'<\u\no\\n]-2'{3'Hyone; 1 l-{[5-(trifluoromethyl)-2-furyl]methyl}-5,6-dihydro-1 'H-spiro[benzo[1 ,2-6:5,4-6 ]difuran-
3A'-qumo\\n]-2'(3'H)-one; 1 '-(2-cyc!opropylethyl)-1 'H-sρiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinoline]-2'(3'H)- thione;
Figure imgf000283_0002
a^'-quinolinel^^'HJ-thione; 1 '-[(5-chloro-2-thienyl)methyl]-1 Η-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinoline]-
2'(3'H)-thione ; 5-methoxy-r-{[5-(trifluoromethyl)-2-furyl]methyl}-1'H-spiro[furo[3,2-f)]pyridine-3,41- quinolin]-2'(3'H)-one ; 1'-[(5-chloro-2-furyl)methyl]-5-methoxy-1l/-/-spiro[furo[3,2-b]pyridine-3,4'-quinolin]-
2'(3'H)-one ; r-[(5-chloro-2-thienyl)methyl]-5-methoxy-1Η-spiro[furo[3,2-fo]pyridine-3,4'-quinolin]-
2'(3'H)-one ; and 1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-5-methoxy-1 'H-spiro[furo[3,2-jb]pyridine-3,4'- quinolin]-2'(3'H)-one.
45. The compound of claim 42, wherein: j is O; k is 1 ; n is 1 ; X is O or S;
Figure imgf000283_0003
is a fused heteroaryl ring; and Y is fused aryl or heteroaryl.
46. The compound of claim 45 selected from the group consisting of the following: 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-
[1 ,5]naphthyridin]-2'(3'H)-one; 1 '-[(5-chloro-2-furyl)methyl]-1 "H-spiro[furo[2,3-f][1 ,3]benzodioxole-7,4'- [1 ,5]naphthyridin]-2'(3'H)-one ; 1 '-[(5-chloro-2-thienyl)methyl]-1 Η-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-
[1 ,5]naphthyridin]-2'(3'H)-one ; r-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-1'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-
[1.δJnaphthyridin^S'HJ-one; 5-methoxy-4'-{[5-(trifluoromethyl)-2-furyl]methyl}-4'H-spiro[furo[3,2-/7]pyridine-3,7'- tb\eno[3,2-b]pyr\d\n]-5'(6'hi)-one ; 4l-[(5-chloro-2-furyl)methyl]-5-methoxy-4'H-spiro[furo[3,2-/3]pyridine-3,7'-thieno[3,2- b]pyridin]-5'(6'H)-one ; 4'-[(5-chloro-2-thienyl)methyl]-5-methoxy-4Η-spiro[furo[3,2-ό]pyridine-3,7'-thieno[3,2- b]pyridin]-51(6'/-/)-one ; and 4'-[(2-isopropyl-1,3-thiazol-5-yl)methyl]-5-methoxy-4'H-spiro[furo[3,2-ib]pyridine-3,7'- thieno[3,2-b]pyridin]-5'(6'H)-one.
47. A compound of formula (VIII):
Figure imgf000284_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5; Z is -N(R5)- or -O-;
Figure imgf000284_0002
are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5,
-R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or
-R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R6 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5, -R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4, -R8-S(O)mR4 (where m is O1 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alky], alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
48. The compound of claim 47, wherein: j is O; k is 1 ; Z is -O-; Q is -O-; X is O or S; and
Figure imgf000287_0001
and v — ' are each independently a fused aryl ring or a fused heteroaryl ring.
49. The compound of claim 48 selected from the group consisting of the following:
1-pentylspiro[3,1-benzoxazine-4,7'-furo[2,3-f][1 ,3]benzodioxol]-2(1/-/)-one; 1'-pentyl-5,6-dihydrospiro[benzo[1 ,2-b:5,4-b]difuran-3,4'-[3,1]benzoxazin]-2'(1'/-/)-one; 5,6-difluoro-1'-pentylspiro[1-benzofuran-3,4'-[3,1]benzoxazin]-2'(1'/-/)-one; 1 -{[5-(trifluoromethyl)-2-furyl]methyl}spiro[3, 1 -benzoxazine-4,7'-furo[2,3- f\{\ ,3]benzodioxol]-2(1 H)-one; 1 -[(5-chloro-2-thienyl)methyl]spiro[3, 1 -benzoxazine-4,7'-furo[2,3-/][1 ,3]benzodioxol]-
2(1H)-one;
Figure imgf000288_0001
[3, 1 ]benzoxazin]-2'( 1 'H)-one; 1'-{[5-(trifluoromethyl)-2-furyl]methyl}-5,6-dihydrospiro[benzo[1 ,2-ib:5,4-t)ldifuran-3,4'-
[3, 1 ]benzoxazin]-2'( 1 '/-/)-one; 1-[(5-chloro-2-thienyl)methyl]-2',3'-dihydrospiro[3,1-benzoxazine-4,8'-furo[2,3- g][1 ,4]benzodioxin]-2(1 H)-one; 1 -{[5-(trifluoromethyl)-2-furyl]methyl}-2',3'-dihydrospiro[3, 1 -benzoxazine-4,8'-furo[2,3- g][1 ,4]benzodioxin]-2(1 H)-one; I'-^δ-chloro^-thienyOmethyllspiroIfuro^.S-flti .SJbenzodioxole-y^'-pyridotS^- d][1 ,3]oxaz\n]-2'(VH)-one ; 1'-[(5-chloro-2-furyl)methyl]spiro[furo[2,3-fl[1 ,3]benzodioxole-7,4'-pyrido[3,2- c/J[1 ,3]oxazin]-2'(rH)-one ; r-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-pyrido[3,2- dJ[1 ,3]oxazin]-2'(rH)-one ; 1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'- pyrido[3,2-d][1 ,3]oxazin]-2'(1'H)-one ; 1 -[(5-chloro-2-thienyl)methyl]-5'-methoxyspiro[3, 1 -benzoxazine-4,3'-furo[3,2- b]pyridine]-2(1H)-thione; 1 -[(5-chloro-2-furyl)methyl]-5'-methoxyspiro[3, 1 -benzoxazine-4,3'-furo[3,2-ib]pyridine]-
2(1H)-thione; 5'-methoxy-1 -{[5-(trifluoromethyl)-2-furyl]methyl}spiro[3, 1 -benzoxazine-4,3'-furo[3,2- ύ]pyridine]-2(1H)-thione; 1 -[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-5'-methoxyspiro[3, 1 -benzoxazine-4,3'-furo[3,2- b]pyridine]-2(1 H)-thione; 1-[(5-chloro-2-thienyl)methyl]spiro[3,1-benzoxazine-4,7'-furo[2,3-/][1 ,3]benzodioxole]- 2(1H)-thione; 1-[(5-chloro-2-furyl)methyl]spiro[3,1-benzoxazine-4,7'-furo[2,3-/][1 ,3]benzodioxole]-
2(1H)-thione; 1-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[3,1-benzoxazine-4,7'-furo[2,3- f\[\ ,3]benzodioxole]-2(1 H)-thione; and i-^-isopropyM .S-thiazol-δ-yOmethylJspiroβJ-benzoxazine^J'-furoP.S- f|[1 ,3]benzodioxole]-2(1H)-thione.
50. The compound of claim 47, wherein: j is O; k is 1 ; Z is -NH-; Q is -O-; X is O or S;
Figure imgf000289_0001
and are each independently a fused aryl ring or a fused heteroaryl ring.
51. The compound of claim 50 selected from the group consisting of the following:
1 '-pentyl-1 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinazolin]-2'(3'/-/)-one; r-pentyl-5,6-dihydro-1'/-/-spiro[benzo[1 ,2-jb:5,4-b]difuran-3,4l-quinazolin]-2'(3l/-/)-one; 1 '-pentyl-1 'H-spiro[furo[2,3-fj[1 ,3]benzodioxole-7,41-quinazolin]-2'(3'H)-one; 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'- quinazolin]-2'(3Η)-one; 1 '-[(5-chloro-2-thienyl)methyl]-1 Η-spiro[furo[2,3-fl[1 ,3]benzodioxole-7,4'-quinazolin]-
2'(3'H)-one; 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}-5,6-dihydro-1 '/-/-spiro[benzo[1 ,2-b:5,4-ib]difuran-
3,4'-quinazolin]-2'(3'H)-one; 1 '-[(5-chloro-2-thienyl)methyl]-5,6-dihydro-1 '/-/-spiro[benzo[1 ,2-ό:5,4-ib]difuran-3,4'- quinazolin]-2'(3'/-/)-one; 1 '-[(5-chloro-2-thienyl)methyl]-2,3-dihydro-1 'H-spiro[furo[2,3-g][1 ,4]benzodioxine-8,4'- quinazolin]-2'(3'/-/)-one; r-{[5-(trifluoromethyl)-2-furyl]methyl}-2,3-dihydro-1'H-spiro[furo[2,3- g][1,4]benzodioxine-8,4'-quinazolin]-2'(3'/-/)-one; 1 '-[(5-chloro-2-thienyl)methyl]-1 'H-spiro[furo[2,3-/][1 ^ibenzodioxole^'-pyridotS^- c/]pyrimidin]-2'(3'/-/)-one; 1 '-[(5-chloro-2-furyl)methyl]-1 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-pyrido[3,2- of]pyrimidin]-2'(3'/-/)-one; 1 ^[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'- pyrido[3,2-c/]pyrimidin]-2'(3'/-/)-one; 1 '-[(2-isopropyl-i ,3-thiazol-5-yl)methyl]-1 '/-/-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'- pyridoIS^-cOpyrimidinJ^XS'HJ-one; ^-[(S-chloro^-thienyOmethyll-S-methoxy-i'H-spirotfurotS^-iblpyridine-S^'-quinazoline]-
2'(3'H)-thione; 1'-[(5-chloro-2-furyl)methyl]-5-methoxy-r/-/-spiro[furo[3,2-ιb]pyridine-3,4l-quinazoline]-
2'(3'H)-thione; 5-methoxy-1'-{[5-(trifluoromethyl)-2-furyl]methyl}-1'/-/-spiro[furo[3,2-jb]pyridine-3,4'- quinazoline]-2'(3'/-/)-thione; 1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-5-methoxy-1 'H-spiro[furo[3,2-jb]pyridine-3,4'- quinazoline]-2'(3'H)-thione; 1 '-[(5-chloro-2-thienyl)methyl]-1 'H-spiro[furo[2,3-f][1 ,3]benzodioxole-7,4'-quinazoline]-
2'(3'H)-thione; 1 '-[(5-chloro-2-furyl)methyl]-1 "H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,4'-quinazoline]-
2'(3'H)-thione; 1 l-{[5-(trifluoromethyl)-2-furyl]methyl}-1 'H-spiro[furo[2,3-f][1 ,3]benzodioxole-7,4'- quinazoline]-2'(3'/-/)-thione; and 1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]-1 '/-/-spiro[furo[2,3-^][1 ,3]benzodioxole-7,4'- quinazoline]-2'(3'H)-thione.
52. A compound of formula (IX):
Figure imgf000290_0001
wherein: t and q are each independently 0, 1, 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)m- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5; p is 1 , 2 or 3, wherein when p is 1 , v is 0, 1 , 2, 3, 4, 5 or 6, when p is 2, v is 0, 1 , 2, 3,
4, 5, 6, 7 or 8, and when p is 3, v is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10;
Figure imgf000291_0001
a annrdl are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; each R2a is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2a may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2a together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4J2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl, and wherein each of the fused ring may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy and aryl. each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2> -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4 -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
53. The compound of claim 52, wherein: j is O; k is 1 ; each R2b is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2b may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2l -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and
Figure imgf000294_0001
and are each independently a fused aryl ring.
54. The compound of claim 53 selected from the group consisting of the following: 2,2',3,3',4,5-hexahydrospiro[1 ,3-diazepino[1 ,2-a]indole-11 ,8'-furo[2,3- g][1 ,4]benzodioxine];
2,3,4,5-tetrahydrospiro[1 ,3-diazepino[1 ,2-a]indole-11 ,7'-furo[2,3-/][1 ,3]benzodioxole]; 3',4'-dihydro-2'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,10'-pyrimido[1 ,2-a]indole]; (IZJ-SΛ.δ.δ-tetrahydro^H-spiroti .S-diazocinofi ^^indole-^J'-furop.S-
/][1 ,3]benzodioxole];
5,6-difluoro-2\3\4\5'-tetrahydrospiro[1-benzofuran-3,1141 ,3]diazepino[1 ,2-a]indole]; 5,6-difluoro-3',4'-dihydro-2Η-spiro[1-benzofuran-3,10'-pyrimido[1 ,2-a]indole]; (rZ^δ.θ-difluoro-S'^'.δ'.e'-tetrahydro^'H-spiroti-benzofuran-S.^'-II .Sldiazocinoti ^- ajindole]; 2',3',4',5,5',6-hexahydrospiro[benzo[1 ,2-ύ:5,4-jb]difuran-3,11'-[1 ,3]diazepino[1 ,2- ajindole]; S'.^^.θ-tetrahydro^'H-spirotbenzoti ^-biδ^-ibldifuran-S.IO'-pyrimidoII ^-aJindole]; and
Figure imgf000294_0002
[1 ,3]diazocino[1 ,2-a]indole].
55. The compound of claim 52, wherein: j is O; k is 1 ; p is 1 ; v is 2, 3 or 4; Q is -O-;
Figure imgf000295_0001
and are each independently a fused aryl ring or a fused heteroaryl ring; and two adjacent R2b together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl, and wherein each of the fused ring may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy and aryl.
56. The compound of claim 55 selected from the group consisting of the following: 2'-(trifluoromethyl)-4'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,101- furo[2',3':4,5]pyrimido[1 ,2-a]indole]; 2'-chloro-4'/-/-spiro[furo[2,3-/][1 ,3]benzodioxole-7,10'-thieno[2',3':4,5]pyrimido[1 ,2- ajindole]; 2l-chloro-5-methoxy-4'H-spiro[furo[3,2-lb]pyridine-3, 10'-thieno[2',3':4,5]pyrimido[1 ,2- ajindole]; 5-methoxy-2'-(trifluoromethyl)-4'H-spiro[furo[3,2-6]pyridine-3)101- furo[2',3':4,5]pyrimido[1 ,2-a]indole]; 2'-(trifluoromethyl)-4'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7, 10'-furo[2,3- of]pyrido[3',2':4,5]pyrrolo[1 ,2-a]pyrimidine]; 8'-(trifluoromethyl)-6'/-/-spiro[furo[2,3-f|[1 ,3]benzodioxole-7, 11 '-furo[2,3- cf]pyrido[2',3':4,5]pyrrolo[1 ,2-a]pyrimidine]; g'-fluoro^'-CtrifluoromethylH'H-spirotfuro^.S-flti .Slbenzodioxole^.iO1- furo^'.S'^^lpyrimidofi ^-aJindole]; 6l-fluoro-2'-(trifluoromethyl)-4'/-/-spiro[furo[2,3-/][1 ,3]benzodioxole-7, 10'- furo[2',3':4,5]pyrimido[1 ,2-a]indole]; 2"-(trifluoromethyl)-11 'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7,5'- furo[3',2':4,5]pyrimido[1 ,2-a]indole]; 2'-chloro-11 'H-spiro[furo[2,3-/][1 ^benzodioxole-Z.δ'-thienoβ'^'Λδtøyrimidoπ ,2- ajindole]; 2'-chloro-5-methoxy-11 '/-/-spiro[furo[3,2-b]pyridine-3,5'-thieno[3',2':4,5]pyrimido[1 ,2- a]indole]; 5-methoxy-2'-(trifluoromethyl)-i r/-/-spiro[furo[3,2-ό]pyridine-3,5'- furo[3',2':4,5]pyrimido[1 ,2-a]indole]; 5-methoxy-2'-(trifluoromethyl)-11'/-/-spiro[furo[3,2-ib]pyridine-3>5l-furo[3,2-
Figure imgf000296_0001
,2-a]pyrimidine]; and 5-methoxy-2'-(trifluoromethyl)-11'/-/-spiro[furo[3,2-jb]pyridine-3,5'-furo[2,3- cOpyridoP'.SM.δlpyrroloII ^-alpyrimidine].
57. A compound of formula (X):
Figure imgf000296_0002
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000296_0003
and are each independently a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring; X is O or S; R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R 36 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5,
-R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4,
-R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)171R4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4; -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
58. The compound of claim 57, wherein: j is O; k is 1 ;
X is O or S;
Q is -O-; and
Figure imgf000299_0001
are each independently a fused aryl ring.
59. The compound of claim 58 selected from the group consisting of the following:
2'-pentyl-1',2l-dihydro-3lH-spiro[furo[2,3-/][1 ,3]benzodioxole-7)4'-isoquinolin]-3'-one; 2'-pentyl-1')2',5,6-tetrahydro-3'H-spiro[benzo[1 ,2-jb:5,4-t»]difuran-3,4l-isoquinolin]-3I- one; 2'-pentyl-1l,2',6,7-tetrahydro-3'/-/-spiro[benzo[1 ,2-6:4,5-fo]difuran-3,4'-isoquinolin]-31- one; 6'-fluoro-2'-pentyl-r,2'-dihydro-3'/-/-spiro[furo[2,3-/][1 )3]benzodioxo!e-7>4'-isoquinolin]-
3'-one; 2l-pentyl-1',2,2',3-tetrahydro-3I/-/-spiro[furo[2,3-g][1 >4]benzodioxine-8I4'-isoquinolin]-3'- one; δ.e-difluoro^'-pentyl-i'^'-dihydro-S'H-spiroII-benzofuran-S^'-isoquinolinl-S'-one; 2'-{[5-(trifluoromethyl)-2-furyl]methyl}-r)2'-dihydro-3'H-spiro[furo[2>3-
/][1 ,3]benzodioxole-7,4'-isoquinolin]-3'-one; 2'-[(5-chloro-2-thienyl)methyl]-r,2'-dihydro-3'H-spiro[furo[2,3-/][1 l3]benzodioxole-7>4'- isoquinolin]-3'-one; 2l-(piperidin-4-ylmethyl)-1',2l-dihydro-3'/-/-spiro[furo[2,3-/][1 ,3]benzodioxole-7>41- isoquinolin]-3'-one; 2'-(2-cyclopropylethyl)-1l,2l-dihydro-3'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7I41- isoquinolin]-3'-one; 2'-{[5-(trifluoromethyl)-2-furyl]methyl}-1l >2l-dihydro-3'H-spiro[furo[2,3- f\{\ ,3]benzodioxole-7,4'-isoquinoline]-3'-thione ; 2l-[(5-chloro-2-furyl)methyl]-1',2'-dihydro-3'H-spiro[furo[2,3-/][1 ,3]benzodioxole-7)4'- isoquinoline]-3'-thione; 2'-{[5-(trifluoromethyl)-2-thienyl]methyl}-1l,2l-dihydro-3'H-spiro[furo[2,3- f\{\ ,3]benzodioxole-7,4'-isoquino!ine]-3'-thione; and 2'-[(5-chloro-2-thienyl)methyl]-1',2'-dihydro-3lH-spiro[furo[2,3-/][1,3]benzodioxole-7,4'- isoquinoline]-3'-thione.
60. The compound of claim 57, wherein: j is O; k is 1 ;
X is O or S; Q is -O-;
is a fused aryl ring; and
Figure imgf000300_0001
is a fused heteroaryl ring.
61. The compound of claim 60 selected from the group consisting of the following: 5-methoxy-2l-{[5-(thfluoromethyl)-2-furyl]methyl}-1 ',2I-dihydro-3'H-spiro[furo[3,2- b]pyridine-3,4'-isoquinoline]-3'-thione; 2'-[(5-chloro-2-furyl)methyl]-5-methoxy-1'>2'-dihydro-3'H-spiro[furo[3,2-ib]pyridine-3,4'- isoquinoline]-3'-thione; 5-methoxy-2I-{[5-(trifluoromethyl)-2-thienyl]methyl}-1',2l-dihydro-3'H-spiro[furo[3,2- b]pyridine-3,4'-isoquinoline]-3'-thione; and 2'-[(5-chloro-2-thienyl)methyl]-5-methoxy-1 l,2'-dihydro-3'/-/-spiro[furo[3,2-ύ]pyridine-
3,4'-isoquinoline]-3'-thione.
62. A compound of formula (Xl):
Figure imgf000301_0001
wherein: t and q are each independently 0, 1 , 2, 3 or 4; j and k are each independently 0, 1 , 2 or 3;
Q is -C(R1a)H-, -C(O)-, -O-, -N(R5)-, -S(O)n,- (where m is 0, 1 or 2), -CF2-, -C(O)O-,
-OC(O)-, -C(O)N(R5)- or -N(R5)C(O)-; R1a is hydrogen or -OR5;
Figure imgf000301_0002
is a fused aryl ring, a fused heterocyclic ring or a fused heteroaryl ring;
X is O or S;
R1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, -R8-C(O)R5, -R8-C(O)OR5, -R8-C(O)N(R4)R5, -S(O)2-R5, -R9-S(O)mR5 (where m is 0, 1 or 2), -R8-OR5, -R8-CN, -R9-P(O)(OR5)2 or -R9-O-R9-OR5; or R1 is aralkyl substituted by -C(O)N(R6)R7 where:
R 36 is hydrogen, alkyl, aryl or aralkyl; and
R7 is hydrogen, alkyl, haloalkyl, -R9-CN, -R9-OR5, -R9-N(R4)R5, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; or R6 and R7, together with the nitrogen to which they are attached, form a heterocyclyl or heteroaryl; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroaryl groups for R6 and R7 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, -R8-CN, -R8-OR5, heterocyclyl and heteroaryl; or R1 is aralkyl optionally substituted by one or more substituents selected from the group consisting of -R8-OR5, -C(O)OR5, halo, haloalkyl, alkyl, nitro, cyano, aryl, aralkyl, heterocyclyl and heteroaryl; or R1 is -R9-N(R10)R11, -R9-N(R12)C(O)R11 or -R9-N(R10)C(O)N(R10)R11 where: each R10 is hydrogen, alkyl, aryl, aralkyl or heteroaryl; each R11 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R9-OC(O)R5, -R9-C(O)OR5, -R9-C(O)N(R4)R5, -R9-C(O)R5, -R9-N(R4)R5, -R9-OR5 or -R9-CN;
R12 is hydrogen, alkyl, aryl, arakyl or -C(O)R5; and wherein each aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for R10 and R11 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, halo, haloalkyl, nitro, -R8-CN, -R8-OR5, -R8-C(O)R5, heterocyclyl and heteroaryl; or R1 is heterocyclylalkyl or heteroarylalkyl where the heterocyclyl or the heteroaryl group is optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-OR5,
-R8-C(O)OR5, -R8-N(R4)R5, -R8-C(O)N(R4)R5, -R8-C(O)R5, -R8-N(R5)C(O)R4,
-R8-S(O)mR4 (where m is 0, 1 or 2), -R8-CN or -R8-NO2; each R2 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(=N-CN)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R2 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R2 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; or R1 and R2 together with the adjacent nitrogen atoms to which they are directly attached, may form a fused ring selected from heterocyclyl and heteroaryl; each R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2) -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2; or two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl; each R4 and R5 is independently selected from group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl; or when R4 and R5 are each attached to the same nitrogen atom, then R4 and R5, together with the nitrogen atom to which they are attached, may form a heterocyclyl or heteroaryl; and each R8 is a direct bond or a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; and each R9 is a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain; as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
The compound of claim 62, wherein:
Figure imgf000304_0001
fused heteroaryl ring; R3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2, -R8-OR5, -R8-N(R4)R5, -N=C(R4)R5, -S(O)mR4, -OS(O)2CF3, -R8-C(O)R4, -C(S)R4, -C(R4)2C(O)R5, -R8-C(O)OR4, -C(S)OR4, -R8-C(O)N(R4)R5, -C(S)N(R4)R5, -N(R5)C(O)R4, -N(R5)C(S)R4, -N(R5)C(O)OR4, -N(R5)C(S)OR4, -N(R5)C(O)N(R4)R5, -N(R5)C(S)N(R4)R5, -N(R5)S(O)nR4, -N(R5)S(O)nN(R4)R5, -R8-S(O)nN(R4)R5,-N(R5)C(=NR5)N(R4)R5 and -N(R5)C(N=C(R4)R5)N(R4)R5, wherein each m is independently 0, 1, or 2 and each n is independently 1 or 2; and wherein each of the cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl groups for each R3 may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R8-CN, -R8-NO2) -R8-OR5, -R8-N(R4)R5, -S(O)mR4, -R8-S(O)nN(R4)R5, -R8-C(O)R4, -R8-C(O)OR4, -R8-C(O)N(R4)R5, -N(R5)C(O)R4 and -N(R5)S(O)nR4, wherein each m is independently 0, 1 , or 2 and each n is independently 1 or 2.
64. The compound of claim 63 selected from the group consisting of the following: 5-methoxy-1l-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[3,2-b]pyridine-3,3'- pyrrolo[1 ,2-jb]pyrazol]-2'(1'H)-one; 3-methyl-1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-c]isoxazole-4,3'- pyrrolo[1 ,2-b]pyrazol]-2'(1 'H)-one; 5'-methoxy-5,6,7,8-tetrahydrospiro[4a,8b-diazacyclopenta[cc(]azulene-3,3'-furo[3,2-
6]pyridin]-4-one; and 5-methoxy-1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[3,2-ύ]pyridine-3,3'- pyrrolo[1 ,2-/fc>]pyrazole]-2'(1Η)-thione.
65. The compound of claim 62, wherein: j is O; k is 2; Q is -O-; X is O or S; q is 2;
Figure imgf000306_0001
is a fused aryl ring; and two adjacent R3 together with the atoms to which they are directly attached, may form a fused ring selected from cycloalkyl, aryl, heterocyclyl and heteroaryl
66. The compound of claim 65 selected from the group consisting of the following: 1 '-[(5-chloro-2-furyl)methyl]spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'-pyrrolo[1 ,2-6]pyrazol]-
2'(1'H)-one ; 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'-pyrrolo[1 ,2- b]pyrazol]-2'(1'H)-one ; 1'-{[5-(trifluoromethyl)-2-thienyl]methyl}spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'- pyrrolo[1 ,2-b]pyrazol]-2'(1'/-/)-one ; 1 '-[(5-chloro-2-thienyl)methyl]spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'-pyrrolo[1 ,2-
<b]pyrazol]-2'(1'H)-one; 1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'- pyrrolo[1 ,2-jb]pyrazol]-2'(1 '/-/)-one; 1 '-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'-pyrrolo[1 ,2- b]pyrazole]-2'(1'H)-thione ; 1 '-[(5-chloro-2-furyl)methyl]spiro[furo[2,3-/|[1 ,3]benzodioxole-7,3'-pyrrolo[1 ,2-
6]pyrazole]-2'(1'H)-thione ; 1'-{[5-(trifluoromethyl)-2-thienyl]methyl}spiro[furo[2,3-/][1 ,3]benzodioxole-7)3'- pyrrolo[1 ,2-jb]pyrazole]-2'(1'/-/)-thione ; 1 '-[(5-chloro-2-thienyl)methyl]spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'-pyrrolo[1 ,2-
6]pyrazole]-2'(1'H)-thione; and 1 '-[(2-isopropyl-1 ,3-thiazol-5-yl)methyl]spiro[furo[2,3-/][1 ,3]benzodioxole-7,3'- pyrrolo[1 ,2-jb]pyrazole]-2'(1'/-/)-thione.
PCT/US2007/081320 2006-10-12 2007-10-12 Spiroheterocyclic compounds and their uses as therapeutic agents WO2008046084A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85182806P 2006-10-12 2006-10-12
US60/851,828 2006-10-12
US85279606P 2006-10-18 2006-10-18
US60/852,796 2006-10-18

Publications (2)

Publication Number Publication Date
WO2008046084A2 true WO2008046084A2 (en) 2008-04-17
WO2008046084A3 WO2008046084A3 (en) 2009-06-25

Family

ID=39204951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081320 WO2008046084A2 (en) 2006-10-12 2007-10-12 Spiroheterocyclic compounds and their uses as therapeutic agents

Country Status (1)

Country Link
WO (1) WO2008046084A2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799798B2 (en) 2005-04-11 2010-09-21 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
US7935721B2 (en) 2005-04-11 2011-05-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
WO2010132352A3 (en) * 2009-05-11 2011-09-01 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
JP2012505895A (en) * 2008-10-17 2012-03-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド Spirooxindole compounds as therapeutic agents and their use
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US8450358B2 (en) 2009-06-29 2013-05-28 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2015151001A1 (en) 2014-03-29 2015-10-08 Lupin Limited Sulfonamide compounds as voltage gated sodium channel modulators
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2017037682A1 (en) 2015-09-04 2017-03-09 Lupin Limited Sulfonamide compounds as voltage-gated sodium channel modulators
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CN108017643A (en) * 2016-11-01 2018-05-11 中国科学院上海有机化学研究所 A kind of efficient IDO/TDO double inhibitors containing azacyclo- helical structure
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2003037890A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2003037890A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Piperidines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 10 January 1992 (1992-01-10), SAUVIAT M P ET AL: "Blockade of sodium channels by Bistramide A in voltage-clamped frog skeletal muscle fibres." XP002510615 Database accession no. NLM1309656 & BIOCHIMICA ET BIOPHYSICA ACTA 10 JAN 1992, vol. 1103, no. 1, 10 January 1992 (1992-01-10), pages 109-114, ISSN: 0006-3002 *
HIEMSTRA, H. C. ET AL: "Models of folate coenzymes - VIII. An approach to yohimbane alkaloids via carbon-fragment transfer from N5,N10-methylenetetrahydrofolate models" TETRAHEDRON, vol. 39, no. 23, 1983, pages 3981-3986, XP002510614 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106087B2 (en) 2005-04-11 2012-01-31 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
US7935721B2 (en) 2005-04-11 2011-05-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
US7799798B2 (en) 2005-04-11 2010-09-21 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US8916580B2 (en) 2008-10-17 2014-12-23 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US9458178B2 (en) 2008-10-17 2016-10-04 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8415370B2 (en) 2008-10-17 2013-04-09 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents
JP2015010090A (en) * 2008-10-17 2015-01-19 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Spiro-oxindole compounds and their use as therapeutic agents
JP2012505895A (en) * 2008-10-17 2012-03-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド Spirooxindole compounds as therapeutic agents and their use
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010132352A3 (en) * 2009-05-11 2011-09-01 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
US8450358B2 (en) 2009-06-29 2013-05-28 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8883840B2 (en) 2009-06-29 2014-11-11 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US9480677B2 (en) 2009-06-29 2016-11-01 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US9695185B2 (en) 2009-10-14 2017-07-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US8742109B2 (en) 2009-10-14 2014-06-03 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9260446B2 (en) 2009-10-14 2016-02-16 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
WO2015151001A1 (en) 2014-03-29 2015-10-08 Lupin Limited Sulfonamide compounds as voltage gated sodium channel modulators
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017037682A1 (en) 2015-09-04 2017-03-09 Lupin Limited Sulfonamide compounds as voltage-gated sodium channel modulators
US10239869B2 (en) 2015-09-04 2019-03-26 Lupin Limited Sulfonamide compounds as voltage-gated sodium channel modulators
CN108017643A (en) * 2016-11-01 2018-05-11 中国科学院上海有机化学研究所 A kind of efficient IDO/TDO double inhibitors containing azacyclo- helical structure
CN109890826A (en) * 2016-11-01 2019-06-14 中国科学院上海有机化学研究所 A Highly Efficient IDO/TDO Dual Inhibitor Containing Nitrogen Helical Structure
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators

Also Published As

Publication number Publication date
WO2008046084A3 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
AU2006235329B2 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046084A2 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
EP2350091B1 (en) Spiro-oxindole compounds and their use as therapeutic agents
US20100160291A1 (en) Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
WO2008046049A1 (en) Spiro (furo [3, 2-c] pyridine-3-3 &#39; -indol) -2&#39; (1&#39;h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046087A2 (en) Spiro compounds and their uses as therapeutic agents
EP1879892A2 (en) 2-pyrrolidone derivatives and their uses for the treatment of inflammatory conditions and pain
WO2010053998A1 (en) Spiro-condensed indole derivatives as sodium channel inhibitors
WO2010078307A1 (en) Spiro-oxindole-derivatives as sodium channel blockers
WO2008134553A1 (en) Methods of using bicyclic compounds in treating sodium channel-mediated diseases
AU2008213836A1 (en) Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
WO2010045251A2 (en) Spiro-oxindole compounds and their use as therapeutic agents
WO2010132352A2 (en) Spiro compounds and their use as therapeutic agents
WO2008109856A2 (en) Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
WO2008121859A1 (en) Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854026

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07854026

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载